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Congenital diaphragmatic hernia (CDH) is a rare congenital anomaly characterized by a
diaphragmatic defect, pulmonary hypertension (PH) and lung hypoplasia (LH). It has a
worldwide incidence of approximately 1 in 3000 live births [1, 2] and mortality varies from
20-40% [3], leading parents and treatment teams to termination of pregnancy or to consider
ongoing therapy as futile. In some cases chromosomal aberrations have been found, but the
etiology of CDH is largely unknown [4–6]. Approximately 60% of all cases are isolated, showing
no additional congenital defects [6]. The high mortality and morbidity rates may depend on the
presence of associated malformations and/or genetic abnormalities, but are mostly due to the
concomitant PH. PH is the result of the altered development of the pulmonary vasculature, the
unpredictable vascular reactivity and the disordered process of pulmonary vascular remodeling
[7, 8]. Nowadays, at least in large parts of Europe and the USA, CDH is usually diagnosed
at 20 weeks of gestation by ultrasound and/or Magnetic Resonance Imaging (MRI). Despite
the signiﬁcant improved management and survival in CDH over the last decade, potentially
due to the release of and compliance to international guidelines initiated by the CDH EURO
consortium [9, 10], PH in these patients remains a signiﬁcant challenge.
Pulmonary development
Human lung development can be divided into diﬀerent stages, starting with the embryonic
stage at 4 weeks of gestation, followed by the pseudoglandular stage in which branching of the
lung buds continues. During the canalicular stage, starting around 16 weeks of gestation, gas
exchange regions will be formed. From 24 weeks of gestation until term, the saccular stage,
airspaces will widen and alveoli are formed. During the alveolar stage, which persists into the
postnatal period, maturation of the airways occurs [11]. In contrast to previous thoughts, our
group and others showed that pulmonary vasculature develops in close relation with the airways
already during the embryonic stage and might even be a rate limiting factor in the branching
morphogenesis [12–14]. This implies that the pulmonary vasculature plays an important role
in lung development. The formation of new blood vessels primarily occurs through distal
angiogenesis where new capillaries are formed from preexisting vessels. This has been shown in
lungs of mice with intact blood circulation to maintain vascular tone and integrity [14].
Normally, pulmonary vascular resistance is high during gestation and decreases rapidly after
birth under the inﬂuence of both the increased ventilation and oxygenation and the release of
diﬀerent factors of the three major vasoactive pathways; the endothelin (ET), nitric oxide (NO)
and prostacyclin (PGI2) pathways [15–17] (Figure 1.1). Over the last decades research has
shown changes in several molecular pathways involving the pulmonary vascular development
in patients with PH. In diﬀerent animal models abnormal retinoic acid (RA) signaling has
been found to be involved in the etiology of CDH [18–21]. RA signaling has been shown
to be important in lung development [22]. Active RA is formed from vitamin A through
several enzymatic reactions. Subsequently it can form a complex with one of the retinoic
acid receptors (RAR) which can bind to a retinoic acid responsive element (RARE) and can
modulate transcription of target genes [23]. As described previously in a mouse model, lower
levels of RA can cause an increase in Transforming Growth Factor β (TGFβ), which plays an
important role in airway branching and muscularization of the pulmonary vasculature [24].
Important pathways involved in the etiology of pulmonary
vascular defects in CDH
Current treatment of PH in CDH is based on targeting one of the three major vasoactive
pathways involved in vasoconstriction and vasodilation of the pulmonary vasculature. The
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Figure 1.1: Overview of the vasoactive pathways. ECE-1 = endothelin converting enzyme 1, ETA =
endothelin A, ETB = endothelin B, eNOS = endothelial nitric oxide synthase, sGC =
soluble guanylate cyclase, COX = cyclooxygenase, PGIS = prostaglandin synthase, PGI2 =
prostaglandin I2, AC = adenylate cyclase, TBXAS1 = thromboxane synthase, TXA2 =
thromboxane.
ET pathway is activated by three ligands: ET-1, ET-2 and ET-3, of which ET-1 is the most
common isoform [25, 26]. The ET-1 precursor protein, Prepro-ET-1 is cleaved by furin into
the Big-ET-1, which is subsequently processed to its active form by the endothelin converting
enzyme (ECE-1) and binds and activates two diﬀerent G-protein coupled receptors, ETA and
ETB, with equal aﬃnity. The ETA receptor is located at the cell surface of vascular smooth
muscle cells and induces vasoconstriction and cell proliferation by activating phospholipase
C, whereas the ETB receptor is located mainly in the cell membrane of the endothelium and
induces vasodilation by regulating the release of NO and PGI2 [27, 26]. Furthermore, ET-1
promotes cell growth, cell adhesion and thrombosis and is increased in lung tissue of patients
with pulmonary hypertension. A negative feedback loop is triggered by NO that reduces the
aﬃnity of the ETA receptor for ET-1 and can therefore prevent ET-1 mediated signaling [27].
NO can be synthesized by one of three diﬀerent NO synthases (NOS), of which endothelial
NOS (eNOS) is the most important synthase involved in the regulation of the pulmonary
vascular tone and is highly expressed in the endothelial cells [28]. NO can bind to its receptor,
soluble guanylyl cyclase (sGC), which can synthesize the second messenger cyclic guanosine
monophosphate (cGMP), thereby inducing vasodilation. The third important pathway involves
prostaglandins and thromboxanes that act on prostanoid receptors which can be divided in
receptors that cause relaxation (IP (PTGIR), EP2, EP4 and DP) or contraction (TP, EP1 and
FP) of the vascular tone [29]. PGI2 is an important mediator of vasodilation which binds and
activates the prostaglandin-I2 receptor (PTGIR) [30, 31]. This activation results in vasodilation
through the release of cyclic adenosine monophosphate (cAMP).
The alveolar formation starts late in development and continues into the ﬁrst years of life to
expand the gas exchanging capacity of the lung. Concomitant with the expansion of the airways
is the adaptation of the microvasculature to optimize the transport of oxygen and carbon
dioxide from the blood to the airways and vice versa. This process is partly regulated by TGFβ.
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Figure 1.2: Overview of the TGFβ and BMP pathways. TGFβ = transforming growth factor β,
BMP = bone morphogenetic protein, ZEB2 = zinc ﬁnger E-box binding homeobox 2, P =
phosphorylation.
There are two main branches in the TGFβ superfamily; the TGFβ/activin family and the bone
morphogenetic protein (BMP) family. All proteins of the TGFβ superfamily act through two
classes of receptor serine/threonine kinases; type 1 and type 2. Active TGFβ or BMP can be
bound to a speciﬁc type 2 receptor, which phosphorylates and activates a type 1 receptor. The
activated type 1 receptor subsequently phosphorylates a set of receptor-regulated Smads, which
form a complex with co-Smad (Smad4). TGFβ is responsible for the phosphorylation of Smad2
and Smad 3, where BMP phosphorylates Smad 1, 5 and 8. Eventually, the R-Smad/co-Smad
complex modulates the transcription of target genes in the nucleus [32] (Figure 1.2). TGFβ is a
negative regulator of airway branching in early lung development. However, TGFβ signaling is
necessary in vascular and airway smooth muscle cells, and in alveolar and airway epithelial cells
during late lung development [33]. Previous studies in rodents showed an arrest in alveolarization
both in animals with upregulated TGFβ signaling [34] as well as after a complete blockade of
TGFβ signaling [35], indicating the important diﬀerences in TGFβ signaling between early and
late lung development.
Current treatment options of pulmonary hypertension
pre- and postnatally
The signiﬁcance of PH in the mortality and morbidity of patients with CDH has been increasingly
recognized since 1971 [36, 37]. The ﬁrst vasodilators used in these neonatal patients with PH,
tolazoline [38], an α-adrenergic receptor antagonist, and prostacyclin [39], a prostaglandin-I2
(PGI2) agonist, resulted in variable results. Tolazoline infusion showed a response in 21 of 36
neonatal patients with lung disease, where systemic hypotension and bleeding tendency were
seen as a side eﬀect in several patients [38]. Treatment with PGI2 improved pulmonary arterial
pressure and oxygenation in 2 of 3 neonatal patients with idiopathic PH and PH caused by
meconium aspiration. However, it had no beneﬁcial eﬀect in 2 patients with CDH, whereas
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systemic hypotension was seen as a side eﬀect in one of these patients [39]. Currently, patients
with CDH still respond unpredictable to the available vasodilator therapy due to the lack of
understanding of the underlying mechanisms which can be diﬀerent in individual patients.
Inhaled nitric oxide (iNO) is most commonly used, but studies have failed to show its eﬃcacy
in this speciﬁc group of patients [40–43]. Apart from iNO, sildenaﬁl and some prostaglandin
analogues are used as rescue therapy in a compassionate way in the most severe cases, but with
variable results [44–48]. No appropriate trials have been performed on these drugs and, with a
few exceptions, no data on pharmacokinetics are available for CDH neonates.
Currently, the only prenatal intervention used in CDH in the form of a clinical trial is
Fetoscopic Endoluminal Tracheal Occlusion (FETO), where a small balloon will be inserted
in the fetal trachea to temporarily block the airway for a period of 4-6 weeks (TOTAL;
NCT02875860 (clinicaltrials.gov)) [49]. As a result, ﬂuid will be trapped in the lungs, creating
internal pressure which forces the lung to grow. This idea of blocking the airway emerged
from the enlargement of the lungs seen in patients with congenital high airway obstruction
syndrome (CHAOS) [50]. Previous research has shown that tracheal occlusion can indeed cause
an increase in lung growth [51, 52] and removing the balloon before birth has shown to be
necessary for a better maturation of the lung by decreasing the apoptosis of the alveolar type 2
cells which produce surfactant, an essential compound for lung function [53]. So far, FETO has
shown to improve survival rate in high risk CDH patients but at the cost of increased morbidity
and premature delivery [54–56]. As a consequence, the results of the FETO trial have to be
awaited which will take another 1-2 years (personal communication J. Deprest).
At the moment treatment with vasodilators in patients with CDH is only used postnatally,
where previous research has shown already major diﬀerences in the pulmonary vasculature
early during development [57]. Over the last years some studies have been performed on the
antenatal use of the phosphodiesterase-5 inhibitor sildenaﬁl in diﬀerent animal models of CDH,
showing improvement in alveolarization and pulmonary vascular development [58–62]. However,
treatment in these studies was already initiated very early during pregnancy, at the start of
lung development and before CDH symptoms and pathology develop. At this time human CDH
would not yet be detectable. Furthermore, pulmonary pathology in these treated animals was
not totally reversed.
The absence of an integrated analysis of TGFβ signaling and of the pathways regulating
vascular tone as well as the ineﬀective postnatal treatment in individual patients with CDH
makes it essential to obtain more insight into these pathways during development to optimize
targeting and timing of administration of these drugs. Furthermore, adequate prenatal treatment
could be beneﬁcial for the pulmonary development in CDH.
Experimental animal model
Diﬀerent animal models have been developed to evaluate the abnormalities in CDH of which
the nitrofen rat model is one of the best studied. In this model, pregnant Sprague-Dawley rats
receive the herbicide nitrofen (2,4-dichlorophenyl-p-nitrophenyl ether) by gavage on gestational
age day E9.5, which induces a developmental defect in the diaphragm of the fetuses and
pathological signs of PH and LH. Nitrofen inhibits retinal dehydrogenase (RALDH-2), an
enzyme that normally synthesizes RA, which, as described above, plays an important role
in lung development [20, 63]. The ﬁrst indication of abnormal RA signaling in CDH came
from a study where 25-40% of pups born to rat dams with a vitamin A deﬁcient diet had
a diaphragmatic hernia [18]. Furthermore, administration of large amounts of vitamin A to
nitrofen-treated animals has shown to reduce the incidence of CDH in the oﬀspring [64]. These
observations in animal models were strengthened by decreased retinol and retinol binding
protein plasma levels in a small number of newborn CDH patients [65] and the discovery of
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deregulated RA signaling genes in human CDH patients [66]. Additionally to the diaphragmatic
defect, cardiovascular and skeletal defects, similar to those found in human CDH patients, have
been seen in nitrofen-treated rat fetuses, which makes it a useful model for the research of the
underlying pathology of this disease [63].
Aims and outline of this thesis
The aim of this thesis is to evaluate the expression of important factors in the diﬀerent vasoactive
pathways in CDH and to develop a potential prenatal intervention for the altered pulmonary
vascular development.
In the ﬁrst place important factors in the TGFβ pathway and the major vasoactive pathways,
the endothelin, prostacyclin and nitric oxide pathways, were evaluated in human CDH patients
and the well-established nitrofen rat model for CDH. Second, prenatal intervention using
treatment with the phosphodiesterase-5 inhibitor sildenaﬁl and/or prostaglandin-I2 agonist
NS-304 is implemented in this rat model.
Chapter 2 gives an overview of current knowledge on pulmonary vascular development in
health and disease, describing aberrant expression of factors in both CDH and some other
neonatal diseases. Chapter 3 describes the alterations in the TGFβ pathway in CDH. In
Chapter 4 the three major vasoactive pathways are examined in exclusive material of human
CDH patients and the well-established nitrofen rat model. Chapter 5 and 6 describe two
experimental animal studies on the antenatal use of the phosphodiesterase-5 inhibitor sildenaﬁl
and the prostaglandin-I2 receptor agonist NS-304 in the nitrofen rat model. At last, in Chapter
7 the results of these studies are placed in a broader perspective and future possibilities are
discussed.
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Abstract
Pulmonary vascular diseases of the newborn comprise a wide range of pathological conditions
with developmental abnormalities in the pulmonary vasculature. Clinically, pulmonary arterial
hypertension (PH) is characterized by persistent increased resistance of the vasculature and
abnormal vascular response. The classiﬁcation of PH is primarily based on clinical parameters
instead of morphology and distinguishes ﬁve groups of PH. Congenital lung anomalies such as
alveolar capillary dysplasia (ACD) and PH associated with congenital diaphragmatic hernia
(CDH), but also bronchopulmonary dysplasia (BPD), are classiﬁed in group three.
Clearly, tight and correct regulation of pulmonary vascular development is crucial for normal
lung development. Human and animal model systems have increased our knowledge and make it
possible to identify and characterize aﬀected pathways and study pivotal genes. Understanding
of the normal development of the pulmonary vasculature will give new insights in the origin of
the spectrum of rare diseases such as CDH, ACD and BPD, which render a signiﬁcant clinical
problem in neonatal intensive care units around the world.
In this review we will describe the normal pulmonary vascular development and we will focus
on four diseases of the newborn in which abnormal pulmonary vascular development play a
critical role in the morbidity and mortality. In the future perspective we indicate the lines of
research that seems to be very promising for elucidating the molecular pathways involved in
the origin of congenital pulmonary vascular disease.
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The morphological development of pulmonary vasculature
In mammals, blood is transported through the cardiovascular system that can be divided in the
systemic and the pulmonary circulation. These two types of circulations have histological
similarities but diﬀer in their physiological function and anatomic position to the heart.
Oxygenated blood is transported and distributed throughout the body by the systemic
circulation, whereas oxygen-depleted blood is transported to the lungs by the pulmonary
circulation. The blood supply in the lung can be divided into the bronchial circulation and
the pulmonary circulation. The bronchial circulation is mainly separated from the pulmonary
circulation, although some overlap exists in the pre-capillary region. The bronchial circulation
comprises arteries, which align with the bronchial tree. A third of the blood in the bronchial
circulation returns to the right atrium through the bronchial vein. The pulmonary circulation
transports oxygen-deprived blood to the gas exchange areas and oxygen-rich blood back to the
left atrium. The bronchial circulation is part of the systemic circulation and delivers oxygen-rich
blood to the cells of the lung at high systemic pressure.
The pulmonary vasculature comprises anatomically and functionally diﬀerent compartments:
the arterial tree, the capillary bed and the venular tree. The pulmonary arteries also support the
intrapulmonary structure and ultimately regulate gas exchange via the capillary bed. Prenatally,
the pulmonary circulation is characterized by high pulmonary vascular resistance (PVR) and
low blood ﬂow (compared to the ventricular output). The thick wall and high vasomotor tone
contribute to the high PVR. The majority of the blood ﬂow of the cardiac output is diverted to
other organs than the lung through the foramen ovale and the ductus arteriosus. This process is
facilitated by the relative high resistance in the pulmonary circulation compared to the systemic
circulation. After birth, there is a large transition from relative hypoxic conditions to normoxic
condition. This transition induces dramatic changes in the PVR leading to physiological
adaptations in the lung. This adaption of the lung is required to exert its important function:
exchange gas and oxygenate the blood.
The cellular composition of the pulmonary vascular wall varies depending on the functionality
of the vessel. The outer layer of the pulmonary arteries, the adventitia, is a loosely organized
structure consisting of an extracellular matrix with ﬁbroblasts, vasa vasorum and a neuronal
network [1, 2]. There is gradual change in structure from the proximal to distal end of the
lung, which corresponds with the maturation of the developing airways. The large pulmonary
arteries at the proximal end of the lung have a media consisting of a layer of smooth muscle
cells in between the lamina elastic interna and externa. Towards the distal area of the lung, the
arteries have a smaller lumen with a thinner smooth muscle cell layer and no lamina elastica.
The smooth muscle cells in the tunica media form a heterogeneous population, ranging from
cuboidal, synthetic cells to the characteristic elongated contractile cells. The contractile smooth
muscle cells have more contractile ﬁbers, have less proliferation and less migration activity
compared to the synthetic phenotype [3, 4]. The pulmonary capillaries are the most distal
compartment of the pulmonary vasculature and are the site where gas exchange takes place.
Capillaries exist of a monolayer of endothelial cells, which are in direct contact with perivascular
cells. The structure of the pulmonary veins is comparable to the structure of small arteries.
Pulmonary veins consist of a thin intima, smooth muscle cell containing media in the larger
veins and an adventitia containing a vaso vasorum, nerves and bundles of collagen and elastin
ﬁbers [2].
The development of the pulmonary vasculature
Understanding the process of normal pulmonary vascular development is a prerequisite to
comprehend the origin of pulmonary hypertension (PH) and its associated diseases of the
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Table 2.1: Overview of Stages in Lung Development in Mouse and Human
Stage I Embryonic II Pseudoglandular III Canalicular IV Saccular V Alveolar
Mouse E9–11.5 E11.5–16.5 E16.5–17.5 E17.5–PN5 PN5–30
Human Wk 3–7 Wk 5–17 Wk 16–26 Wk 26–36 Wk 36–3 years
newborn. The pulmonary vasculature develops in close relation with the airways and has
extensively been studied in rodent models. In mice, the ﬁrst molecular sign of lung development
is around embryonic day 8 (E8) when the expression of Nkx2-1 starts in the ventral wall of the
anterior foregut (see table 2.1 for lung developmental stages of human and mouse). At E9.5
in the mouse, a primitive bud evaginates from the ventral side of the foregut and invades the
surrounding mesenchyme [5]. This bud splits into two buds, which will form the right and left
lung, but this embryonic phase is very short and rapidly turns into the pseudoglandular phase
when the primary buds expand into the mesenchyme and start budding and branching until
E16.5. After E16.5, when the bronchial tree is formed, development of the lung goes into a
new stage, the canalicular phase. In mice it is very short (E16.5-E17.5) and during this period
the terminal buds narrow. From E17.5 until postnatal day 5 (P5) lung development goes into
the saccular stage and the precursors of the alveoli are formed. And ﬁnally from postnatal
life onwards alveolarization starts and ends around P14. In humans, lung development follows
a similar sequence of stages, but with a diﬀerent timetable. Budding starts at 4 weeks of
gestation, the pseudoglandular stage ends around week 6, followed by the canalicular (week
16-26), saccular (week 26-36) and alveolarisation (postnatal until 3 years of age) stages (Table
2.1).
The lung endoderm and mesoderm are interacting during all these developmental stages via
multiple molecular pathways. These molecular pathways controlling these stages have been
discussed in extensively in two recent reviews [6, 5]. In this review we focus on congenital
diseases associated with pulmonary abnormalities and only describe the molecular players that
have been associated with these diseases.
The past two decades new insights into the development of the pulmonary vasculature have
been obtained. It was suggested that pulmonary vasculature in mice developed through two
main mechanisms: the central vasculature through angiogenesis and the distal vasculature
through vasculogenesis and either angioblasts from the mesenchyme or blood lakes would provide
endothelial cells for vessel development [7]. These two structures would fuse around E13/E14
through a lytic process and circulation would start [8]. A histological and morphological study
seemed to conﬁrm this hypothesis and the same processes would underlie pulmonary vascular
development in human [9]. The results from these studies were mainly obtained by histological
analysis. However, ﬁxation artifacts have led to inappropriate conclusion and analysis of lung
development using transgenic mice expressing a lacZ reporter gene under the control of an
early marker for endothelial cells (fetal liver kinase 1 (FLK1)) [10], showed that the proximal
and distal pulmonary vasculature was already connected at E10.5 [11]. In addition, detailed
analysis of lung samples of transgenic mice expressing the lacZ reporter under the control of the
endothelium speciﬁc Tie2 promoter showed that already at day E9.5 the presence of a vascular
network surrounded the primitive lung bud connected to the systemic circulation. This network
mainly expands as the lung develops through angiogenesis, a process called distal angiogenesis
[12]. It is still not completely understood how the pulmonary vasculature develops and where
progenitor cells involved in angiogenesis in the lung come from. Lineage trace experiments,
instrumental in deciphering the origin and the fate of early precursor cells in the lung, indicate
that speciﬁc, cardiopulmonary, progenitor cells diﬀerentiate into both cardiac and pulmonary
Pulmonary vascular development goes awry in congenital lung abnormalities
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mesenchymal cells. Moreover, these progenitor cells can diﬀerentiate into vascular smooth
muscle cells and pericyte-like cells, but were only observed in the proximal end of the lung [13].
It remains unclear what the progenitors are for the perivascular cells and endothelial cells in the
distal end of the lung. Proper lineage trace studies throughout pulmonary vascular development
could serve to answer these questions.
Important molecular players in pulmonary vascular
development
Normal pulmonary vascular development requires tight regulation of cell migration, proliferation
and diﬀerentiation. The family of Vascular endothelial growth factors (VEGF), and their
receptors Fetal liver kinase1 (KDL1 or VEGFr1) and Kinase domain receptor (Kdr or VEGFr2),
are one of the most potent angiogenic factor signaling cascades and are required for vascular
growth and endothelial cell proliferation [14, 15]. Early during lung development, VEGF is
expressed by the epithelium and mesenchyme, but later its expression is restricted to the
epithelium [16] where it is required for epithelial branching and morphogenesis [17]. In response
to hypoxic conditions, as in the prenatal lung, VEGF expression is induced by Hypoxia-
inducible transcription factor-1 and 2 (HIF1/HIF2). HIF1 and HIF2 are heterodimers existing
of an oxygen-sensitive subunit, HIF1α or HIF2α, and a constitutive Arnt/HIF1β subunit.
At normoxic conditions, speciﬁc prolyl hydroxylases (Phd) hydroxylate the HIFα subunit,
which is subsequently ubiquitinated and targeted for degradation via the Von-Hippel-Lindau
tumour suppressor protein pathway [18–20]. Under hypoxic conditions, the HIFα subunit is not
hydroxylated and the HIFα/HIFβ complex translocates to the nucleus where it binds to hypoxic
responsive elements in the regulatory unit of target genes to induce the transcription of these
genes. Among the genes that are activated under hypoxic conditions are several angiogenic
genes, such as VEGF, which results in the growth and expansion of the vasculature.
Vascular development consists of vasculogenesis and angiogenesis: vasculogenesis is the
process where the vascular plexus is formed de novo from mesodermal progenitor cells [21], and
angiogenesis is the process where endothelial cells sprout from preexisting vessels to form new
tubes. There is constant competition between the leading cell, the tip cell, and the trailing
cell, the stalk cell, to become or to stay on the tip of the sprout. Endothelial cells of the
newly formed tubes recruit pericytes in a Platelet-derived growth factorβ (PDGFβ) depended
manner (Figure 2.1). Pericytes wrap around the newly formed endothelial tubes and induce
stabilization and maturation [22, 23] and the interaction between these two cells is crucial for
normal vascular development. This interaction is regulated by diﬀerent growth factors and
their receptors, such as PDGF(r) and TGFβ(r) [24]. Tight regulation of this interaction is
required for normal vascular development and disruption of this process may lead to pathological
conditions. However, pericytes comprise a very heterogenic population in the lung and therefore
they are rather diﬃcult to identify. New, speciﬁc markers are required to better understand the
interaction of pericytes and endothelial cells in both health and disease.
The speciﬁcation of arteries and veins is one of the ﬁrst events that take place in the
development of the circulatory system. Arteries and veins can be distinguished from each other
by the expression of members of a tyrosine kinase family Ephrin2 and Eph4 [25]. However, the
speciﬁcation of the pulmonary network occurs relatively late and the expression of Ephrin2 and
Eph4 is not restricted to artery endothelial or vein endothelial cells, respectively until late in
the pseudoglandular stage (Figure 2.1). In mice, at E13.5 endothelial cells still express both
Ephrin2 and Eph4, but from E15.5 onwards the endothelial cells express either Ephrin2 or Eph4
when they become committed to arteries or veins, respectively. Furthermore, Ephrin expression
in the lung is not restricted to endothelial cells but is also highly expressed by mural cells
[26]. Modulation of the Notch pathway results in arterial defects and can lead, depending on
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Figure 2.1: Simplified scheme of pulmonary vascular compartments. Schematic overview of pulmonary
vasculature, with veins (A), arteries (B), and capillaries (C). Endothelial cells recruit pericytes
in a PDGFβ dependent manner in the distal end of the lung (C). The pulmonary arteries are
characterized by the expression of Eph2 and Notch family member Dll4 (A). Speciﬁcation of the
pulmonary veins includes expression of Ephrin4 and CouptfII (B).
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which member of the pathway is aﬀected, to early prenatal death. For example, heterozygous
Dll4 embryos suﬀer from remodeling defects in the yolk sac and have a smaller dorsal aorta
[27] while the full Dll4 -deﬁcient embryos die due to early lethal loss of arterial identity at
E9.5 [28]. To study the lung developmental phenotype, tissue speciﬁc inhibition of the Notch
pathway is necessary and may give new insights in the speciﬁcation of pulmonary arteries
and veins. Speciﬁcation of venous endothelium includes expression of the nuclear receptor
Chicken ovalbumin upstream transcription factor II (CouptfII), which is expressed in venous and
lymphatic endothelium (Figure 2.1). CouptfII is highly expressed in the foregut mesenchyme
at the site where later in development the lung will be formed. CouptfII knock-out mice die
at E10 from heart defects and loss of venous identity in the vasculature [29]. Lung-speciﬁc
deﬁcient CouptfII mice show a Bochdalek-type congenital diaphragmatic hernia (CDH) [30],
lung hypoplasia associated with CDH indicates the importance of CouptfII in normal lung
development.
Fibroblast growth factors (FGF) belong to a family of mitogens that are identiﬁed as regulators
of lung development [31]. Early during lung development FGF10 is expressed in the mesoderm
around the budding lung endoderm, which expresses its receptor FGFr2. Knockout mice
of FGF10 [32] or FGFr2 [33] resulted in mice without lungs, indicating the crucial role for
this signaling pathway in the development of the lung [34]. However, recently it was shown
that FGF10 is not just inducing budding and branching of the lung during development,
but that expression of FGF10 is also important for the maintenance of epithelial progenitor
cells by preventing these cells to diﬀerentiate [35]. Another member of the ﬁbroblast growth
family, FGF9, is important for lung mesenchyme growth and proliferation [36]. More speciﬁc,
FGF9 stimulates proliferation of mesenchymal cells and regulates mesenchymal Sonic hedgehog
signaling (SHH) [37]. Furthermore, it is also shown that FGF9 and SHH regulate VEGFa
expression what is required for capillary development in the distal end of the lung [17].
Retinoic acid (RA) signaling has been shown to be of high importance for lung development
[38]. Vitamin A in the blood plasma is transported by Retinol binding protein 4 (RBP4), it
binds to the extracellular receptor stimulated by retinoic acid 6 (STRA6) and then through
several enzymatic reactions it is converted into its active form RA. Active RA is secreted and
taken up by retinoic acid responsive cells. In the cytoplasm RA binds to one of the three
Retinoic Acid Receptors (RAR), RARα, RARβ or RARγ [39]. These complexes bind to a
Retinoic Acid active Responsive Element (RARE) in the regulatory elements of their target
genes and modulate transcription of these genes [40, 41]. Targeted deletions of members of
RAR and Rxr family have diﬀerent eﬀects. Double knockouts of RARα and RARβ result
in failure to separate the esophagus and trachea and hypoplasia of the left and right lung.
However, deletion of other members of the RAR and RXR family did not result in an obvious
lung phenotype [42]. Binding of retinoic acid to its receptor directly aﬀects the target genes
either by inducing or repressing gene expression. Many genes regulated by the RA pathway
are involved in embryogenesis [39]. However, it is possible that still many target genes have
yet to be discovered. Tracing the activity of RARE’s in embryonic development revealed high
activity of the RA pathway in multiple developing organs, for example in heart, hindbrain
and diaphragm [43, 44]. Activity of the retinoic acid receptors is important for proper lung
development and at E9 in mice, when the ﬁrst lung buds start to develop from the foregut,
RA signaling is highly active [38]. Furthermore, in absence of retinoic acid, levels of FGF10
decrease and levels of TGFβ increase, and there is reduced budding and branching of the lung
[45]. More speciﬁc, molecular processes required for formation of the lung primordium from
the foregut are controlled by RA receptor activity. RA is a major regulator of Wnt signaling
and the TGFβ pathway and thereby controls FGF10 expression, early in lung development
[46]. The role of RA signaling in vascular development has so far only been shown in the
development of the systemic blood circulation. In RA-deﬁcient embryos endothelial cell growth
and proliferation is uncontrolled, indicating a role for RA in suppression of endothelial cells
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during vasculogenesis [47]. Although there is no direct evidence yet that the RA pathway is
involved in the development of the pulmonary vasculature, it may be that this pathway is
involved based on the intimate relation between the airways and the vasculature.
Abnormal pulmonary vascular development
Perturbations of the described molecular pathways in the pulmonary vascular development may
cause congenital anomalies, like PH, in newborns, infants and children [48]. PH is characterized
by persistent increased resistance of the vasculature and abnormal vascular tone, which is
regulated by the contraction of smooth muscle cells. Five groups of PH can be distinguished:
pulmonary arterial hypertension, PH due to left heart disease, PH due to lung diseases and/or
hypoxia, chronic thromboembolic PH (CTEPH) and PH with unclear multifactorial mechanisms
[49, 50] (Table 2.2). Normally the PVR is high antenatally and decreases immediately after
birth, reaching levels that are comparable to adult values within 2 months after birth. PH
has an incidence of approximately 63.7 per million children [51] and can be idiopathic or
associated with other diseases. It can cause signiﬁcant morbidity and mortality. In children,
idiopathic pulmonary arterial hypertension (iPAH) and PH due to congenital heart disease
comprise the majority of cases. Other important causes include persistent PH of the newborn
(PPHN), bronchopulmonary dysplasia (BPD) and developmental lung diseases, like CDH,
alveolar capillary dysplasia (ACD) and lung hypoplasia and surfactant protein abnormalities
[48, 49]. Mutations in speciﬁc genes have been reported (Table 2.3), but PH in children can also
be associated with genetic syndromes, like Down syndrome, DiGeorge syndrome, VACTERL
syndrome, CHARGE syndrome and Noonan syndrome [52]. Perinatal care and prognosis in
pediatric PH has improved over the last years, but despite the fact that there are signiﬁcant
diﬀerences in pulmonary vascularity between adults and children, most treatment is based on
experimental research or trials in adults [53]. We will focus on iPAH, CDH, ACD and BPD
which are all characterized by an abnormal pulmonary vascular development and in which PH
plays an important role in the mortality and morbidity.
Idiopathic pulmonary arterial hypertension
iPAH is characterized by restricted blood ﬂow through the pulmonary arterial circulation,
elevated pulmonary vascular resistance and progressive right heart failure [66]. iPAH, previously
known as primary PH, has an incidence of approximately 0.7 per million [49] with hypertensive
vasculopathy exclusively in the pulmonary circulation without a demonstrable cause. Young
children have a reduction in arterial number and a failure of the vasculature to relax, whereas in
older children intimal hyperplasia, occlusive changes and plexiform lesions are found (Figure 2.2).
In contrast to adults, children with iPAH have more pulmonary vascular medial hypertrophy
and less intimal ﬁbrosis and fewer plexiform lesions [67, 68]. Younger children have a more
reactive pulmonary vascular bed with an increased prevalence of acute pulmonary hypertensive
crises [69, 68]. Possible mechanisms that play a role in PAH development are endothelial cell
dysfunction, smooth muscle cell migration and dysfunction, and abnormal apoptosis. In adult
iPAH, in-vitro studies showed increased expression of endogenous vasoconstrictors and decreased
expression of vasodilators [70–73]. The same vasoactive factors could play a role in pediatric
iPAH. An increased expression of thromboxane and endothelin-1 (ET-1), both vasoconstrictive
and proliferative mediators, are elevated in both adults and children [69, 74, 75]. However,
besides these two factors, this might also be the case for other vasoactive factors.
Heritable forms of PH are caused by mutations in several genes. Point mutations and deletions
in the bone morphogenetic protein receptor 2 (BMPR2 ) have been identiﬁed in approximately
10-40% of all patients with iPAH and are the major cause of heritable PAH [76]. Both pediatric
and adult patients with BMPR2 mutations appeared to have more severe disease compared to
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Table 2.2: Classiﬁcation of pulmonary hypertension
Pulmonary arterial hypertension
Idiopathic PAH (iPAH)
Heritable PAH
BMPR2
ALK-1, ENG, SMAD9, CAV1, KCNK3
Unknown
Drug- and toxin-induced
Associated with other diseases
Connective tissue disease
HIV infection
Portal hypertension
Congenital heart diseases
Schistosomiasis
Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
Persistent pulmonary hypertension of the newborn (PPHN)
Pulmonary hypertension due to left heart disease
Left ventricular systolic dysfunction
Left ventricular diastolic dysfunction
Valvular disease
Congenital/acquired left heart inﬂow/outﬂow tract obstruction and congenital cardiomyopathies
Pulmonary hypertension due to lung diseases and/or hypoxia
Chronic obstructive pulmonary disease (COPD)
Interstitial lung disease
Other pulmonary diseases with mixed restrictive and obstructive pattern
Sleep-disordered breathing
Alveolar hypoventilation disorders
Chronic exposure to high altitude
Developmental lung diseases
Congenital diaphragmatic hernia (CDH)
Bronchopulmonary dysplasia (BPD)
Alveolar capillary disease (ACD)
Lung hypoplasia
Surfactant protein abnormalities
Pulmonary interstitial glycogenosis
Pulmonary alveolar proteinosis
Pulmonary lymphangiectasia
Chronic thromboembolic pulmonary hypertension (CTEPH)
Pulmonary hypertension with unclear multifactorial mechanisms
Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
Others: tumoral obstruction, ﬁbrosing mediastinitis, chronic renal failure, segmental PH
Adapted from the updated Dana point classification [50]
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Table 2.3: Genes involved in pulmonary hypertension in children
Disease Gene Chromosome Reference
iPAH BMPR2 2q33 [54–56]
ACVRL1 12q13 [55, 56]
ENG 9q34.11 [55]
5HTT 17q11.2 [57]
BMPR1B 4q22.3 [58]
CDH FOG2 8q22.3–23.1 [59]
COUP-TFII 15q26.1–26.2 [60]
STRA6 15q23–25.1 [61]
FREM1 9p22.3 [62]
WT1 11p12–15.1 [63]
ACD FOXF1 16q24.1 [64, 65]
iPAH = idiopathic pulmonary arterial hypertension, CDH = congenital diaphragmatic hernia, ACD =
alveolar capillary dysplasia
those without this mutation [69]. Pfarr et al. found mutations in BMPR2 and two receptors
of the TGFβ/BMP pathway, activin receptor-like kinase 1 (ACVRL1 ) and endoglin (ENG),
in 8/29 (27.6%) of the pediatric iPAH patients [55]. A genetic polymorphism detected in the
serotonin 5-hydroxy tryptamine transporter (5HTT ) gene is associated with iPAH in adults
and might also play a role in iPAH in children. This polymorphism leads to elevated levels
of 5HT and results in increased smooth muscle cell proliferation [57]. Most of the genetic
mutations in iPAH are only studied in adults and in contrast to adults, PAH in children is often
associated with genetic syndromes. However, not all patients with a mutation in the same gene
will develop severe PAH, suggesting that modiﬁers and or epigenetic regulation of expression
could also play a role.
Congenital diaphragmatic hernia
Congenital diaphragmatic hernia (CDH) has an incidence of approximately 1 in 2500-3000
live births. Beside a diaphragmatic defect, CDH is characterized by pulmonary hypoplasia
and PH, which may be due to an altered development of the pulmonary vasculature and a
disordered process of pulmonary vascular remodeling [77, 78]. Previous studies showed excessive
muscularization of the pulmonary arteries and maladaptive pulmonary vascular remodeling in
CDH patients [79, 77, 78, 4, 80] (Figure 2.2). In contrast to the positive eﬀect of inhaled nitric
oxide (iNO) in preterms with PH, the eﬀectiveness of this treatment is only around 30-40% of
patients with CDH.
Over the last years several factors involved in the abnormal pulmonary vascular development
in CDH have been identiﬁed. Expression levels of these factors have been analyzed both in
lung tissue of CDH patients and experimental animal models. We studied the role of the Von
Hippel-Lindau protein (pVHL) and HIF1α and found a decrease of pVHL and HIF1α expression
in the arterial endothelium and an elevated expression of pVHL in the pulmonary arterial media
of human CDH cases compared to age-matched controls [81]. Shehata et al. showed increased
VEGF expression in the bronchial epithelium and medial smooth muscle cells and positive
VEGF staining in endothelial cells, which were negative in age-matched controls [82]. However,
we have found lower expression of VEGF mRNA in the alveolar stage in CDH patients [83]. In
the process of normal remodeling of the pulmonary vasculature, extracellular matrix membrane
proteins (MMPs) are of fundamental importance. Altered expression of certain MMPs and
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Figure 2.2: Characteristic histology of four pulmonary vascular disease samples. Hematoxylin- and eosin-
staining of human lungs: control, alveolar capillary dysplasia (ACD), congenital diaphrag-
matic hernia (CDH), idiopathic pulmonary arterial hypertension (iPAH) and bronchopulmonary
dysplasia (BPD). Scale bars 100 mm. ACD: medial hypertrophy and muscularization (#),
malpositioning of the pulmonary veins (*) and central positioning of the capillaries in the alveolar
septa, CDH: excessive muscularization of the arteries (arrows), iPAH: thickening of the arteries
(arrows), BPD: ﬁbrosis with widening of the alveolar septa.
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tissue inhibitors of MMPs (TIMPs) was found in human CDH lungs compared to controls
[84]. Decreased expression of VEGF and its receptors is also seen in the nitrofen rat model of
CDH [85, 86]. In summary, an increase in pVHL may downregulate HIFα, leading to decreased
expression of VEGF and a disturbance of vascular growth and endothelial cell proliferation
during development. It would be interesting to investigate the oxygen concentration during the
development of the (CDH) lung, to evaluate whether this may contribute, through HIFα, to
the structural changes that contribute to PH.
Abnormal RA signaling contributes to the etiology of CDH, and the ﬁrst evidence of its
involvement in CDH came from observations of pups born to rat dams with vitamin A deﬁcient
diets. In 25-40% of these pups a diaphragmatic hernia was present [87]. This ﬁnding is supported
by the development of a diaphragmatic defect, pulmonary hypoplasia and pulmonary vascular
abnormalities after disruption of the retinoid signaling pathway by nitrofen [88]. Furthermore,
RAR α/β double knock-out mice were found to have oﬀspring with a diaphragmatic hernia
[89]. In addition to the animal models, measurements of the levels of retinol and retinol-binding
protein (RBP) in the ﬁrst hours after birth in human CDH newborns showed a signiﬁcant
reduction compared to matched controls, independent of maternal retinol status [90, 91]. As
described above, Chen et al. showed that lower levels of RA could cause an increase in TGFβ
and a decrease in FGF10 [45]. Increased expression of TGFβ1 with immunostaining at the
midpseudoglandular, late pseudoglandular and saccular stage of lung development is detected
in the nitrofen rat model of CDH [92]. Also increased mRNA levels of TGFβ and TGFβRII
are observed in the same model [93]. Teramoto et al. described a decrease in gene expression of
FGF10 in the nitrofen rat model [94]. Since TGFβ plays a role in the airway branching and
muscularization of the pulmonary vasculature and FGF10 was thought to regulate lung budding
and branching, this might implicate that the neomuscularization and reduced branching in
CDH may be caused by disturbances in the RA-TGFβ-FGF10 interactions.
Over 450 chromosomal aberrations have been reported in CDH [95]. Some of the recurrent
genetic changes are found in retinoid-related genes. In autosomal recessive conditions as Matthew-
Wood syndrome (Microophthalmia syndromic 9 (MCOPS9) or Donnai-Barrow syndrome; OMIM
#222448 mutations in the STRA6 and LRP2 genes have been reported. STRA6 is the membrane
receptor for retinol binding protein (RBP1) and mutations of the LRP2 gene lead to proteinuria
with spillage of retinol-binding proteins. Deletions of COUP-TFII on chromosome 15q26.1-26.2
[60], and of FOG2 (ZFPM2; chromosome 8q23.1) or SOX7 (8p23.1) lead to an autosomal
dominant form of CDH with variable penetrance [96, 97]. Beck et al. showed that a deletion
of the FRAS1-related extracellular matrix 1 (FREM1 ) gene, which encodes an extracellular
matrix protein, can cause CDH in both human and mice [62].
Several CDH animal models have been developed, such as the surgical models in lambs and
rabbits, several knockout models in mice and teratogenic models in rats [88, 98]. Surgical animal
models are useful for the investigation of interventional therapies, but are less informative in
studying the etiology and pathogenesis of CDH [98]. The nitrofen model is the most commonly
used teratogenic model for CDH. When administered to pregnant rat dams at gestational
day 9.5, the herbicide nitrofen (2,4-dichlorophenyl-p-nitrophenyl ether) causes diaphragmatic
defects, lung hypoplasia and PH in pups, strikingly similar to the human condition [99, 98].
Alveolar capillary dysplasia
Alveolar capillary dysplasia (ACD) is a rare lethal developmental lung disorder with failure of
alveolar capillary formation, often accompanied by misalignment of the pulmonary veins. This
results in abnormal gas exchange, severe hypoxemia and PH. The prevalence and incidence
is not known, but the mortality rate approaches 100%. ACD is characterized by premature
growth arrest with immature lobular development, reduced capillary density, thickened alveolar
septa, medial hypertrophy and muscularization of small pulmonary arteries and distal arterioles
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and malposition of pulmonary veins (Figure 2.2). In 50-80% of patients, ACD is associated
with other congenital anomalies. Although at the moment a deﬁnitive diagnose can only be
obtained by histological examination of lung tissue [100], the detection of genetic changes of
the Forkhead Box F1(FOXF1 ) locus on chromosome 16q24 can aid in the diagnosis of ACD.
Mutations of FOXF1 and deletions of the 5’ regulatory region of this transcription factor
gene have been reported in most patients with ACD [65, 64]. FOXF1 deﬁciency is associated
with reduced numbers of pulmonary capillaries in patients with ACD and similar observations
have been made studying Foxf1 heterozygous knockout mice. Conditional deﬁcient Foxf1 mouse
models showed that loss of Foxf1 in the endothelial lineages resulted in an impaired angiogenesis,
endothelial proliferation and VEGF signaling [101]. Involvement of the FOXF1 protein in SHH
signaling has been shown both in vitro and in vivo in human and mice [100, 101, 65]. Mahlapuu
et al. showed that SHH induces the transcriptional activation of Foxf1 [102]. This may imply
that other genes from this pathway are involved in the etiology of ACD. In addition to the
large phenotypic overlap between human ACD and the mouse Foxf1-mutant mice, overlapping
expression proﬁles of lung specimens indicate that the Foxf1 mouse model is an excellent animal
model for ACD.
In addition to the Foxf1 ACD mouse model other knock-out models show similarities to
ACD and may potentially be used to study ACD. For example, the pulmonary phenotype and
associated congenital defects observed in endothelial nitric oxide synthase (eNOS)-deﬁcient mice
are strikingly similar to the pathological features seen in ACD [103]. NO plays a role in the
downstream signaling of angiogenic factors and the regulation of angiogenic gene expression in
the developing lung. Furthermore, mice lacking the phosphatase and tensin homologue deleted
from chromosome 10 (Pten) showed defects in the pulmonary microvasculature similar to those
seen in ACD. Pten inactivation caused increased expression of FGF9, FGF10 and FGF7 and
decreased expression of SHH, PTCH1 and GLI1. They also found a decreased expression of
FOXF1 in these mice [104], which might indicate a role for Pten in the regulation of FOXF1.
As described above, FGF9 signaling, SHH signaling and VEGFa expression in lung mes-
enchyme are required for the pulmonary capillary formation. In an in vitro study in mice it
was observed that FGF9 and SHH regulate each other and the expression of angiogenic factors
such as VEGFa [17]. FGF9 and SHH might play a possible role in the development of ACD.
It is important to improve our knowledge of the pathology of ACD. The discovery of mutations
in the FOXF1 gene locus has been a great improvement in the research on ACD. However not in
all patients with ACD a mutation in this gene locus can be found, indicating that there might
be other genetic or etiological factors involved in the genesis of this disease. Since the HIF1 and
HIF2 complexes are involved in vascular expansion during development of the lung, alterations
in HIF1/HIF2 may play a role in the premature growth arrest and vascular abnormalities in
ACD. However, no altered expression of HIF1α in lungs of human ACD patients has been
observed [105], but other genes in this pathway like HIF2α could play a role.
Bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) is a chronic lung disease associated with preterm newborns
that weigh <1000g and receive respiratory support with mechanical ventilation and/or prolonged
oxygenation [106]. More than 30% of preterm infants born before 30 weeks of gestation develop
BPD and the incidence is still rising [107]. It is characterized by decreased or arrested
alveolarization and pulmonary microvascular development (Figure 2.2). The deﬁnition of BPD
changed over the past 50 years. It was last redeﬁned in 2000 by the National Institute of Child
Health and Human Development (NICHD) [108]. The current deﬁnition is graduated by the
severity of the disease, where mild BPD is deﬁned as the need for supplemental oxygen at ≥28
days but not at 36 weeks of gestation, moderate BPD as the need for supplemental oxygen
at 28 days in addition to supplemental oxygen at ≤30% at 36 weeks of gestation, and severe
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BPD as the need for supplemental oxygen at 28 days and the need for mechanical ventilation
and/or oxygen >30% at 36 weeks of gestation [109]. Since the alveolar and distal vascular
development in premature born infants are still in a crucial state, BPD results from the need
for the lung to develop while continued injury and repair are occurring [109, 110]. The vascular
pathology in BPD shows immature vessels with a dysmorphic structural conﬁguration of the
distal microvasculature and an abnormal distribution of alveolar capillaries with more distance
from the air surface [111]. Just like in CDH, intrapulmonary shunting through precapillary
arteriovenous anastomotic vessels was found in the lungs of patients with severe BPD [112].
This dysmorphic growth and impaired function of the pulmonary vasculature can be caused by
various prenatal and postnatal factors and can result in PH [113].
Mechanical ventilation and oxygen therapy in preterm infants can result in impaired angiogenic
signaling with an increased expression of antiangiogenic genes and a decreased expression of
proangiogenic genes [113]. After short periods of ventilation fewer arteries and endothelial
cells are seen, whereas longer periods of ventilation can cause decreased vessel branches and
increased endothelial cell proliferation [114]. Changes in VEGF expression are observed in
lungs of human BPD patients and in an experimental animal model. Where most of the in
vitro studies in humans and animals showed a decrease in VEGF expression [115–117], one in
vitro study in a baboon model of BPD showed an increase in VEGF protein [118]. Levels of
soluble VEGFR1 (sVEGFR1), an endogenous antagonist of VEGF, were found to be elevated
in amniotic ﬂuid and maternal blood in preeclampsia and intra-amniotic administration of
sVEGFR1 to pregnant rats resulted in pups with blunted alveolarization and reduced lung vessel
density [119, 120]. This implicates a role for preeclampsia by perturbations in VEGF levels
in the development of BPD. During fetal lung development, levels of HIF1α are high and are
important for the expression of VEGF and other angiogenic factors. In premature born children,
levels of HIFα decline rapidly [118], possibly because of the absence of a hypoxic environment
or even because of the use of oxygen therapy. This may cause a decrease in angiogenic factors
resulting in less vascular expansion. Also HIF2α is a regulator of VEGF and is critical for fetal
lung maturation. However, it plays a more important role in the alveolar epithelial cells than in
the vascular cells [121]. We showed earlier that HIF2α is a key regulator in the maturation of
type II pneumocytes and that ectopic expression of an oxygen-insensitive, constitutive active
form of HIF2α leads to a severe surfactant deﬁciency in the newborn [122], which is also seen
in BPD patients. In contrast to the downregulated angiogenic factors found by others, Paepe et
al. found an upregulation of endoglin mRNA and protein levels in ventilated preterm infants.
Endoglin is a hypoxia-inducible TGFβ coreceptor and is an important regulator of angiogenesis.
They speculated that there might be a shift in angiogenic regulators which contributes to the
dysangiogenesis in BPD. Furthermore, the upregulated endoglin possibly modulates vascular
permeability resulting in interstitial edema, which is a morphological feature of early BPD [123].
As such BPD forms an interesting model of postnatal injury and repair showing similarities in
expression proﬁles of a number of transcription factors involved in normal development. This
disease can thus be used to gain knowledge on these processes and can be implemented in our
developmental studies.
Besides the angiogenic factors, there may be a possible role for the retinoid signaling pathway
in the development of BPD. As already shown in CDH, a shortage in vitamin A can disrupt the
retinoid signaling pathway. Preterm infants have low vitamin A levels at birth and supplementing
very low birth weight infants with vitamin A was found to be associated with a reduction
in incidence of BPD [124]. The shortage in vitamin A could possibly be a cause of impaired
pulmonary vascular development and PH in BPD.
Many genes with a putative role in the development of BPD have been investigated in
genotype association studies. These genes have been described in a recent review [125]. Many
of these studies have tested polymorphisms in potential candidate genes such as surfactant
proteins or cytokines but only weak associations implicating susceptibility to the disease have
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been reported [126].
Over the last decades many animal models have been developed to study the impairments in
lung development in BPD. These models are based on hyperoxia, mechanical ventilation and
inﬂammation. Since newborn rodents are born during the saccular stage of lung development,
they are well suited to model BPD. The hyperoxia animal model is most commonly used
and results in acute lung injury, disrupted lung structure and impaired alveolarization and
vascularization, resembling the pathology seen in BPD. However, in contrast to the used
animal models, preterm infants normally receive lower concentrations of oxygen with a lot of
ﬂuctuations, possibly resulting in diﬀerences in molecular signaling. Over the last years animal
models gave us a better insight in the pathogenesis of BPD and resulted in the development
of new therapies [107]. Since HIF1α and its expression of angiogenic factors seem to play an
important role in the development of BPD, this may be a good target for the treatment of
BPD.
Conclusion and future perspectives
Over the past decades, human studies focusing on abnormal pulmonary vascular development
have primarily been descriptive and molecular players have been investigated in archival and
resection material. Human cell cultures have been instrumental in describing molecular pathways
that may contribute to speciﬁc aspects of these congenital anomalies. Although these studies
have been very valuable for generating hypotheses about the origin of congenital pulmonary
diseases, the majority of the studies fail to identify the underlying mechanisms. Human studies
linking molecular mechanisms to diseases remain rare, because the limited number and quality
of human material prevents the initiation of large-scale studies. The combination of human
studies with animal models facilitates the analysis of molecular mechanisms and pathways,
although the diﬀerent animal models only partly reﬂect and phenocopy the human pathology.
For instance, the mouse model for BPD is induced by exposing mice to much higher levels
of oxygen than the levels that are used in the clinical situation. The surgical CDH rabbit
model is suﬃcient to explore surgical techniques, but cannot be used to study the etiology and
pathogenesis of the disease.
The -omics era has opened new ways to generate and analyze large data sets, which facilitated
discovery and characterization of speciﬁc chromosomal locations, SNPs, associated with speciﬁc
diseases by Genome Wide Association Studies (GWAS). However, it remains unclear in the
majority of cases how the identiﬁed loci or SNP are involved in the origin of diseases. In the
near future, it will be interesting to investigate whether these SNPs harbor speciﬁc binding sites
for transcription factors or other DNA associating proteins, like DNA methylases. Alterations
in binding eﬃciency may have a huge impact on downstream processes, such as transcription,
leading to changes in developmental processes. It may also be that these loci SNPs are involved
in spatial and or temporal long-range chromosomal interactions, which may be investigated
with speciﬁc techniques, such as 3C-Seq [127].
Another putative approach is to investigate the interaction network between proteins, which
may identify speciﬁc partners that are involved in developmental processes. Searching for SOX2
binding partners in neural stem cells, we recently showed that SOX2 interacts with CHD7.
Mutations in SOX2 cause Anophthalmia-Esophageal-Genital (AEG) syndrome and mutations
in CDH7 are associated with CHARGE syndrome (Coloboma of the eye, Heart defects, Atresia
of the nasal choanae, Retardation of growth and/or development, Genital and/or urinary
abnormalities, and Ear abnormalities and deafness). AEG and CHARGE have overlapping
clinical features, and disturbing the interaction between SOX2 and CHD7, or other members
of this cascade, may cause a variety of clinical symptoms. Moreover, several genes that are
implicated in related syndromes, like JAG1 (Alagille) and GLI3 (Pallister-Hall), were shown
to be activated by SOX2/CHD7. In addition, we showed that the HMG domain of SOX2 and
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SRY contains a binding site for the nuclear-cytoplasmic shuttling protein Exportin4. Several
mutations have been described in the human SRY gene, which were shown to be involved in XY
sex reversal. These mutations prevented SRY from associating with EXP4, leading to a block
in its translocation to the nucleus and thus its transcriptional activity [128]. So, the study of
protein-protein interactions may provide mechanistic insights in speciﬁc disease.
Aside from (familial) genetic studies, epigenetics has become a major ﬁeld of interest, and
encompasses three classes: chromatin modiﬁcations (DNA methylation), histone modiﬁcations
(methylation, acetylation, phosphorylation) and noncoding RNA molecules (lncRNA, miRNA).
Recently, microRNA-206 (miR-206) was found as a possible triggering factor of early stage
hypoxia-induced PH by targeting the HIF-1α/Fhl-1 pathway [129]. Others have identiﬁed
epigenetic changes in adult patients suﬀering from chronic obstructive pulmonary disease
(COPD), asthma and interstitial lung disease (reviewed by Yang and Schwartz, 2011 [130]),
and it would be interesting to analyze pulmonary vascular diseases with these whole genome
epigenetics techniques to establish the full methyl-Cap-RNA Sequence, miRNA or lncRNA
proﬁles of the congenital pulmonary vascular diseases.
Fetal lung explants have been studied for a long time, and have generated ample evidence
for branching morphogenesis in the developing lung. Human lung explants have been used,
but these cultures also suﬀer from technical limitations [131]. As human samples are very
scarcely available, and mostly derived from end-stage disease, it is mandatory to investigate
alternative ways of setting up culture systems beyond the classical cell culture. Currently,
several emerging 3-D culture systems, such as tracheospheres [132], alveolar spheres [133], lung
organoids [134], decellularized lungs [135], bioartiﬁcial lung [136] and lung on a chip [137, 138],
are being employed to address speciﬁc developmental mechanisms or to optimize systems for
regenerative medicine (for reviews, see Brouwer et al., 2013 [139]; Lancaster and Knoblich,
2014 [140]; Nichols et al., 2014 [141]). Moreover, the generation of hiPS cells has become a
standard technique in most institutes, and the use of patient-speciﬁc cells in combination with
protocols to diﬀerentiate these cells into cells representing the three germ layers has provided new
ways to explore human (pulmonary vascular) diseases [142–147]. Especially the development
and employment of bioartiﬁcial lungs, such as the lung on a chip and related cultures, with
patient derived hiPS cells will contribute signiﬁcantly to the understanding of how diﬀerent cell
layers interact during development and disease. We believe that the use of these systems in
combination with patient-speciﬁc hiPS cells will also beneﬁt the testing of putative therapeutic
agents.
In summary, understanding lung development and the molecular pathways leading to the
mature gas exchanging organ is necessary to decipher the underlying causes of congenital
pulmonary vascular diseases. It is obvious from the above perspectives that the interaction
between diﬀerent scientiﬁc disciplines, such as development, cell science, genetics, bioengineering,
bioinformatics, will be a prerequisite to take the next steps in this process.
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Abstract
Background: Pulmonary hypertension is the major cause of mortality and morbidity in
congenital diaphragmatic hernia (CDH). Mutations in diﬀerent genes of the transforming
growth factor β (TGFβ) and bone morphogenetic protein (BMP) pathways have previously been
described in both adult and pediatric patients with diﬀerent forms of pulmonary hypertension.
Since studies on the activation of these pathways in CDH are scarce and show inconsistent
results, we analyzed the downstream activity of both pathways in the nitrofen-CDH rat model.
Methods and results: Pregnant Sprague-Dawley rats were treated with nitrofen at day 9.5
of gestation (E9.5) to induce CDH in the oﬀspring. At E21 the whole lungs were analyzed at
RNA and protein level for the expression of important factors of both pathways. Subsequently,
we focused on the pulmonary vasculature, which showed increased phosphorylation of the
receptor-regulated Smad2 and decreased phosphorylation of Smad5 in the muscular wall of the
small pulmonary vessels using immunostaining. This was accompanied by increased proliferation
of the smooth muscle layer of these vessels.
Conclusions: We showed increased activation of the TGFβ pathway and decreased activation
of the BMP pathway in combination with increased proliferation in the pulmonary vasculature
of CDH rats, possibly indicating an important role of these pathways in the development of
pulmonary hypertension in this disease.
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Introduction
Congenital diaphragmatic hernia (CDH) is a severe developmental anomaly characterized by a
diaphragmatic defect and a variable extent of bilateral pulmonary hypoplasia and pulmonary
hypertension (PH). The concomitant PH can cause major problems in the newborn and is
responsible for the high mortality and morbidity in these patients. Although the morphology
of the pulmonary vessels is well described and consist of increased muscularization of the
pulmonary vessels in CDH [1], the molecular mechanisms and pathways involved in PH in these
patients are still largely unknown. Mutations in diﬀerent genes involved in the transforming
growth factor β (TGFβ) and bone morphogenetic protein (BMP) pathways have been described
in both adult and pediatric patients with familial, heritable and idiopathic pulmonary arterial
hypertension (PAH). Of these genes the BMP receptor 2 (BMPr2) is most commonly aﬀected
[2].
TGFβ is a negative regulator of airway branching in early lung development. However, TGFβ
signaling is also active in the vascular and airway smooth muscle and alveolar and airway
epithelium during late lung development. Both up- and down-regulation of TGFβ signaling
impairs the alveolarization process [3, 4], depending on a time dependent manner. Both TGFβ
and BMP have shown to inﬂuence proliferation of endothelial and smooth muscle cells and
control apoptosis and extracellular matrix secretion and deposition [5]. Studies on the TGFβ
pathway in CDH failed to show consistent results. Decreased expression of TGFβ1 was found
at mRNA level in the hearts of the nitrofen-CDH rat pups [6], where increased expression of
this factor was shown on immunostaining of the lung in the same animal model [7]. Others
even showed no diﬀerences at all in TGFβ and its activity on the phosphorylation of Smad2/3
in both human samples and the nitrofen-CDH rat model [8]. A study performed in pregnant
women carrying CDH fetuses showed decreased TGFβ in the amniotic ﬂuid, but no diﬀerences
in expression of this factor in the lungs of these children after birth [9]. Both the TGFβ receptor
(TGFβr) 1 and 2 as well as endoglin, an auxiliary receptor of TGFβ, were found to be decreased
in nitrofen-CDH rat pups [10].
In contrast to the TGFβ pathway, results on factors of the BMP pathway in CDH seem to be
more consistent. Reduced expression of BMPr2 [11, 12] and BMP4 [13, 12] were found in the
lungs of diﬀerent animal models of CDH. Furthermore, apelin, a target gene of BMPr2 which
can have a hypotensive eﬀect, has shown to be decreased in nitrofen-CDH rat pups [14] and
activin receptor-like kinase 1 (ALK1), another receptor in this pathway, was upregulated in the
same animal model [15]. However, others did not ﬁnd any diﬀerences in signaling downstream of
the BMPr [16] and so far no mutations were found in the BMPr2 gene in human CDH patients
[17]. Literature data on the TGFβ and BMP pathways in CDH is summarized in Table 3.1 and
an overview of both pathways is displayed in Figure 3.1.
Since most of the research has been done on the receptors in both pathways and not much is
known about the actual activation of these pathways, we analyzed the eﬀect of downstream
signaling in the well-established nitrofen-CDH rat model.
Methods
Animal Model
Pregnant Sprague-Dawley rats received either 100 mg nitrofen dissolved in 1 ml olive oil or just
1 ml olive oil by gavage on gestational age day E9.5. Nitrofen induces CDH in approximately
70% of the oﬀspring, while all pups have pulmonary hypertension [18]. At day E21 pups were
delivered by caesarean section and euthanized by lethal injection of pentobarbital.
All animal experiments were approved by an independent animal ethical committee and
according to national guidelines.
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Table 3.1: Overview of studies in TGFβ in CDH
Factor Animal Human
TGFβ Decreased [6] Decreased [9]
Increased [7] No diﬀerence [8]
No diﬀerence [8]
TGFβ receptor Decreased [10]
BMPr2 Decreased [12] No diﬀerence [17]
Decreased [11]
BMP4 Decreased [13]
Decreased [12]
ALK1 Increased [15]
pSmad 1/5/8 No diﬀerence [16]
Apelin Decreased [14]
Ce
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Figure 3.1: Overview of the TGFβ and BMP pathways. TGFβ = transforming growth factor β,
BMP = bone morphogenetic protein, ZEB2 = zinc ﬁnger E-box binding homeobox 2, P =
phosphorylation.
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Table 3.2: Primer sequences
Gene Sequence (forward 5’- 3’) Sequence (reverse 5’- 3’)
Tgfβ1 AACCAAGGAGACGGAATACAG GACTGATCCCATTGATTTCCA
Tgfβr1 CCATTGGCGGAATCCACGAAGAC CGCAAAGCTGTCAGCCTAGCTG
Tgfβr2 CGTGACACTGTCCACTTGTGAC GACGCACGTGGGAGAAGTGGCATC
Bmp4 CCATCACGAAGAACATCTGG GGATGCTGCTGAGGTTAAAGA
Bmpr1b ATGTGTTTCTGGAGGTATAGTGG CTCATGTCCTCATAAGAAGGGTC
Bmpr2 ATTGAGGGTGGGGTGGTAGT GTGAAACAAGGGTGCTGGTC
Alk1 GTCAAGAAGCCTCCAGCAAC CTCAACTCAGGCTTCGGG
Smad1 TCAATAGAGGAGATGTTCAAGCAGT GAAACCATCCACCAACACGC
Smad2 AGAATACCGGAGGCAGACAG GTTAATACTTTGTCCAACCACTGC
Smad3 GCTGTCTACCAGTTGACTCG TCACTGTCTGTCTCCTGTACTC
Smad4 TCATCCTGCTCCTGAATATTGGT AGTTACAATAGGACAGCTTGAAGG
Smad5 CAATAACAAGAGCCGCTTCTG ATAGATGGACACCTTTCCCG
Smad6 GTCCGATTCTACATTGTCTTACAC TGCTGGCATCTGAGAATTCAC
Smad7 AAACCAACTGCAGACTGTCC AGAAGAAGTTGGGAATCTGAAAGC
Zeb2 CCTATACCTACCCAACGGGA AGCAATTCTCCCTGAAATCCT
Actb AGATGACCCAGATCATGTTTGAG GTACGACCAGAGGCATACAG
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
RNA isolation, cDNA synthesis and subsequent qPCR analysis was performed as previously
[19]. The gene-speciﬁc primers used are listed in 6.2.
Immunohistochemistry and Immunoﬂuorescence Staining
Immunohistochemistry (IHC) was performed on 5 µm paraﬃn sections of lungs of both rats
and humans according to standard protocols, using the EnvisionTM detection system (Dako
Cytomatic, Glostrup, Denmark) [19]. Primary antibody used for IHC was ZEB2 (Sip1; 1:400,
[20]). Primary antibodies used for IF were smooth muscle actin (α-SMA; MS-113-P1; 1:500,
Thermo Scientiﬁc, Fremont, CA, USA), phosphorylated SMAD 2 (pSMAD2; 1:250, Cell
Signaling, Danvers, MA, USA), phosphorylated SMAD 1/5/8 (pSMAD1/5/8; 1:500, Kerafast,
Boston, MA, USA) and Ki-67 (1:100, Abcam, Cambridge, UK). Secondary antibodies against
mouse (α-SMA) and rabbit (pSMAD2, pSMAD1/5/8 and Ki-67) were used. Negative controls
were performed by omitting the primary antibody. Antigen retrieval with Citric Acid buﬀer
(pH 6.0) was used. Negative controls were performed by omitting the primary antibody.
Immunoblotting
Snap frozen lungs were homogenized on ice in Carin buﬀer, containing protease inhibitor
Complete (Roche, Basel, Switzerland). Samples were centrifuged at 14.200 RPM for 15
min and protein concentration in the supernatant was measured using the Bradford method.
Subsequently 50 microgram of protein per lane was loaded on SDS-PAGE and transferred to
nitrocellulose membranes using wetblotting. Blots were labeled with TGFβ (1:1000, Abcam),
pSMAD2 (1:1000, Cell Signaling), SMAD2 (1:1000, Cell Signaling), pSMAD5 (1:1000, Abcam),
SMAD5 (1:1000, Cell Signaling) and Sip1 (1:1000, [20]). Coﬁlin (1:400, Abcam) and β-actin
(1:1000, Cell Signaling) were used for loading control.
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Statistical Analyses
Data are presented as percentages, means (SD) for normally distributed variables. Univariate
analyses were performed using independent samples t-tests for normally distributed variables.
The analyses were performed using SPSS 21.0 for Windows (Armonk, NY, USA: IBM Corp.).
All statistical tests were two-sided and used a signiﬁcance level of 0.05.
Results
TGFβ activation is upregulated in CDH
We ﬁrst checked the expression of important factors in the TGFβ pathway in whole lung
homogenates at mRNA level, which showed an increase in both the Tgfβr1 and Tgfβr2, but
no diﬀerences in the ligand Tgfβ1. Both the receptor-activated Smads, Smad2 and Smad3, as
well as the co-Smad, Smad4, which form together an important complex for the translocation
into the cell nucleus, were increased in CDH (Figure 3.2A). No diﬀerences were found in
expression of the ligand Tgfβ1 at protein level (Figure 3.2B). For the activation of this pathway,
receptor-activated Smads are phosphorylated. The amount of phosphorylation of Smad2 was
not diﬀerent in whole lung homogenates of CDH pups compared to control (Figure 3.2C).
Since the major problems in CDH are based on abnormalities in the pulmonary vasculature,
we focused on changes in the small pulmonary vessels (25-50 µm) using immunoﬂuorescence
staining. This showed an increased number of SMA positive cells in the small vessels of CDH
pups expressing phosphorylated Smad2 (pSmad2), which points to an increased activation of
this pathway in the pulmonary vasculature (Figure 3.2D).
BMP activation is reduced in CDH
In contrast to the TGFβ receptors, we found a decrease in Bmpr1b in CDH and no diﬀerences
in the well-studied Bmpr2 between both groups at mRNA level in whole lung homogenates.
Activin receptor-like kinase 1 (Alk1), another receptor in the BMP/TGFβ pathway, was slightly
increased in CDH. Bmp4, one of the important ligands in this pathway, and the receptor-
activated Smad1 and Smad5 showed an increase in CDH (Figure 3.3A). Western blot on whole
lung homogenates showed a decreased expression of Smad5 in CDH with no diﬀerences in
relative phosphorylation (Figure 3.3B). However, when focusing on the pulmonary vasculature
in detail, the number of SMA positive cells expressing phosphorylated Smad1/5/8 (pSmad158)
Figure 3.2 (following page): TGFβ activation is upregulated in CDH. (A) Quantitative PCR shows a
signiﬁcant increase in Tgfβr1 and Tgfβr2 in CDH (respectively p < 0.001 and
p = 0.033), but no diﬀerence in Tgfβ1. Smad2, Smad3 and Smad4 are all
signiﬁcantly higher in CDH (respectively p = 0.001, p = 0.002 and p = 0.002).
N = 6 for both groups. (B) Western blot on whole lung homogenates shows
no diﬀerences in Tgfβ1 between control and CDH when corrected for total
protein amount, using β-actin as a loading control. N = 5 for both groups.
(C) pSmad2 protein expression related to the total Smad2 protein expression
is not diﬀerent between control and CDH in whole lung homogenates. Coﬁlin
was used as a loading control. N = 5 for both groups. (D) Representative
images of immunoﬂuorescence staining show an increase of pSmad2/Sma
double positive cells in small pulmonary vessels in CDH (p = 0.049). N = 3
samples for both groups. Per sample 6 vessels were counted. Scale bars
represent 10 µm.
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SD.
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was reduced in CDH on immunoﬂuorescence staining, indicating decreased activation of this
pathway in the pulmonary vasculature (Figure 3.3C).
Downstream effects of TGFβ and BMP signaling
Both the TGFβ and BMP pathways can be inhibited by the inhibitory Smads, Smad6 and
Smad7. These proteins compete with Smad4 in the formation of complexes and can therefore
prevent transcription of genes. We found no diﬀerences in expression of Smad6 at mRNA
level, but Smad7 was slightly increased in CDH. Zeb2, a transcriptional corepressor of the
activated pathway, showed an increase in CDH at mRNA level (Figure 3.4A). However, no
signiﬁcant diﬀerences in protein level of ZEB2 were found on western blot using whole lung
homogenates (Figure 3.4B) and no clear changes were seen in expression in the small vessels
with immunohistochemistry staining (Figure 3.4C). Since increased activation of the TGFβ
pathway can induce proliferation of pulmonary artery smooth muscle cells, we checked the
expression of Ki-67, a marker for proliferation. In small pulmonary vessels in CDH more SMA
positive cells expressed Ki-67 (Figure 3.5A,B).
Discussion
In this paper we show the upregulated activation of the TGFβ pathway and downregulated
activation of the BMP pathway in small pulmonary vessels in the nitrofen-CDH rat model.
No diﬀerences were observed in the amount of phosphorylation of the ligand TGFβ1 and both
Smad2 and Smad5 at protein level in whole lung homogenates. Striking is that the total amount
of Smad5 and pSmad5 were both less expressed at protein level in whole lung homogenates
of CDH pups, but no changes were present in the relative phosphorylation in the total lung.
However, the important pulmonary vessels of nitrofen-CDH pups showed increased expression
of pSmad2 and decreased expression of pSmad1/5/8 in the smooth muscle layer speciﬁcally.
Phosphorylation of the receptor-activated Smads is necessary for the activation of downstream
mediators and plays therefore an important role in this pathway. The increased expression of
the inhibitory Smad7 and corepressor Zeb2 at mRNA level might point to increased production
of these inhibitors in order to inhibit the increased activity of the TGFβ pathway. The absence
of changes in Smad6, which only inhibits the BMP pathway, strengthens this idea. However,
the expression of ZEB2 at protein level in whole lungs only showed a trend to increase and
no clear diﬀerences were seen on immunostaining of the pulmonary vessels. Both TGFβ and
BMP can regulate proliferation of the vascular cells and previous studies have shown increased
proliferation of pulmonary artery vascular smooth muscle cells from patients with PAH without
CDH in response to TGFβ1 [21, 22]. We showed increased proliferation of the smooth muscle
layer of small pulmonary vessels in the nitrofen-CDH pups as well, which might indicate an
abnormal response of these cells to the increased TGFβ activity.
TGFβ has found to be a target candidate of retinoic acid (RA) [23]. Increased activity of
the TGFβ pathway with higher levels of pSmad2 has been described in RA deﬁcient foreguts
and a mouse model with RA deﬁciency. In that study lung agenesis was observed both by
decreasing RA levels as well as by increasing TGFβ levels, indicating the interaction between
both pathways early in development [24]. Furthermore, a study in rats with alveolar hypoplasia
caused by caloric restriction showed improvement of the alveolar formation after treatment
with RA, accompanied by a decrease in TGFβ activity at postnatal day 21 [25]. These ﬁndings
strengthen our results of increased TGFβ activity in the nitrofen treated rat model, where
nitrofen has been shown to disrupt the retinoid signaling pathway [26]. Since a reduction
in retinol and retinol binding protein (RBP) has been found in human newborns with CDH
as well [27, 28], the increased activity of the TGFβ pathway might play an important role
Opposite effects of TGFβ and BMP in the pulmonary vasculature of CDH
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Figure 3.3: BMP activation is reduced in CDH. (A) Quantitative PCR shows a signiﬁcantly decreased
expression of Bmpr1b (p = 0.016), no diﬀerences in Bmpr2 and an increased expression of Alk1
(p = 0.003) in CDH. Bmp4, Smad1 and Smad5 are all signiﬁcantly higher in CDH (respectively
p < 0.001, p = 0.009 and p < 0.001). N = 3 (Alk1 and Bmp4) or 6 (rest) for both groups. (B)
pSmad5 protein expression related to the total Smad5 protein expression is not diﬀerent between
control and CDH in whole lung homogenates. Coﬁlin was used as a loading control. N = 5
for both groups. (C) Representative images of immunoﬂuorescence staining show a decrease of
pSmd158/Sma double positive cells in small pulmonary vessels in CDH (p = 0.016). N = 3
samples for both groups. Per sample 6 vessels were counted. Scale bars represent 10 µm.
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SD.
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Figure 3.4: No clear differences in inhibitors of TGFβ in CDH (A) Quantitative PCR shows no difference
in the inhibitory Smad6, but increased expression of inhibitory Smad7 and Zeb2 (respectively
p < 0.001 and p = 0.003). N = 3 (Zeb2) or 6 (rest) per group. (B) Western blot of whole lung
homogenates shows no diﬀerences of Zeb2 between both groups. β-actin was used as a loading
control. N = 5 for both groups. (C) Representative images of immunohistochemistry staining
show no diﬀerences in expression of Zeb2 in the small vessels of all lungs. N = 3 samples for
both groups. Scale bars represent 100µm (low power) and 20µm (high power).
**p < 0.01, ***p < 0.001. Error bars represent SD.
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Figure 3.5: Increased proliferation of the muscular cells in the vessel wall in CDH. Representative images
of immunoﬂuorescence staining show an increase in Ki-67/Sma double positive cells in small
pulmonary vessels in CDH (p = 0.001). N = 3 samples for both groups. Per sample 4 vessels
were counted. Scale bars represent 10µm.
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SD.
in this disease. The previous described involvement of TGFβ and BMP in the proliferation
of pulmonary vascular cells [21, 22] in combination with our results on the relation between
proliferation and TGFβ/BMP activation in the pulmonary vasculature possibly indicate a role
of these pathways in the development of the pulmonary vasculature and pulmonary hypertension
in particular.
The inconsistent results found in the literature on the expression of diﬀerent factors in this
pathway might possibly be explained by the large diﬀerences during gestation. In this study
we found some variability between samples as well, showing that only small diﬀerences in age
might already have large consequences.
In conclusion, we found increased phosphorylation of Smad2 and decreased phosphorylation
of Smad5 in the vessel wall of small pulmonary vessels of nitrofen-CDH pups, indicating an
increased activation of the TGFβ pathway and a decreased activation of the BMP pathway in
the pulmonary vasculature of these animals at day 21 of gestation, possibly leading to increased
proliferation of the muscularized vessel wall. Since the diﬀerent factors in these pathways
are diﬀerently expressed during gestation and might diﬀer from the human situation, further
research has to be done at diﬀerent developmental stages and most importantly in material of
human patients.
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Changes in vasoactive pathways in congenital
diaphragmatic hernia associated pulmonary hypertension
explain unresponsiveness to pharmacotherapy
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Abstract
Background: Patients with congenital diaphragmatic hernia (CDH) have structural and
functional diﬀerent pulmonary vessels, leading to pulmonary hypertension. They often fail to
respond to standard vasodilator therapy targeting the major vasoactive pathways, causing a
high morbidity and mortality. We analyzed whether the expression of crucial members of these
vasoactive pathways could explain the lack of responsiveness to therapy in CDH patients.
Methods: The expression of direct targets of current vasodilator therapy in the endothelin
and prostacyclin pathway was analyzed in human lung specimens of control and CDH patients.
Results: CDH lungs showed increased expression of both ETA and ETB endothelin receptors
and the rate-limiting Endothelin Converting Enzyme (ECE-1), and a decreased expression of
the prostaglandin-I2 receptor (PTGIR). These data were supported by increased expression
of both endothelin receptors and ECE-1, endothelial nitric oxide synthase and PTGIR in the
well-established nitrofen-CDH rodent model.
Conclusions: Together, these data demonstrate aberrant expression of targeted receptors
in the endothelin and prostacyclin pathway in CDH already early during development. The
analysis of this unique patient material may explain why a signiﬁcant number of patients do
not respond to vasodilator therapy. This knowledge could have important implications for the
choice of drugs and the design of future clinical trials internationally.
Vasoactive pathways in congenital diaphragmatic hernia
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Background
Pulmonary hypertension (PH) is the leading cause of morbidity and mortality in patients
with congenital diaphragmatic hernia (CDH) [1]. The altered development of the pulmonary
vasculature and the disordered pulmonary vascular remodeling [2] in combination with the
imbalance of vasoactive mediators caused by endothelial dysfunction result in the arrest of
pulmonary vascular growth in these patients. Current treatment of CDH patients is not evidence
based [3] and is derived from studies in adults, leading mainly to oﬀ-label and unlicensed use of
drugs. Current knowledge is based on compassionate use and case reports, while some patients
with CDH were included in trials that were underpowered for deﬁnitive conclusions. Even
international therapy guidelines are based on consensus only (level 3 evidence) [4]. In 2012,
experts evaluated the current antenatal and postnatal management of CDH and emphasized the
importance of optimal management of PH in these patients [5]. Worldwide, PH treatment is
mainly directed against the receptors of the endothelin (ET) and prostacyclin (PGI2) pathways
or the conversion of cyclic guanosine monophosphate (cGMP) in the nitric oxide (NO) pathway
(Figure 4.1A). In spite of these targeted treatments, it is still largely unknown how the diﬀerent
components of these pathways are expressed in lungs of unaﬀected individuals and CDH patients.
Previous studies reported increased levels of both the endothelin A (ETA) and B (ETB)
receptors in human CDH as well as in the nitrofen rat model [6, 7]. Endothelin-1 (ET-1) is a
potent vasoconstrictor [8] and is increased in lung tissue of patients with pulmonary hypertension.
Moreover, high plasma levels of circulating ET-1 associated with the severity of PH in human
CDH [9]. NO reduces the aﬃnity of the ETA receptor for ET-1 and may therefore terminate
the ET-1 mediated signaling [10]. NO is synthesized by diﬀerent NO synthases (NOS), of
which endothelial NOS (eNOS) was decreased in some human and rat CDH studies [11–13].
However, we and others showed no diﬀerences or even an increased expression of eNOS in both
human and rat CDH [14–17]. PGI2 is an important mediator of vasodilation, acting through
the prostaglandin-I2 receptor (PTGIR) [18]. Several prostacyclin receptor agonists have been
used in the treatment of persistent pulmonary hypertension of the newborn with variable eﬀects
[19–21]. Limited data are available about the use of these drugs in patients with CDH, but the
few case reports show contrasting results [22–24]. An overview of the current data for human
and the rat model is provided (Table 4.1 and 4.2).
Since CDH patients respond poorly to current treatment strategies, we analyzed for the ﬁrst
time the expression of the direct targets of the most commonly used vasodilator drugs, as well
as some of the important members of all three major pathways. Using unique patient lung
material, we show an increased expression of both endothelin receptors and the rate-limiting
endothelin converting enzyme (ECE-1), as well as a decreased expression of the prostaglandin-I2
receptor in human CDH. Moreover, we found changes in the expression of these and other
important factors of the pathways in rat CDH (Figure 4.1B).
Methods
Human Lung Samples
Human lung samples were retrieved from the archives of the Department of Pathology of
the Erasmus Medical Center, Rotterdam. In our high-volume, leading center of the EURO
consortium [4], approximately 15 to 20 CDH patients a year are born, which ensures a large
experience in the treatment of this disease. Paraﬃn-embedded lung samples, which did not
show severe hemorrhage or necrosis, were selected of control and CDH patients and of patients
with lung hypoplasia or pulmonary hypertension with other cause than CDH. Only the most
extreme cases of left-sided CDH with a survival of less than 7 hours were selected to prevent
secondary sequelae. Patient characteristics are described in Table 4.3.
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Figure 4.1: Pathways in vasodilation and vasoconstriction Overview of the major pathways involved in
vasodilation and vasoconstriction (A) and the aberrant expression in both human and rat
congenital diaphragmatic hernia (CDH) (B).
Solid arrows represent up- or downregulation in human CDH, dashed arrows represent up- or
downregulation in rat CDH. ECE-1 = endothelin converting enzyme 1, ETA = endothelin A, ETB
= endothelin B, eNOS = endothelial nitric oxide synthase, sGC = soluble guanylate cyclase, COX
= cyclooxygenase, PGIS = prostaglandin synthase, PGI2 = prostaglandin-I2, AC = adenylate
cyclase, TBXAS1 = thromboxane synthase, TXA2 = thromboxane.
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Table 4.1: Overview of studies in human CDH
Our group Others
Increased expression of ETA and ETB (protein
level), Increased expression of ECE-1 (protein level)
Increased ET-1 (plasma levels and protein level)
[25], Increased ET-1 (plasma levels) [9], Increased
expression of ETA and ETB (RNA and protein
level) [6]
No diﬀerences in eNOS expression [15] Increased expression of eNOS in arteriolar endothe-
lium and alveolar epithelium (protein level) [16],
No diﬀerences in eNOS expression (protein level)
[12], Decreased expression of eNOS (protein and
RNA level) [13]
Decreased expression of Ptgir (protein level) No information about prostaglandin-I2
Table 4.2: Overview of studies in experimental rat CDH
Our group Others
Increased expression of ETA (RNA and protein
level) and ETB (RNA level), Increased expression
of ECE-1 (RNA level)
Increased expression of ETA and ETB (RNA and
protein level) [7], Increased expression of ET-1
after 1 and 6 hours of ventilation (RNA level) [17],
Increased response of arterioles to ET-1 [26]
Increased expression of eNOS (RNA and protein
level)
Increased expression of eNOS (RNA and protein
level) [14], Increased expression of eNOS after 1
hour of ventilation (RNA level) [17], Decreased
expression of eNOS (RNA and protein level) [11]
Increased expression of Ptgir (RNA level) and
decreased expression of Tbxas1 (RNA level)
Increased levels of prostaglandin-I2 and an in-
creased ratio of prostaglandin-I2 and thromboxane
(protein level) [27]
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Table 4.3: Patient characteristics
Disease GA Sex Age of death Cause of death
Control 18+0 Male - Abortion
24+6 Female Minutes Prematurity
26+5 Female 1 hour Prematurity
33+0 Male Minutes Developmental delay
38+3 Male Minutes Asphyxia
38+5 Male 1.5 hours Anencephaly
40+0 Female 18 hours Asphyxia
CDH 17+6 Male - Abortion
21+4 Male - Abortion
36+2 Male Some hours Respiratory failure
36+2 Female Some hours Respiratory failure
37+2 Male 7 hours Respiratory failure
38+0 Male 2 hours Respiratory failure
40+0 Female Some hours Respiratory failure
LH 22+3 Male - Abortion
28+5 Female 15 minutes Respiratory failure
41+0 Male 30 minutes Respiratory failure
PH 34+3 Female 4 days PPHN
37+1 Male 4 days Respiratory failure
GA = gestational age (weeks + days), CDH = congenital diaphragmatic hernia, LH = lung hypoplasia,
PH = pulmonary hypertension, PPHN = persistent pulmonary hypertension of the newborn.
Animal Model
The well-established animal model was used, where in short pregnant Sprague-Dawley rats
received either 100 mg nitrofen dissolved in 1 ml olive oil or just 1 ml olive oil by gavage on
gestational age day E9.5. Nitrofen induces left-sided CDH in approximately 70% of the oﬀspring,
while all pups have pulmonary hypertension. At day E21 pups were delivered by caesarean
section and euthanized by lethal injection of pentobarbital.
All animal experiments were approved by an independent animal ethical committee and
according to national guidelines.
Immunohistochemistry and Immunoﬂuorescence Staining
Immunohistochemistry (IHC) was performed on 5 µm paraﬃn sections of lungs of both rats
and humans according to standard protocols, using the EnvisionTM detection system (Dako
Cytomatic, Glostrup, Denmark) [28]. Primary antibodies used for IHC were Endothelin receptor
A (ETA; 1:5000 (rat) 1:100 (human); Alamone, Jerusalem, Israel), Endothelin receptor B (ETB;
1:2500 (rat) 1:500 (human); Alamone), Endothelin Converting Enzyme (ECE-1; 1:500 (human);
Abcam, Cambridge, MA, USA), endothelial nitric oxide synthase (eNOS; 1:400 (rat); Thermo
Fisher Scientiﬁc, Waltham, MA, USA) and prostaglandin-I2 receptor (Ptgir; 1:1000 (rat) 1:500
(human); Cayman Chemical, Ann Arbor, Michigan, USA). Antigen retrieval with Tris-EDTA
buﬀer (pH 9.0) was used. Negative controls were performed by omitting the primary antibody.
Vasoactive pathways in congenital diaphragmatic hernia
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Table 4.4: Primer sequences
Gene Sequence (forward 5’- 3’) Sequence (reverse 5’- 3’)
Eta AACCTGGCAACCATGAACTC ATGAGGCTTTTGGACTGGTG
Etb CAGGATTCTGAAGCTCACCCTTT TCCAAAACCAGCAAAAAACTCA
Et-1 TGTGCTCACCAAAAAGACAAGAA GGTACTTTGGGCTCGGAGTTC
Ece-1 GCAAGAACATAGCCAGCGAG CTCCGAGTATCTTCATCCATCC
eNos CATACTTGAGGATGTGGCTG CCACGTTAATTTCCACTGCT
Sma TGACCCAGATTATGTTTGAGAC AGAGTCCAGCACAATACCAG
Ptgis CATCAAACAGTTTGTGGTCCT CAAAGCCATATCTGCTAAGGT
Ptgir CACGAGAGGATGAAGTTTACCA AATCCTCTGATCGTGAGAGGC
Tbxas1 AGACTCAGGTTCCACTTCAG TCACACCTGCCTTCTATGTC
Tbxa2r ACTGTGAGGTGGAGATGATGG CAGGATGAAGACCAGCAAGG
Actb AGATGACCCAGATCATGTTTGAG GTACGACCAGAGGCATACAG
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
RNA isolation of whole lungs of rat pups, cDNA synthesis and subsequent qPCR analysis was
performed as previously described [28]. The gene-speciﬁc primers used are listed in Table 4.4.
Actb was used as housekeeping gene.
Statistical Analyses
Data are presented as percentages, means (SD) for normally distributed variables. Univariate
analyses were performed using independent samples t-tests for normally distributed variables.
The analyses were performed using SPSS 21.0 for Windows (Armonk, NY, USA: IBM Corp.).
All statistical tests were two-sided and used a signiﬁcance level of 0.05.
Results
In order to identify a possible explanation for the unresponsiveness of CDH patients to diﬀerent
vasodilator therapies, the expression of receptors which are currently targeted during treatment
as well as other critical factors of the diﬀerent vasoactive pathways were analyzed. Therefore, a
unique set of lungs from CDH patients were used and these data were veriﬁed using the more
dynamical nitrofen rat model.
Human
Since current treatment is, besides the use of inhaled NO (iNO), based on targeting the
receptors in both the prostacyclin and endothelin pathway, we started by analyzing the
expression of the critical proteins of both pathways in human lungs of control and CDH
patients. Previously, we and others already showed no apparent diﬀerences in the NO pathway
[12, 15]. Immunohistochemistry was used to determine the expression pattern of the receptors in
lung samples of CDH patients and age-matched controls. Human control lung samples showed
little expression of the main target of the prostacyclin therapy, the important prostacyclin
receptor PTGIR, in the fetal period, which sharply increased later during gestation at the
preterm and term age (Figure 4.2A). However this signiﬁcant increase was absent in CDH
(Figure 4.2B). The ETA receptor, which induces vasoconstriction and cell proliferation, was
expressed in the small (25-50 µm) and larger (> 50µm) vessels as well as in the very small
capillaries < 25µm) in CDH, contrasting the control lungs in which only the small and larger
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Figure 4.2: Suppressed progression of prostaglandin-I2 receptors during gestation in human CDH
Representative images show progressive expression of PTGIR in the vessels during gestation
in human control patients (A). In human CDH patients there is only progression to a lesser
extent (B).
Scale bars represent 20µm. Patients: GA 18+0, 33+0 and 38+0 (control), GA 21+4, 36+2
and 37+2 (CDH).
vessels expressed this receptor (Arrowheads in Figure 4.3A,B). The ETB receptor, involved
in vasodilation through the release of NO and PGI2 (Figure 4.1), was expressed both in the
bronchial epithelium and in some of the larger vessels (> 50µm) in CDH (Arrowheads in Figure
4.3A,B), whereas in control lungs expression of ETB was found only in the bronchial epithelium
(Figure 4.3B). Since ECE-1, a membrane-bound metalloprotease that converts big-endothelin
into the biologically active compound, is the rate-limiting factor in the ET pathway, we analyzed
this enzyme as well in the human samples. Early during gestation, in the fetal period, ECE-1
is minimally expressed in the vessels of the human control lung samples, with an increase
at preterm and term age (Figure 4.3C). Increased expression of this enzyme at both fetal,
preterm and term age was observed in CDH (Figure 4.3D), indicating a potential increased
bio-availability of active ET-1.
To exclude that the diﬀerences in expression patterns of the crucial prostacyclin and endothelin
receptors and the rate-limiting factor ECE-1 was solely an eﬀect of lung hypoplasia (LH) or PH,
we performed immunohistochemistry on lungs of patients with LH and PH with other cause
than CDH. The PTGIR receptor expression was reduced in both LH and PH (Figure 4.4A).
Increased expression of ETA was detected in the smallest vessels in lungs of both LH and PH
(Arrowheads in Figure 4.4B), whereas increased expression of ETB was only observed in both
small and very small vessels of lungs of PH patients (Arrowheads in Figure 4.4C). ECE-1 was
not expressed diﬀerently in both LH and PH lung samples (Figure 4.4D).
Rat
In order to validate these interesting human data, we evaluated the expression patterns of the
proteins of these three pathways in the nitrofen rat model, which was supplemented with RNA
and protein expression analysis of related factors. Real-time qPCR showed that the mRNA
expression of both the Eta and Etb receptors was signiﬁcantly higher in lungs of E21 pups with
CDH compared to those of control pups. We also analyzed the expression of the ETA and
ETB ligand, Et-1, but no signiﬁcant diﬀerences were found between the groups. However, the
mRNA encoding the rate-limiting factor Ece-1 was signiﬁcantly increased in CDH compared to
control, conﬁrming the human data (Figure 4.5A). Next, we analyzed the protein expression
pattern of the ET receptors with immunohistochemistry. The ETA receptor was expressed
Vasoactive pathways in congenital diaphragmatic hernia
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Figure 4.3: Increased expression of both the ETA and ETB receptor and endothelin converting enzyme in
human CDH. Representative images show expression of the ETA receptor in the larger vessels
and no expression of ETB in control (A), where there is increased expression of ETA in the
smaller vessels in CDH patients and expression of the ETB receptor in some of the vessels
in CDH (B). ECE-1 is progressively expressed in the vessels in human control patients during
gestation (C), where this expression is decreased in CDH patients at both fetal, preterm and
term age (D).
Arrows indicate vessels, A indicates airways. Scale bars represent 100 µm (low power) and 20
µm (high power). Patients: GA 38+3 (control), GA 38+0 and 37+2 (CDH) (A+B). Patients:
GA 18+0, 26+5 and 38+0 (control), GA 21+4, 36+2 and 37+2 (CDH) (C+D).
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Figure 4.4: Expression of prostaglandin and endothelin factors in human LH and PH patients Represen-
tative images show decreased expression of PTGIR in both patients with LH and PH (A). The
expression of ETA is increased in the smaller vessels of patients with lung hypoplasia (LH) and
pulmonary hypertension (PH) with other cause than CDH (B) and the expression of ETB is
only increased in the vessels of patients with PH (C). ECE-1 is not diﬀerently expressed in the
vessels both LH and PH lung samples (D).
Scale bars represent 20 µm. Arrows indicate very small vessels. Patients: GA 38+3 (control),
GA 41+0 (LH), GA 34+3 (PH).
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in the small capillaries of both groups at E15 until E21 with a stronger expression level in
CDH (Figure 4.5B). At E21 only CDH lungs showed expression of the ETA receptor in the
larger vessels (> 50µm) (Arrowheads in Figure 4.5C). The ETB receptor was expressed in the
bronchial epithelium of all lungs without signiﬁcant diﬀerences between control and CDH at all
ages (Figure 4.5D-E). There was a signiﬁcant higher mRNA expression of eNos in CDH rats
compared to control in relation to all cells as well as in relation to only the smooth muscles
cells (Figure 4.6A) or endothelial cells (data not shown). This increased expression was clearly
detectable with immunostaining in the larger and smaller (< 50µm) vessels at E21 (Arrowheads
in Figure 4.6B). However, no obvious diﬀerences were noted earlier during development (E15 till
E19) (Figure 4.6C). Although there was no diﬀerence in expression of prostaglandin-I2 synthase
(Ptgis) between control and CDH rat pups, there was a slight increase in the expression of
Ptgir and the prostaglandin-E1 receptor (Ptger1 ) in CDH at the mRNA level in both the whole
lung as well as compared to the number of smooth muscle cells. In contrast, thromboxane
synthase (Tbxas1 ), a contractile ligand in the prostanoid pathway, was clearly lower expressed in
CDH, whereas the thromboxane receptor (Tbxa2r) did not show signiﬁcant diﬀerences (Figure
4.7A). However immunostaining showed no clear diﬀerences in the vessels between both groups
(Arrowheads in Figure 4.7B).
Discussion
This is the ﬁrst study showing the aberrant expression of diﬀerent important factors in the
endothelin, NO and PGI2 pathways all combined together in CDH patients (Figure 4.1B) and
human patients with LH or PH with other cause, possibly explaining why a large number of
patients do not respond to the current vasodilator therapy. We focused our research on direct
targets of the most frequent used drugs to investigate the eﬀectiveness of the current approach
and combined this with the analysis of some key factors of the diﬀerent pathways.
Since our unique human CDH material is scarce and a limiting factor, because only specimens
of newborns who lived for a short period were analyzed to prevent secondary morphological
changes, supplemental analyses were done on lung tissue of the dynamical nitrofen rat model.
In line with previous results in both human and rat studies, we found a signiﬁcant increased
expression of the ETA and ETB receptor, important targets of vasodilator therapy, in human
CDH patients and the nitrofen rat model [6, 7, 29]. However, we are the ﬁrst to show an
increased expression of the crucial ECE-1 enzyme in both human pulmonary vessels of CDH
patients and whole lung homogenates of nitrofen treated rat pups. ECE-1 converts big ET-1 into
the active form of ET-1 and is the rate-limiting step in the production of ET-1 [30]. Although
there was no apparent diﬀerence in total ET-1 in CDH pups, the higher expression of ECE-1 in
lungs of CDH pups may lead to an increase in the active form of ET-1.
In contrast to other studies [11–13, 29], we found an increased expression of eNOS in CDH
rats. The increased eNOS expression in CDH may be explained by activation of eNOS because
of the decreased NO availability, or the process of eNOS uncoupling. In case of decreased
bioavailability of the cofactor tetrahydrobiopterin (BH4), eNOS produces superoxide instead of
NO [31]. This superoxide leads to oxidative stress, which has been observed in vessels of patients
with PH [32]. The enhanced activation of the ETA receptor might lead to the increase in
superoxide production through the induction of reactive oxygen species (ROS) and can thereby
induce SMC proliferation and vasoconstriction. Thus, eNOS uncoupling leads to a reduction
in NO bioavailability without a necessary change in the amount of eNOS [31]. Previously, we
showed a slight increase in expression of the cGMP-speciﬁc phosphodiesterase 5 (Pde5) in
nitrofen treated rat pups. However, no diﬀerences were found in its phosphorylation or its
downstream targets, protein kinase G1 (Prkg1) and Prkg2 [33].
The increased expression of PTGIR in control lungs during gestation could be expected since
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Figure 4.5: Upregulation of ET-receptors in CDH rat pups. RNA expression of the ETA receptor (Eta)
and ETB receptor (Etb) shows a signiﬁcant increase in rat CDH pups (p < 0.001 and p < 0.05,
respectively). RNA expression of ET-1 shows no diﬀerences between control and CDH, where
Ece-1 is signiﬁcantly increased (p < 0.05) (A). Representative images show increased expression
of the ETA receptor in the parenchyma of CDH pups at all ages during development (E15-E21)
(B) and in the larger vessels at E21 (C). Representative images show expression of the ETB
receptor in only the bronchial epithelium in both control and CDH pups at all ages during
development (E15-E21) (D,E).
*p < 0.05, ***p < 0.001. Error bars represent SD. Arrows indicate vessels, A indicates airways.
Scale bars represent 100µm (low power) and 20µm (high power).
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Figure 4.6: eNOS expression is increased at the end of gestation in CDH rat pups. RNA expression of
eNOS is increased in rat CDH in all cells (p < 0.01) and in the smooth muscle cells (Sma) only
(p < 0.001) (A). Representative images show increased expression of eNOS in the vessels of
CDH pups at E21 (B), but not at other ages during gestation (C).
**p < 0.01, ***p < 0.001. Error bars represent SD. Arrows indicate vessels, A indicates airways.
Scale bars represent 100µm (low power) and 20µm (high power) (B) and 50µm (C).
it has been shown that the placental PGI2 increases gradually toward term [34]. The decreased
expression in CDH could be a sign of less activation of this pathway. In contrast to our human
results, we found no diﬀerences in the expression of Ptgir in CDH rat pups and an increase
of this receptor on mRNA level. Since PGI2 is a potent vasodilator and thromboxane A2
(TXA2) a potent vasoconstrictor, the increased expression of Ptgir and decreased expression of
Tbxas1 was unexpected. However, this aberrant balance between PGI2 and TXA2 in CDH was
already previously described by our group [27]. We showed an increased level of 6-keto-PGF1α,
the stable metabolite of PGI2, and an increased ratio of 6-keto-PGF1α and TXA2 in both
lung homogenates and broncho-alveolar lavage (BAL) ﬂuid of nitrofen treated rat pups. The
discrepancy between the increased mRNA expression of Ptgir in CDH lungs and the absence of
diﬀerences at the protein level, may be explained by a negative feedback because of a decreased
activation of downstream targets of prostacyclin signaling. This may lead to an enhanced
degradation of the Ptgir, or a decreased translation of the mRNA.
Current treatment of CDH patients with PH is not evidence based [3] and most patients
respond poorly to the used medication. Inhaled NO (iNO) is most commonly used as a ﬁrst line
drug, but its use varies signiﬁcantly among diﬀerent centers internationally [35]. In contrast to
the promising results of iNO in patients with persistent pulmonary hypertension of the newborn
[36], in CDH studies have failed to show its eﬃcacy [35, 37], as no trials have been performed
to evaluate the potential role of iNO speciﬁcally in CDH patients. Apart from iNO therapy
there are some case reports on the use of sildenaﬁl and prostacyclins in CDH patients with
variable results [23, 24, 38, 39]. However, administration of enteral sildenaﬁl in neonates leads to
highly variable plasma concentrations because of variable gut absorption and/or limited hepatic
clearance [40]. The recent availability of intravenous sildenaﬁl may change its application [41],
but solid pharmacokinetic data on optimal dosage are still to be published. Treatment with
endothelin receptor antagonists is even a bigger problem since these drugs are only available in
oral form, while data of its use in newborns are virtually absent concerning dosage absorption
and safety. The fact that the current therapy should be considered mainly as ”trial and error”
and is eﬀective in the minority of patients with CDH strengthens our results that there are
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Figure 4.7: Prostacyclin expression in rat pups. RNA expression of the prostaglandin-I synthase (Ptgis)
did not show any diﬀerences between control and CDH rat pups, but there was a signiﬁcant
increased expression of the prostaglandin-I2 receptor (Ptgir) (p < 0.001) and the prostaglandin-
E1 receptor (Ptger1) (p < 0.01) in CDH rat pups. In contrast, thromboxane synthase (Tbxas1)
was signiﬁcantly decreased in CDH (p < 0.01) with no diﬀerences in the thromboxane receptor
(Tbxa2r) (A). Representative images do not show clear diﬀerences of PTGIR expression in the
pulmonary vessels between both groups (B).
**p < 0.01, ***p < 0.001. Error bars represent SD. Arrows indicate vessels, A indicates airways.
Scale bars represent 100µm (low power) and 20µm (high power).
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more pathways aﬀected. Furthermore, the severity of PH in CDH patients has been known as
an important predictor of the outcome and further evaluation of current therapies has been
recommended by experts in the ﬁeld [5]. Future treatment should become more personalized in
this group of patients using pathway directed clinical trials and risk stratiﬁcation [42].
Ideally, we would like to be able to directly correlate the ﬁndings of aberrant expression of
the diﬀerent vasoactive pathways with the individual response of patients to speciﬁc vasoactive
drugs. However, given the overall limitations of these types of studies and the lack of material of
patients who did respond to one of the three therapies, this remains impossible as repeated lung
biopsies would be needed to accomplish this. This approach is unethical for obvious reasons
and no IRB would ever approve such an approach.
In conclusion, our study shows the aberrant expression of speciﬁc vasodilator drug targets and
crucial, rate-limiting factors in human CDH and the nitrofen rat model in both the endothelin,
NO and PGI2 pathway already early during development. Since PH is still a major problem
and the most important cause of morbidity and mortality in CDH patients nowadays while
current treatment strategies are disappointing, a good insight in these pathways is needed for
speciﬁc and patient directed targeting of pharmacotherapy.
Acknowledgements
This study was supported in part by the Sophia Foundation for Medical Research grant number
678.
70
∣
∣ Chapter 4
References
[1] Lally KP. Congenital diaphragmatic hernia - the past 25 (or so) years. J Pediatr Surg.
2016;51(5):695–8.
[2] Sluiter I, Reiss I, et al. Vascular abnormalities in human newborns with pulmonary hypertension.
Expert Rev Respir Med. 2011;5(2):245–56.
[3] Puligandla PS, Grabowski J, et al. Management of congenital diaphragmatic hernia: A systematic
review from the APSA outcomes and evidence based practice committee. J Pediatr Surg.
2015;50(11):1958–70.
[4] Snoek KG, Reiss IK, et al. Standardized Postnatal Management of Infants with Congenital
Diaphragmatic Hernia in Europe: The CDH EURO Consortium Consensus - 2015 Update.
Neonatology. 2016;110(1):66–74.
[5] Kotecha S, Barbato A, et al. Congenital diaphragmatic hernia. Eur Respir J. 2012;39(4):820–9.
[6] de Lagausie P, de Buys-Roessingh A, et al. Endothelin receptor expression in human lungs of
newborns with congenital diaphragmatic hernia. J Pathol. 2005;205(1):112–8.
[7] Dingemann J, Doi T, et al. Upregulation of endothelin receptors A and B in the nitrofen induced
hypoplastic lung occurs early in gestation. Pediatr Surg Int. 2010;26(1):65–9.
[8] Davenport AP, Hyndman KA, et al. Endothelin. Pharmacol Rev. 2016;68(2):357–418.
[9] Keller RL, Tacy TA, et al. Congenital diaphragmatic hernia: endothelin-1, pulmonary hyperten-
sion, and disease severity. Am J Respir Crit Care Med. 2010;182(4):555–61.
[10] Michael JR, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med. 1996;154(3
Pt 1):555–81.
[11] North AJ, Moya FR, et al. Pulmonary endothelial nitric oxide synthase gene expression is decreased
in a rat model of congenital diaphragmatic hernia. Am J Respir Cell Mol Biol. 1995;13(6):676–82.
[12] Shehata SM, Sharma HS, et al. Pulmonary hypertension in human newborns with congenital
diaphragmatic hernia is associated with decreased vascular expression of nitric-oxide synthase.
Cell Biochem Biophys. 2006;44(1):147–55.
[13] Solari V, Piotrowska AP, et al. Expression of heme oxygenase-1 and endothelial nitric oxide
synthase in the lung of newborns with congenital diaphragmatic hernia and persistent pulmonary
hypertension. J Pediatr Surg. 2003;38(5):808–13.
[14] Hofmann A, Gosemann JH, et al. Imbalance of caveolin-1 and eNOS expression in the pulmonary
vasculature of experimental diaphragmatic hernia. Birth Defects Res B Dev Reprod Toxicol.
2014;101(4):341–6.
[15] de Rooij JD, Hosgor M, et al. Expression of angiogenesis-related factors in lungs of patients with
congenital diaphragmatic hernia and pulmonary hypoplasia of other causes. Pediatr Dev Pathol.
2004;7(5):468–77.
[16] Sood BG, Wykes S, et al. Expression of eNOS in the lungs of neonates with pulmonary
hypertension. Exp Mol Pathol. 2011;90(1):9–12.
[17] Shinkai T, Shima H, et al. Expression of vasoactive mediators during mechanical ventilation in
nitrofen-induced diaphragmatic hernia in rats. Pediatr Surg Int. 2005;21(3):143–7.
[18] Gao Y, Raj JU. Regulation of the pulmonary circulation in the fetus and newborn. Physiol Rev.
2010;90(4):1291–335.
[19] De Jaegere AP, van den Anker JN. Endotracheal instillation of prostacyclin in preterm infants
with persistent pulmonary hypertension. Eur Respir J. 1998;12(4):932–4.
[20] Kelly LK, Porta NF, et al. Inhaled prostacyclin for term infants with persistent pulmonary
hypertension refractory to inhaled nitric oxide. J Pediatr. 2002;141(6):830–2.
[21] Sood BG, Delaney-Black V, et al. Aerosolized PGE1: a selective pulmonary vasodilator in
neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial. Pediatr
Res. 2004;56(4):579–85.
[22] De Luca D, Zecca E, et al. Transient eﬀect of epoprostenol and sildenaﬁl combined with iNO for
pulmonary hypertension in congenital diaphragmatic hernia. Paediatr Anaesth. 2006;16(5):597–8.
[23] Olson E, Lusk LA, et al. Short-Term Treprostinil Use in Infants with Congenital Diaphragmatic
Hernia following Repair. J Pediatr. 2015;167(3):762–4.
[24] Skarda DE, Yoder BA, et al. Epoprostenol Does Not Aﬀect Mortality in Neonates with Congenital
Vasoactive pathways in congenital diaphragmatic hernia
∣
∣ 71
C
h
a
p
te
r
4
Diaphragmatic Hernia. Eur J Pediatr Surg. 2015;25(5):454–9.
[25] Kobayashi H, Puri P. Plasma endothelin levels in congenital diaphragmatic hernia. J Pediatr Surg.
1994;29(9):1258–61.
[26] Coppola CP, Au-Fliegner M, et al. Endothelin-1 pulmonary vasoconstriction in rats with
diaphragmatic hernia. J Surg Res. 1998;76(1):74–8.
[27] Ijsselstijn H, Zijlstra FJ, et al. Lung eicosanoids in perinatal rats with congenital diaphragmatic
hernia. Mediators Inﬂamm. 1997;6(1):39–45.
[28] Rajatapiti P, van der Horst IW, et al. Expression of hypoxia-inducible factors in normal human
lung development. Pediatr Dev Pathol. 2008;11(3):193–9.
[29] Makanga M, Maruyama H, et al. Prevention of pulmonary hypoplasia and pulmonary vascular
remodeling by antenatal simvastatin treatment in nitrofen-induced congenital diaphragmatic
hernia. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L672–82.
[30] Kuruppu S, Smith AI. Endothelin Converting Enzyme-1 phosphorylation and traﬃcking. FEBS
Lett. 2012;586(16):2212–7.
[31] Roe ND, Ren J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases.
Vascul Pharmacol. 2012;57(5-6):168–72.
[32] Bowers R, Cool C, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit
Care Med. 2004;169(6):764–9.
[33] Mous DS, Kool HM, et al. Clinically relevant timing of antenatal sildenaﬁl treatment reduces
pulmonary vascular remodeling in congenital diaphragmatic hernia. Am J Physiol Lung Cell Mol
Physiol. 2016;311(4):L734–L742.
[34] Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids.
2004;70(2):223–32.
[35] Putnam LR, Tsao K, et al. Evaluation of Variability in Inhaled Nitric Oxide Use and Pulmonary
Hypertension in Patients With Congenital Diaphragmatic Hernia. JAMA Pediatr. 2016;.
[36] Roberts J J D, Fineman JR, et al. Inhaled nitric oxide and persistent pulmonary hypertension of
the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336(9):605–10.
[37] Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia.
The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics. 1997;99(6):838–45.
[38] Bialkowski A, Moenkemeyer F, et al. Intravenous sildenaﬁl in the management of pulmonary
hypertension associated with congenital diaphragmatic hernia. Eur J Pediatr Surg. 2015;25(2):171–
6.
[39] Noori S, Friedlich P, et al. Cardiovascular eﬀects of sildenaﬁl in neonates and infants with
congenital diaphragmatic hernia and pulmonary hypertension. Neonatology. 2007;91(2):92–100.
[40] Ahsman MJ, Witjes BC, et al. Sildenaﬁl exposure in neonates with pulmonary hypertension after
administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed. 2010;95(2):F109–14.
[41] Steinhorn RH, Kinsella JP, et al. Intravenous sildenaﬁl in the treatment of neonates with persistent
pulmonary hypertension. J Pediatr. 2009;155(6):841–847 e1.
[42] Akinkuotu AC, Cruz SM, et al. Risk-stratiﬁcation of severity for infants with CDH: Prenatal
versus postnatal predictors of outcome. J Pediatr Surg. 2016;51(1):44–8.

Chapter 5
Clinical relevant timing of antenatal sildenafil treatment
reduces pulmonary vascular remodeling in congenital
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Abstract
Patients with congenital diaphragmatic hernia (CDH) suﬀer from severe pulmonary hypertension
due to altered development of the pulmonary vasculature, which is often resistant to vasodilator
therapy. Current treatment starts postnatally even though signiﬁcant diﬀerences in the
pulmonary vasculature are already present early during pregnancy. We examined the eﬀects
of prenatal treatment with the phosphodiesterase-5 inhibitor sildenaﬁl on pulmonary vascular
development in experimental CDH starting at a clinical relevant time. The well-established,
nitrofen induced CDH rodent model was treated daily with 100 mg/kg sildenaﬁl from day
17.5 until day 20.5 of gestation (E17.5-20.5). Importantly, this timing perfectly corresponds to
the developmental stage of the lung at 20 weeks of human gestation, when CDH is detectable
by 2D-ultrasonography and/or MRI. At E21.5 pups were delivered by caesarean section and
euthanized by lethal injection of pentobarbital. The lungs were isolated and subsequently
analyzed using immunostaining, real-time PCR and volume measurements. Prenatal treatment
with sildenaﬁl improved lung morphology and attenuated vascular remodeling with reduced
muscularization of the smaller vessels. Pulmonary vascular volume was not aﬀected by sildenaﬁl
treatment. We show that prenatal treatment with sildenaﬁl within a clinically relevant period
improves pulmonary vascular development in an experimental CDH model. This may have
important implications for the management of this disease and related pulmonary vascular
diseases in human.
Prenatal sildenafil improves pulmonary vasculature
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Introduction
Congenital diaphragmatic hernia (CDH) is a developmental defect characterized by an incomplete
diaphragm and lung hypoplasia [1]. CDH patients have a high risk of mortality and morbidity
due to the associated pulmonary hypertension, which is the result of altered development of the
pulmonary vasculature and disordered pulmonary vascular remodeling [2–4]. Advancement in
medicine has resulted in early detection of CDH by ultrasonography at 20 weeks of gestation,
but the severity of clinical symptoms postnatally remains poorly predictable at this stage due
to signiﬁcant diﬀerences in pulmonary vascular resistance and ﬂow after birth. In addition, the
pulmonary hypertension in CDH is often unaﬀected by standard vasodilator therapy and the
lack of randomized controlled trials prevents the implementation of alternative drugs. Trials
with Nitric Oxide (NO), one of the most commonly used drugs in newborns, failed to show
consistently positive eﬀects in CDH patients [5]. The impaired responsiveness to NO may be due
to rapid degradation of the intracellular messenger cyclic guanosine monophosphate (cGMP) by
phosphodiesterase-5 (PDE5) [6]. Binding of cGMP to PDE5 stimulates the phosphorylation and
activation of PDE5 by cGMP dependent protein kinase G (PKG), which results in the conversion
of cGMP into GMP [7]. Sildenaﬁl is a potent PDE5 inhibitor, leading to an accumulation of
cGMP and thus the continuous activation of PKG. PKG has several physiological substrates,
which are involved in smooth muscle cell (SMC) relaxation by lowering intracellular calcium [8, 9].
Sildenaﬁl also reduces inﬂammation, improves early postnatal survival and prevents pulmonary
vascular remodeling in diﬀerent experimental animal models of pulmonary hypertension without
CDH [10–12] and prolongs survival and improves lung structure in a neonatal hyperoxia rat
model [13]. It has been successfully used in the postnatal treatment of persistent pulmonary
hypertension of the newborn (PPHN) [14–19] and pulmonary hypertension in patients with
congenital heart disease [20]. There are no randomized controlled trials of sildenaﬁl in CDH
patients, but there are case reports showing positive eﬀects after postnatal treatment [21, 22].
Previously, we showed thickening of the smooth muscle cell layer in arterioles, neomuscularization
of small capillaries and phenotypic changes of the smooth muscle cells in the vascular wall
in lungs of CDH patients at 30 weeks of gestation, indicating that signiﬁcant diﬀerences in
vascular structure are already present in unborn children that will develop PH after birth [23].
The premature diﬀerentiation of vascular smooth muscle cells and the early structural changes
in pulmonary vascular development suggest that antenatal treatment of CDH patients could
be beneﬁcial. Recently, Luong et al. showed a reduced pathology in experimental CDH after
prolonged antenatal treatment with sildenaﬁl [24]. However, they started the daily treatment
with sildenaﬁl already at day 10.5 of gestation, when the lung bud is just emerging from the
primitive foregut. At this embryonic phase of lung development there are no signs of CDH
pathology, yet. Therefore, it is unclear whether the prophylactic treatment prevented the
development of pathological features, or that the sildenaﬁl indeed regressed the clinical signs.
Since human CDH can be diagnosed at 20 weeks of gestation, the canalicular phase of lung
development, we analyzed the therapeutic eﬀects of sildenaﬁl in the nitrofen induced rat CDH
model starting at the corresponding gestational age (E17.5). In rat, the CDH pathology is
already noticeable from E13.5 on with a defective diaphragm and aﬀected lungs [25–29]. We
show that starting the treatment of the CDH rat model with sildenaﬁl at the clinical relevant
time point improved lung morphology and attenuated or reversed the vascular remodeling of
the smaller vessels. These ﬁndings may directly be valuable for future treatment modalities of
severe CDH patients.
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Methods
Animal Model
Pregnant Sprague-Dawley rats received either 100 mg nitrofen dissolved in 1 ml olive oil or just
1 ml olive oil by gavage on gestational age day E9.5. Nitrofen induces CDH in approximately
70% of the oﬀspring, while all pups have pulmonary hypertension. Administration of nitrofen at
exactly this time point results in mainly left sided hernias [30]. Pregnant rats were divided into
4 groups: control, nitrofen (CDH), control+sildenaﬁl and nitrofen+sildenaﬁl (CDH + sildenaﬁl).
Sildenaﬁl (100 mg/kg/day, Pﬁzer, New York, USA) dissolved in water was administered via oral
gavage for 4 consecutive days from day E17.5 to day E20.5. At day E21 pups were delivered by
caesarean section and euthanized by lethal injection of pentobarbital. All animal experiments
were approved by an independent animal ethical committee and according to national guidelines.
Plasma Sildenafil Concentration
Maternal and fetal rat blood samples were collected directly after caesarian section. Fetal blood
samples were pooled, and plasma (50 µl) from 6 maternal and 9 fetal samples was isolated
by centrifugation (10.000 RPM, 15 minutes) and sildenaﬁl and its metabolite N-desmethyl-
sildenaﬁl (DMS) concentrations were analyzed using ultra-performance liquid chromatography
with tandem mass spectrometry (UPLC-MS/MS).
Lung Morphology
Fetal rat lungs were isolated, ﬁxed overnight in 4% PFA and embedded in paraﬃn. Serial 5 µm
thick sections were made through the middle of the left lobe and stained with haematoxylin and
eosin (HE). Sections were imaged at 40x magniﬁcation using a BX41 research stereomicroscope
system (Olympus; Tokyo, Japan). Four non-overlapping images in diﬀerent parts of each lung
were acquired. Major airways and vessels were excluded from the analysis. The airspace size
was automatically quantiﬁed using an index (D2-score) that is based on the alveolar airspace
diameter and takes into account the ﬁrst three central moments of the airspace size distribution.
This measurement is designed to account for airspaces of diﬀerent sizes by assigning them
diﬀerent weights. Compared to the well-known mean linear intercept (Lm), this method is more
reliable in the presence of a large variability in airspace sizes [31, 32].
Immunohistochemistry and Immunofluorescence Staining
Immunohistochemistry (IHC) was performed on 5 µm paraﬃn sections of the lungs according to
standard protocols, using the Envision detection system (Dako Cytomatic, Glostrup, Denmark)
[33]. Primary antibodies used for IHC were smooth muscle actin (α-SMA; MS-113-P1; 1:1200,
Thermo Scientiﬁc, Fremont, CA, USA), phosphodiesterase-5 (PDE5A; PD5A-101AP; 1:300,
Fabgennix, Frisco, TX, USA) and phosphorylated phosphodiesterase-5 (phospho-PDE5; PPD5-
140AP; 1:100, Fabgennix). Antigen retrieval with Tris-EDTA buﬀer (pH 9.0) was used for
α-SMA. Primary antibodies used for immunoﬂuorescence (IF) staining on 5 µm paraﬃn sections
were smooth muscle actin (α-SMA; MS-113-P1; 1:500, Thermo Scientiﬁc), smooth muscle actin
(clone 1a4) (α-SMA direct labelled FITC; 1:200, Sigma, The Netherlands) and platelet derived
growth factor β (PDGFrβ; 1:100). Secondary antibodies against mouse (α-SMA) and rabbit
(PDGFrβ) were used. Negative controls were performed by omitting the primary antibody.
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Table 5.1: Primer sequences
Gene Sequence (forward 5’–3’) Sequence (reverse 5’–3’)
Pde5 TCAACAACGGATAGCAGAACTC CCCTGTTCATTAGATCAGCGG
Prkg1 AACTATGCAGGGACAACCCA CCTTCCCAGTTAAAGCCCTC
Prkg2 ACTAGGCATTATCTACAGAGACC TCCAAAGTCAACCAACTTAAGG
Sma TGACCCAGATTATGTTTGAGAC AGAGTCCAGCACAATACCAG
Pdgfr-β AACGACCAGTTCTACAATGCC CATGATCTCATAGATCTCGTCGG
Pecam-1 GCAGTCCCACTTCTGAACTC GTTCTGGGAGTCGTAATGGC
Actb AGATGACCCAGATCATGTTTGAG GTACGACCAGAGGCATACAG
Hprt AGACTGAAGAGCTACTGTAATGAC CAACAATCAAGACGTTCTTTCCAG
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
RNA isolation, cDNA synthesis and subsequent qPCR analysis was performed as previously
described [33]. The gene-speciﬁc primers were custom designed using PerlPrimer 1.1.21 [34]
and all sequences were blasted using Ensembl (RLS 84) [35]. The primer combinations for the
qPCR reactions are listed in Table 6.2. Both Actb and Hprt were used as housekeeping genes
and all represented data are based on Actb.
Volume Measurements Pulmonary Vascularity
Lungs of pups were perfused through the right ventricle with Microﬁl contrast agent (Microﬁl,
Flow Tech; Carver, MA, USA) and imaged with a micro Computed Tomography (micro-CT)
scanner (Quantum FX, PerkinElmer; Waltham, MA, USA; pixel size 10-295 µm). Subsequently,
the images were analyzed with the I-Space (Barco, Kortrijk, Belgium), a CAVETM-like Virtual
Reality system in which 3D holograms can be viewed with depth perception by wearing a pair
of stereo glasses with polarizing lenses. Volumes were calculated by semi-automatic region
growing using the V-Scope volume-rendering software (Department of Bioinformatics, Erasmus
MC, Rotterdam, The Netherlands) as previously described [36, 37]. Volume of the pulmonary
vasculature was measured in relation to the total lung volume. Results obtained with the
I-Space were validated using Analyze Direct software (Kansas City, US).
Statistical Analyses
Data are presented as percentages, means (SD) and univariate analyses were performed using
two-way ANOVA tests for normally distributed variables. The analyses were performed using
SPSS 21.0 for Windows (Armonk, NY, USA: IBM Corp.). All statistical tests were two-sided
and used a signiﬁcance level of 0.05.
Results
Sildenaﬁl Eﬀectively Crosses the Placental Barrier
In order to investigate potential eﬀects of oral sildenaﬁl on fetuses, we ﬁrst analyzed the levels
of sildenaﬁl and its major metabolite N-desmethyl-sildenaﬁl (DMS) in blood plasma of the
mothers and pups approximately 24 hours after the last dose of sildenaﬁl. These measurements
showed that the oral application facilitated eﬃcient uptake of sildenaﬁl in the bloodstream and
subsequent passage through the placental barrier into the fetal circulation (Table 5.2, Figure
5.1A).
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Table 5.2: Plasma level of sildenaﬁl and N-desmehtyl-sildenaﬁl (DMS)
Mothers Pups
Sildenaﬁl (ng/ml) DMS (ng/ml) Sildenaﬁl (ng/ml) DMS (ng/ml)
7.00 14.30 15.00 1.80
1.60 4.40 19.80 1.60
1.30 2.70 4.60 1.50
2.70 3.70 4.70 1.90
0.90 2.80 13.20 1.40
1.30 10.80 7.70 0.90
5.00 1.20
6.70 3.10
5.20 1.70
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Figure 5.1: Eﬀects of maternal sildenaﬁl on pups. (A) Levels of sildenaﬁl and its metabolite desmethyl-
sildenaﬁl (DMS) measured in plasma of mother rats and her fetuses indicate eﬀective placental
passage of sildenaﬁl, median (IQR), n = 6 (mothers), n = 9 (pups). (B) The incidence of CDH
is not aﬀected by sildenaﬁl treatment (63% vs 59%, p = 0.665); n = 5 for all groups. (C)
Bodyweight is decreased in pups with CDH (3.0 gr vs 3.8 gr, p < 0.001), which is reversed by
treatment with sildenaﬁl (3.5 gr, p < 0.001). Sildenaﬁl also caused an increase in bodyweight in
control pups (4.0 gr, p < 0.05); n = 13 (control), n = 23 (CDH), n = 16 (control + sildenaﬁl),
n = 24 (CDH + sildenaﬁl). (D) LW/KW is decreased in CDH (3.0 vs 4.4, p < 0.001), and
slightly improves after sildenaﬁl treatment in CDH (3.5, p < 0.001). Sildenaﬁl caused a decrease
in the ratio in controls (3.9, p < 0.001); n = 33 (control), n = 38 (CDH), n = 23 (control +
sildenaﬁl), n = 28 (CDH + sildenaﬁl).
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent standard error (SD). LW Lung
Weight, KW Kidney Weight.
Prenatal sildenafil improves pulmonary vasculature
∣
∣ 79
C
h
a
p
te
r
5
Since the administration of sildenaﬁl to the rats was started late in gestation after the
development of the diaphragm, we did not observe a reduction in the incidence of CDH after
treatment (Figure 5.1B). The eﬀect of sildenaﬁl on the general development of the fetuses
was analyzed by assessing the body weight. Fetuses of nitrofen treated mothers (CDH) had a
signiﬁcantly lower body weight compared to control at E21.5, but antenatal treatment with
sildenaﬁl resulted in a signiﬁcant increase in body weight in control and CDH fetuses (Figure
5.1C). The lung weight-to-kidney weight ratio (LW/KW) was used as an indicator for lung
hypoplasia, since the kidney weight is less aﬀected by treatment with sildenaﬁl than the body
weight. This LW/KW ratio was signiﬁcantly reduced in CDH fetuses compared to control,
indicating severe lung hypoplasia in the CDH fetuses. Antenatal sildenaﬁl treatment reduced
the hypoplasia as indicated by the signiﬁcant improvement of the LW/KW ratio in CDH fetuses.
However, sildenaﬁl induced a mild hypoplasia in control fetuses (Figure 5.1D).
Sildenaﬁl inhibits PDE5, so we analyzed if sildenaﬁl had an eﬀect on the expression of its
target. RNA expression of Pde5 was increased in fetal CDH lungs, but sildenaﬁl did not reduce
this elevated expression. In addition, the downstream targets of Pde5, Prkg1 and Prkg2, were
not aﬀected in any of the groups (Figure 5.2A). Since we did not ﬁnd diﬀerences in expression
level, we analyzed the distribution of Pde5 in the lungs of the fetuses. The expression pattern of
Pde5 was primarily in the very large (> 100µm) vessels in some of the control samples, but this
pattern was expanded in the CDH lungs to a number of small (< 50µm) and larger (50−100µm)
vessels (Figure 5.2B). Remarkably, treatment with sildenaﬁl resulted in a reduction of the
number of Pde5 positive vessels in CDH, and the staining pattern was comparable to control
lungs, being primarily around some of the larger vessels. The activated, phosphorylated Pde5
was detected in part of both small and larger vessels of all samples with no clear diﬀerences
between all groups.
Sildenafil Improves Lung Morphology and Attenuates Pulmonary Vascular
Remodeling in CDH
We analyzed the histology of the lungs of the diﬀerent treated pups, which clearly showed
diﬀerences in cellular density of the lung structure, with thicker septa and smaller alveolar
airspaces in CDH (Figure 5.3A). The alveolar airspace diameter (D2-score) was used to quantify
the alveolar airspaces. Both alveolar density and the number of alveoli were signiﬁcantly
increased in CDH rats compared to control and returned to normal after treatment with
sildenaﬁl (Figure 5.3B,C).
We and others have previously shown that the nitrofen rat model phenocopies the vascular
defects observed in human CDH patients with increased muscularization of the arterioles [23].
To analyze whether nitrofen and/or sildenaﬁl would aﬀect the development of the vascular tree,
we measured the total pulmonary vascular volume. Three dimensional volume measurements
done in the I-Space showed a signiﬁcant decrease in total lung volume (LV), in pulmonary
vascular volume (PVV) and in the ratio of PVV to LV in CDH fetuses compared to controls.
We observed no signiﬁcant improvement of the vascular volume in CDH fetuses treated with
sildenaﬁl, but antenatal sildenaﬁl decreased pulmonary vascular volume and PVV/LV in control
fetuses (Table 5.3, Figure 5.4A,B). This indicates that starting sildenaﬁl treatment at a clinical
relevant time point did not improve the vascular tree.
Previously, we showed a thickening of the smooth muscle cell layer in small capillaries in rats
with PH [38], and a more extensive peripheral distribution of contractile vascular smooth muscle
cells in human CDH [23]. Based on these results, we analyzed gene and protein expression
of several vascular-associated markers to study the eﬀects of sildenaﬁl treatment on vascular
remodeling. Gene expression analysis of α-Smooth Muscle Actin (α-Sma) and Platelet-Derived
Growth Factor receptor β (Pdgfr-β, pericyte marker) in relation to endothelial cells (Pecam-
1/CD31) showed a signiﬁcant increase of Pdgfr-β in CDH lungs compared to control, indicative
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Figure 5.2: Expression of phosphodiesterase-5 (Pde5) in the lungs of rat fetuses. (A) Expression of Pde5,
Prkg1 and Prkg2 RNA show no signiﬁcant diﬀerences. For all groups 6 independent lung samples
were used. Error bars represent SE. (B) Representative images of immunohistochemistry staining
show expression of Pde5 around the vessels of CDH lungs (top) and phosphorylated Pde5around
the vessels in all groups (bottom). Arrows indicate vessels, A indicates airways. Scale bars
represent 20 µm. For all groups 3 independent lung samples were used.
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Figure 5.3: Prenatal sildenaﬁl improves alveolar development in CDH. (A) Representative images of HE
stained sections show a signiﬁcant decreased mean alveolar airspace diameter in CDH rats
compared to control. Scale bars represent 50µm. (B) Quantiﬁcation of alveolar development
in control and CDH using the D2-score (49.3µm (7.8) and 25.9 µm (2.2), respectively, p =
0.002). Sildenaﬁl clearly showed an increase in alveolar airspace diameter in CDH (52.9µm
(17.6), p = 0.001), taking into account the D2-score (in µm) that incorporates the ﬁrst three
central moments of airspace distribution. (C) The number of alveoli is signiﬁcantly increased in
CDH (p = 0.003), while treatment with sildenaﬁl reverted the alveolar abnormality to normal
(p = 0.001). For all groups 4 non-overlapping images were used of 5 independent lung samples.
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SD.
for an increase of diﬀerentiating perivascular cells in the CDH lungs. Treatment with sildenaﬁl
signiﬁcantly reduced these markers, suggesting a restoration of normal pulmonary vascular
development. However, the expression of Pdgfr-β did not revert completely to the control
levels (Figure 5.5A,B). Analysis of the distribution pattern showed an increased thickening of
the α-Sma+ smooth muscle cell layer in small pulmonary vessels (< 50µm) in CDH fetuses.
Sildenaﬁl treatment reduced this thickening of the media in CDH lungs, corresponding with
the RNA expression data. Remarkably, sildenaﬁl slightly increased the media in control rats
(Figure 5.5C,D).
Immunoﬂuorescence staining of control lungs showed expression of α-Sma almost exclusively
in the media of the large vessels and in the subepithelial layer of the airways, and a peripheral,
parenchymal staining of Pdgfr-β (Figure 5.6). Interestingly, α-Sma and Pdgfr-β co-localized
around the smallest vessels in CDH lungs, most likely staining diﬀerentiating perivascular
cells. Thus, in contrast to control lungs, the small capillaries are muscularized in CDH fetuses.
Table 5.3: Pulmonary vasculature volume in rat fetuses
Control (n = 7) CDH (n = 5) Control + sildenaﬁl
(n = 9)
CDH + sildenaﬁl
(n = 8)
Lung volume mm3 (SD) 134.0 (22.8) 95.2 (22.3)* 110.4 (22.8) 93.4 (8.3)***
Vasculature volume mm3 (SD) 11.3 (3.3) 4.8 (2.3)** 6.9 (3.1)* 3.6 (0.5)***
Ratio vasculature/lung 0.084 (0.019) 0.048 (0.019)** 0.060 (0.017)* 0.039 (0.005)***
Results are shown as mean (SD). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control.
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Figure 5.4: Sildenafil does not affect vasculature volume. (A) Representative images of computed
tomography scans of microﬁl-injected pulmonary vessels analyzed with the I-Space. Scale bars
represent 2 mm. (B) The ratio of the pulmonary vasculature volume to total lung volume is
signiﬁcantly decreased in CDH rats (0.048 vs 0.084, p = 0.001) and control rats treated with
sildenaﬁl (0.060, p = 0.005); n = 7 (control), n = 5 (CDH), n = 9 (control + sildenaﬁl), n = 8
(CDH + sildenaﬁl).
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SD.
Sildenaﬁl treatment of CDH fetuses resulted in a reversion of the staining pattern of α-Sma
and Pdgfr-β to the control situation, indicating that sildenaﬁl may reduce the pulmonary
hypertension. This would suggest a beneﬁcial eﬀect of sildenaﬁl on reducing the pulmonary
hypertension at the cellular level (Figure 5.6).
Discussion
Our study shows that antenatal treatment of CDH pups with the PDE5 inhibitor sildenaﬁl
starting at the clinical relevant time point results in reduced lung hypoplasia and reduced
vascular abnormalities. Administration of sildenaﬁl was started at the canalicular stage of
lung development in the rat, which corresponds with the time point when human CDH can be
detected by routine ultrasound at 20 weeks of gestation. The diaphragm of the rat is already
formed and the major pulmonary vessels are already developed at the time the administration
of sildenaﬁl was started. Therefore we did not observe a reduction in the incidence of CDH or
an improvement of the pulmonary vascular volume in the major branches of the vascular tree.
However, sildenaﬁl improved the body weight and LW/KW ratio, indicating a better lung growth
development compared to untreated CDH pups. Furthermore, the alveolar airspaces increased
in diameter, which could be related to the formation of the primary and secondary septa later
in prenatal lung development. Moreover, sildenaﬁl reduced the thickening of the smooth muscle
cell layer in arterioles normally present in CDH, and prevented the frequently observed aberrant
diﬀerentiation of pericytes in CDH as indicated by the loss of the co-localization of α-Sma and
Pdgfr-β in capillaries [23, 38].
In this study we proved the placental crossing of sildenaﬁl into the fetal circulation with
higher levels of plasma sildenaﬁl and lower levels of plasma DMS in the pups compared to the
mother. Sildenaﬁl is known to be catalyzed by hepatic CYP3A4 and CYP2C9. Prenatal and
early postnatal CYP-mediated N-demethylation is less prominent compared to adults, which
causes less clearance of sildenaﬁl. This reduced clearance in fetuses results in a longer terminal
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Figure 5.5: Sildenafil decreases pathological muscularization in CDH. (A) RNA expression of smooth
muscle actin (Sma) in relation to platelet endothelial cell adhesion molecule (Pecam1) shows no
signiﬁcant changes between the groups. (B) RNA expression of platelet derived growth factor
β (Pdgfr-β) in relation to Pecam1 shows a signiﬁcant increase in CDH (p < 0.001), which is
slightly improved after treatment with sildenaﬁl (p = 0.009). (C,D) Representative images of
immunohistochemistry staining (C) and quantitation (D) show increased expression of Sma and
a signiﬁcant thickening of the vessel wall of small pulmonary vessels (<50 µm) in CDH (12.96
µm vs 6.55 µm, p < 0.001), which is completely reversed by antenatal treatment with sildenaﬁl
in CDH (6.91 µm, p < 0.001) and thickened in control (9.21 µm, p = 0.030). Arrows indicate
vessels, A indicates airways. Scale bars represent 20 µm. For all groups 15 to 20 vessels of 3
independent lung samples were measured.
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SD.
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Figure 5.6: Abnormal smooth muscle cells surround arterioles in CDH. Representative immunoﬂuorescence
staining images of all 4 groups show colocalization of Sma (red) and platelet derived growth
factor β (Pdgfr-β; green) in the parenchyma of CDH lungs. Arrowheads indicate examples of
capillaries with colocalization, A indicates airways, V indicates vessels. Scale bars represent 20
µm.
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half-life [39]. The dose of sildenaﬁl chosen for this study was 100 mg/kg/d, which was based on
a previous study on the pharmacokinetics of sildenaﬁl in rats. Since the metabolism in rats is
tremendously faster than in human, this dose is a lot higher than the normal dose used in the
clinical setting. Although the oral bioavailability of sildenaﬁl in female rats is only 44%, which
is comparable to humans (38%), it remains the preferred method over other methods keeping
in mind the potential translation to a clinical application [40].
Luong et al had previously shown that antenatal sildenaﬁl crosses the placenta without
aﬀecting the PDE5-expressing organs of the pups in the nitrofen-rat model. Consistent with
our study, they show improvement in lung structure in the nitrofen-induced rat model after
antenatal sildenaﬁl. However, Luong et al treated rats for 10 days, starting already at day
10.5 of gestation, which is only one day after the start of lung development in rats and can
therefore be seen as prophylactic [24]. Furthermore, an increase in the number of arterioles [41],
a decrease in vascular remodeling [42], a decrease in medial wall thickness and improvement in
alveolar density [43] and improvement in pulmonary vascular response and lung growth [44] were
shown after antenatal treatment with sildenaﬁl of diﬀerent duration in the nitrofen rat model.
Improvement in parenchymal and lung abnormalities after antenatal sildenaﬁl was shown in
a rabbit model of CDH [45] and in a lamb model, downregulation of eNOS was shown to be
normalized after antenatal treatment with tadalaﬁl, another PDE-5 inhibitor [46]. However, the
treatment strategies in all these studies were already initiated very early during pregnancy, at a
time when human CDH would not yet be detectable and before CDH symptoms and pathology
develop. A summary of the relevant sildenaﬁl studies in the nitrofen rat model is shown in
Table 5.4.
We found that sildenaﬁl caused a decreased LW/KW ratio, increased muscularization of the
arterioles and decreased pulmonary vascular volume in healthy control rats, contrasting the
earlier results of Luong et al. This diﬀerence may be caused by several diﬀerent aspects. First
of all, the oral treatment may provide a sudden increase of sildenaﬁl in the plasma, which is not
achieved by the more steady delivery by subcutaneous treatment. Secondly, our treatment may
be more eﬃcient than the treatment by Luong et al. Thirdly, the long treatment of animals with
sildenaﬁl may induce some kind of adaptation to sildenaﬁl which reduces its eﬀects. Diﬀerences
in lung structure in control rats and rabbits treated with sildenaﬁl were also reported by Luong
et al [24] and Russo et al [45]. The pathophysiology of these side-eﬀects is still not clear, but
might involve the increase in cGMP after PDE-5 inhibition, since increased cGMP can also
lead to toxicity and interfere with normal cellular proliferation [47]. Extreme vasodilation
caused by increased cGMP might also have a deleterious eﬀect on the development of the
pulmonary vasculature. However, sildenaﬁl has been used as a treatment for preeclampsia in
pregnant women with no signiﬁcant adverse eﬀects in both mother and fetus during follow up
of 30 days post-delivery [48]. Furthermore, recently a trial has started for the antenatal use of
sildenaﬁl in pregnancies complicated by early-onset extreme fetal growth restriction (STRIDER;
NCT02277132 (clinicaltrials.gov)) [49].
In the present study we focused on pulmonary vascular development, since pulmonary
hypertension in CDH is the major cause of morbidity and mortality. The major strength of this
study is the timing of the sildenaﬁl treatment at day 17.5 of gestation, which corresponds to 20
weeks of gestation in human pregnancy, when CDH is detectable by routine ultrasound in many
countries. Sildenaﬁl has never been tested in a clinical trial as an antenatal treatment to target
the pulmonary vascular growth. However, the possibility of prenatal diagnosis of CDH oﬀers a
unique opportunity to treat fetuses antenatally. So far, sildenaﬁl is only used postnatally as a
treatment for severe pulmonary hypertension and in some of the most severe CDH patients
who are resistant to current therapies, in an attempt to prevent extracorporeal membrane
oxygenation (ECMO). Therefore, it is not possible to directly compare the pathological changes
seen in these patients with the eﬀects of the antenatal sildenaﬁl treatment in the CDH rat
model.
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Table 5.4: Overview of studies with antenatal sildenaﬁl treatment in the nitrofen rat model
Our study Luong et al [24] Kattan et al
[41]
Lemus-Varela et
al [42]
Yamamoto et al
[44]
100 mg/kg 100 mg/kg 45 mg/kg 100 mg/kg 100 mg/kg
oral 24h subcutaneous
24h
oral 12h oral 24h subcutaneous
24h
E17.5 – E20.5 E10.5 – E20.5 E14 – E22 E16 – E20 E11.5 – E20.5
Fetal body weight CDH signiﬁcantly
decreased
signiﬁcantly
decreased
CDHsil signiﬁcant
improvement
no improvement
Lung weight CDH decreased
lung/kidney
weight
decreased
lung/body
weight
decreased
lung/body
weight
CDHsil signiﬁcant
improvement
no improvement signiﬁcant
improvement
Cosil decreased
lung/kidney
weight
no signiﬁcant
diﬀerences
Morphology CDH decreased
alveolar
airspaces
increased mean
linear intercept
decreased
alveolar
airspaces
decreased
alveolar
airspaces
CDHsil signiﬁcant
improvement
signiﬁcant
improvement
no improvement signiﬁcant
improvement
Cosil No signiﬁcant
diﬀerences
no signiﬁcant
diﬀerences
Vasculature CDH decreased
vascular volume
less pulmonary
vessels
less arterioles
CDHsil No improvement signiﬁcant
improvement
signiﬁcant
improvement
Cosil decreased
vascular volume
less pulmonary
vessels
Vessel wall CDH increased SMC§
layer
no signiﬁcant
diﬀerences
increased SMC§
layer
CDHsil signiﬁcant
improvement
no signiﬁcant
diﬀerences
signiﬁcant
improvement
Cosil increased SMC§
layer
no signiﬁcant
diﬀerences
§ SMC = smooth muscle cell
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The potential to treat CDH already antenatally might be a big improvement in the manage-
ment of this disease in humans. So far the approach for antenatal modulation of the severity of
pulmonary hypoplasia is through mechanical interference with pulmonary ﬂuid drainage. To
this eﬀect antenatal tracheal plugging has been advocated [50, 51]. An alternative approach can
be the provision of antenatal sildenaﬁl in selected high risk prenatally diagnosed CDH fetuses.
However, even for postnatal sildenaﬁl no solid safety data are available [52]. Even more for
antenatal sildenaﬁl (STRIDER; NCT02277132 (clinicaltrials.gov)) questions remain on safety,
dosage as well as repeated prescription and optimal timing of the drug.
In conclusion, our study demonstrates that antenatal treatment with sildenaﬁl started at a
clinical relevant time point improves bodyweight, decreases lung hypoplasia and attenuates
vascular remodeling in nitrofen-induced CDH in rats. Antenatal use of sildenaﬁl might improve
morbidity and mortality in CDH patients by improving lung structure. However, it is important
to determine the optimum dosage for this therapy in a potential phase I trial.
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Abstract
Rationale: Patients with congenital diaphragmatic hernia (CDH) often suﬀer from severe
pulmonary hypertension and the choice of current vasodilator therapy is based on trial and
error.
Objectives: Since pulmonary vascular alterations are already present early during development,
we performed a study to modulate the pulmonary vascular abnormalities at an early stage
during gestation.
Methods: Pregnant Sprague-Dawley rats were treated with nitrofen at day 9.5 of gestation
(E9.5) to induce CDH in the oﬀspring and subsequently the phosphodiesterase-5 inhibitor
sildenaﬁl and/or the novel prostaglandin-I receptor agonist selexipag (NS-304) were administered
at E17.5 until E20.5. This time point of start of treatment corresponds to week 20 of gestation
in human, when CDH is usually detected, making it clinically relevant.
Measurements and main results: CDH pups showed increased density of air saccules which
was reverted after the use of sildenaﬁl solely. The pulmonary vascular wall was thickened and
right ventricular hypertrophy was present in the CDH group and improved both after treatment
with sildenaﬁl and selexipag alone, where combination therapy with both compounds did not
have additive value.
Conclusions: In conclusion, antenatal treatment with sildenaﬁl improved airway morphogenesis
and pulmonary vascular development, while selexipag only acted positively on pulmonary
vascular development. The combination of both compounds did not act synergistically, probably
because of a decreased eﬃciency of both compounds caused by CYP interaction. These new
insights create important possibilities for future treatment of pulmonary vascular abnormalities
in CDH patients already in the antenatal period of life.
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Introduction
Congenital diaphragmatic hernia (CDH) is a rare developmental anomaly characterized by
an incomplete diaphragm, lung hypoplasia and pulmonary hypertension (PH), which is often
unresponsive to current vasodilator therapy [1]. Although the postnatal therapeutic approach
is highly protocolized nowadays [2] the pharmacotherapy of PH in CDH is mainly trial and
error and is based on the modulation of three major vasoactive pathways: the nitric oxide
(NO), endothelin (ET) and prostacyclin (PGI2) pathways. Inhaled NO (iNO) is the most
frequently used drug followed by (i.v.) sildenaﬁl, a phosphodiesterase-5 (PDE5) inhibitor acting
on the same pathway by inhibiting the conversion of cyclic guanosine monophosphate (cGMP).
Currently drugs acting on the PGI2 pathway are used only in a compassionate way, showing
contradicting results [3–5]. Although the ET pathway has shown to be aﬀected in patients with
CDH [6, 7], targeting this pathway is even more challenging because of the clinical availability
of oral formulation only. A recent Cochrane review showed no improvement in patients with
CDH after iNO treatment [8]. However, properly designed trials are lacking while no systematic
research has been performed into the diﬀerent pathways involved. An overview of all studies
performed in humans using postnatal vasodilator therapy in CDH is presented in Table 6.1.
Furthermore, changes in the pulmonary vasculature, leading to PH, have previously been shown
to be present already early during gestation [9], while treatment is only oﬀered postnatally.
Over the last years we and others showed improvement in lung development after antenatal
treatment with sildenaﬁl in diﬀerent animal models of CDH [10–12]. However, the pulmonary
pathology in these animals was not totally reversed. Since CDH-associated abnormalities may
not be limited to only one pathway, antenatal targeting of more pathways could possibly provide
new approaches for therapeutic strategies. Antenatal use of all endothelin receptor antagonists
have shown to be teratogenic [13, 14]. However, prenatal monotherapy with a slow-release
synthetic prostacyclin agonist in a rat model of CDH showed improvement of the diminished
development of alveolar and capillary networks [15]. Until recently most available prostacyclin
analogues could only be administered by continuous intravenous infusion or inhalation, and had
limited stability and a very short half-life [16]. Selexipag is a novel highly selective long-acting
oral PGI2 receptor agonist that has recently been approved for the treatment of PH in adults.
The active compound of selexipag, NS-304, is hydrolyzed by the liver to its active metabolite
ACT-333679, which has an even higher aﬃnity for the PGI2 receptor [17, 18].
Table 6.1: Studies on vasodilatory drugs in CDH
Compound Pathway Patients Eﬀect Reference
Inhaled NO Nitric Oxide 34 No eﬀect [19]
53 No eﬀect in mortality and ECMO [20]
31 No eﬀect in mortality and ECMO [21]
84 No eﬀect in mortality and ECMO [22]
Sildenaﬁl Nitric Oxide 9 Improved oxygenation index [23]
7 Improved cardiac output, Reduced PVR [24]
Milrinone Prostacyclin 6 Improved RV function, Improved oxygenation
index, No eﬀect on PVR
[25]
Prostacyclin Prostacyclin 9 Improved oxygenation index [26]
Bosentan Endothelin No studies performed
ECMO = extracorporeal membrane oxygenation, PVR = pulmonary vascular resistance, RV = right
ventricle.
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Here, we analyzed for the ﬁrst time the eﬀects of antenatal treatment targeting both the NO
pathway and the PGI2 pathway in the nitrofen-CDH rat model, starting at a clinically relevant
time point.
Methods
Animal Model
Pregnant Sprague-Dawley rats received either 100 mg nitrofen dissolved in 1 ml olive oil or just
olive oil by gavage on gestational age day E9.5. Administration of nitrofen at exactly this time
point induces mainly left sided CDH in approximately 70% of the oﬀspring, while all pups have
PH [27]. This study included only pups with an observable diaphragmatic defect. Pregnant
rats were divided into 8 groups: control, nitrofen (CDH), control+sildenaﬁl, nitrofen+sildenaﬁl
(CDH+sildenaﬁl), control+NS-304, nitrofen+NS-304 (CDH+NS-304), control+sildenaﬁl/NS-304
and nitrofen+sildenaﬁl/NS-304 (CDH+sildenaﬁl/NS-304). Sildenaﬁl (100 mg/kg/day, Pﬁzer,
New York, NY, USA) and NS-304 (1 mg/kg/day, MedChem Express, Monmouth Junction, NJ,
USA) were dissolved in 0.8% ethanol in water and administered via oral gavage for 4 consecutive
days from E17.5 to E20.5. At E21 pups were delivered by caesarean section and euthanized by
lethal injection of pentobarbital (Figure 6.1).
All animal experiments were approved by an independent animal ethical committee and
according to national guidelines.
Olive oil or
Nitrofen
0 9.5 17.5 18.5 19.5 20.5 21.5
Treatment
Figure 6.1: Schematic overview of the study design Overview of study design showing interventions at
diﬀerent time points. X-axis shows days during gestation. Flashes indicate time point of
intervention, cross indicates time point of termination. The diﬀerent treatments are placebo,
sildenaﬁl, NS-304 and sildenaﬁl + NS-304. n = 2 litters for control and nitrofen with placebo
(n = 26 and 24 pups, respectively) or sildenaﬁl (n = 15 and 24 pups, respectively), n = 3 litters
for control and nitrofen with NS-304 (n = 35 and 37 pups, respectively) or sildenaﬁl+NS-304
(n = 36 and 37 pups, respectively).
Lung Morphology
Fetal rat lungs were isolated, ﬁxed overnight in 4% PFA and embedded in paraﬃn. Serial 5 µm
thick sections were made through the middle of the left lobe and stained with haematoxylin and
eosin (HE). Sections were imaged at 40x magniﬁcation using a BX41 research stereomicroscope
system (Olympus; Tokyo, Japan). Four non-overlapping images in three diﬀerent sections
of each lung were acquired. Major airways and vessels were excluded from analysis. The
airspace size was automatically quantiﬁed using the two following measures: the D2-score, as
previously described [10], and the mean linear intercept Lm. Approximate value of the latter
was calculated as proposed by Mun˜oz-Barrutia et al. [28], using both horizontal and vertical
test lines. However, previous comparisons between both methods have shown a higher accuracy
of the D2-score [29].
Immunohistochemistry and Immunofluorescence Staining
Immunohistochemistry (IHC) was performed on 5 µm paraﬃn sections of lungs according
to standard protocols, using the EnvisionTM detection system (Dako Cytomatic, Glostrup,
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Table 6.2: Primer sequences
Gene Sequence (forward 5’- 3’) Sequence (reverse 5’- 3’)
Ptgir CACGAGAGGATGAAGTTTACCA AATCCTCTGATCGTGAGAGGC
Ptgis CATCAAACAGTTTGTGGTCCT CAAAGCCATATCTGCTAAGGT
eNos CATACTTGAGGATGTGGCTG CCACGTTAATTTCCACTGCT
Pde3 CCAGCAACCGAATATTGACCA AATCTGAAAGTTCCAGTTGCTC
Pde5 TCAACAACGGATAGCAGAACTC CCCTGTTCATTAGATCAGCGG
Prkg2 ACTAGGCATTATCTACAGAGACC TCCAAAGTCAACCAACTTAAGG
Sma TGACCCAGATTATGTTTGAGAC AGAGTCCAGCACAATACCAG
Pdgfr-β AACGACCAGTTCTACAATGCC CATGATCTCATAGATCTCGTCGG
Actb AGATGACCCAGATCATGTTTGAG GTACGACCAGAGGCATACAG
Denmark) [30]. Primary antibody used for IHC was smooth muscle actin (α-SMA; MS-113-P1;
1:1200, Thermo Scientiﬁc, Fremont, CA, USA). Antigen retrieval with Tris-EDTA buﬀer (10
mmol Tris, 1 mmol EDTA; pH 9.0) was used.
Primary antibodies used for immunoﬂuorescence staining were smooth muscle actin (α-SMA;
MS-113-P1; 1:500, Thermo Scientiﬁc) and Ki-67 (1:100, Abcam, Cambridge, UK). Secondary
antibodies against mouse (α-SMA) and rabbit (Ki-67) were used. Negative controls were
performed by omitting the primary antibody. Antigen retrieval with Citric Acid buﬀer (11.2
mmol; pH 6.0) was used.
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
RNA isolation of whole lungs, cDNA synthesis and subsequent qPCR analysis were performed
as previously described [30]. Primer combinations for the qPCR reactions are listed in Table
6.2. Actb was used as housekeeping gene.
Cardiovascular measurements
Lungs and heart of pups were perfused through the right ventricle with Microﬁl contrast agent
(Microﬁl, Flow Tech; Carver, MA, USA) and imaged with a micro Computed Tomography
(micro-CT) scanner (Quantum FX, PerkinElmer; Waltham, MA, USA; pixel size 10-295 µm).
Subsequently, images of the hearts were analyzed with Dataviewer (Skyscan, Bruker, BioSpin,
Ettlingen, Germany).
Statistical Analyses
Data are presented as means (SD). For the results of the dose study, one-way analysis of variance
(ANOVA) was applied to compare bodyweight and lung-to-kidney weight ratio (LW/KW)
between dose levels (placebo, 0.1, 1 and 10 mg/kg), followed by Tukey’s method for post-hoc
multiple comparisons. For the data of the intervention study, two-way ANOVA with factors
disease (control versus CDH) and treatment (placebo, sildenaﬁl, NS-304 and combination of
sildenaﬁl and NS-304) was used to compare the results of the experiments between groups.
The interaction eﬀect of disease and treatment was included in the model in case this eﬀect
was statistically signiﬁcant. The normality assumption of the ANOVA models was assessed
by creating histograms of the model residuals. The analyses were performed using SPSS 21.0
for Windows (Armonk, NY, USA: IBM Corp.). All statistical tests were two-sided and used a
signiﬁcance level of 0.05.
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Results
Dose study
We ﬁrst established an eﬀective antenatal dose of NS-304 by analyzing the eﬀects on the pups
and monitoring possible side-eﬀects of this compound. Therefore we started a dose study in
control rat pups using 3 diﬀerent dosages based on previous studies in adult rats [31, 32].
Pups of mothers treated with NS-304 did not show any malformations of face, palate, limbs or
other organs. Bodyweight was increased in pups treated with 1 and 10 mg/kg/day and LW/KW
was increased in all treated pups (Figure 6.2A). No diﬀerences in histology were observed in
both lungs and kidneys between all dose levels (Figure 6.2B). The livers of all pups showed
steatosis, which was resolved after adjusting the percentage of ethanol in which the compound
was dissolved from 8 to 0.8% (Figure 6.2C). Based on this dose study the optimal dosage of
NS-304 was found to be 1 mg/kg/day. The dosage of sildenaﬁl was based on our previous study
[10].
Lung morphology
In accordance with our previous study [10], CDH pups had a decreased bodyweight, which
increased after treatment with sildenaﬁl. Lung weight was also reduced in CDH pups, but
this did not improve after treatment with sildenaﬁl, NS-304 or the combination of sildenaﬁl
and NS-304 (Figure 6.3A,B). Both lung-to-bodyweight ratio (LW/BW) and LW/KW were
signiﬁcantly reduced in CDH pups. LW/BW increased only after treatment with NS-304, where
LW/KW increased in all three groups receiving treatment (Figure 6.3C,D)
In correspondence with our previous results [10], the density of the air saccules was increased
in lungs of CDH pups (Figure 6.4A). Statistical analyses showed a signiﬁcant positive correlation
between disease and treatment for both the D2-score, the Lm and the number of air saccules
(p = 0.005, p = 0.024 and p < 0.001, respectively). The lower D2-score and Lm in CDH were
signiﬁcantly higher in the pups treated with sildenaﬁl, while NS-304 alone or the combination of
sildenaﬁl and NS-304 were not signiﬁcantly diﬀerent (Figure 6.4B,C). The number of air saccules
was increased in CDH and diminished after treatment with sildenaﬁl or the combination of
sildenaﬁl and NS-304 (Figure 6.4D). Combined, these results show a therapeutic eﬀect on the
formation of air saccules after antenatal targeting mainly by sildenaﬁl.
Since NS-304 acts on the IP-receptor (Ptgir), we checked the expression of this receptor
and its synthase at mRNA level. We found an increase in Ptgir and a decrease in Ptgis in
CDH with only a trend to improvement after treatment in case of Ptgir (Figure 6.5A,B).
The expression of endothelial NO synthase (eNos), an important enzyme in the production
of vasoactive NO, was increased in CDH and did not change after treatment (Figure 6.5C).
Phosphodiesterase-3 (Pde3 ), which hydrolyses and thus inactivates the secondary messengers
cyclic adenosine monophosphate (cAMP) and cGMP, was not diﬀerently expressed in control
and CDH, but was decreased after treatment with NS-304 in both control and CDH (Figure
6.5D). Phosphodiesterase-5 (Pde5 ), the enzyme which hydrolyses cGMP and is inhibited by
sildenaﬁl, and its downstream target protein kinase G2 (Prkg2 ) were both increased in CDH.
Prkg2 was decreased in CDH in all treatment groups (Figure 6.5E,F). All these changes in
the expression of these factors in both therapeutic pathways conﬁrm the importance of these
pathways in CDH.
Pulmonary vasculature
Next, we analyzed the pulmonary vascular development by whole mount imaging after infusion
of a contrast agent (Figure 6.6A). This revealed a decrease in the vascular branching and
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Figure 6.2: Dose study of NS-304 (A) Bodyweight is signiﬁcantly increased after treatment with NS-304
at 1 mg/kg (p = 0.036) and 10 mg/kg (p = 0.009) (n = 12, 13, 10 and 14, respectively).
Lung-to-kidney weight ratio is signiﬁcantly increased in all treated groups (p = 0.001, p = 0.005
and p < 0.001, respectively) (n = 13, 14, 11 and 15, respectively). (B) Representative images
of H&E staining on lung and kidney show no abnormalities in all groups. Representative images
of the liver show vacuoles in all samples. Scale bars represent 200µm (lung), 500µm (kidney)
and 50µm (liver). (C) Representative images of Oil-Red-O (ORO)-staining showing steatosis of
the liver after use of 8% EtOH, but not after use of 0.8% EtOH. Scale bars represent 20µm.
*p < 0.05, ** p < 0.01, *** p < 0.001. Bars represent means (SD).
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Figure 6.3: Body and lung weight (A) Bodyweight is decreased in pups with CDH (p < 0.001). Sildenaﬁl
increases bodyweight signiﬁcantly in both control and CDH pups (both p < 0.001), where NS-
304 and the combination of both compounds only increases bodyweight in control pups (both
p < 0.001). n = 39, 37, 35 and 36 in the control groups and 19, 31, 14 and 21 in the nitrofen
groups, respectively. (B) Lung weight is signiﬁcantly decreased in CDH pups (p < 0.001) with
no diﬀerence after treatment. N = 53, 50, 26 and 27 in the control groups and 24, 32, 10
and 16 in the nitrofen groups, respectively. (C) The lung-to-body weight ratio is signiﬁcantly
decreased in CDH (p < 0.001) with improvement only after NS-304 (p = 0.003). n = 33, 35,
26 and 27 in the control groups and 17, 28, 10 and 16 in the nitrofen groups, respectively. (D)
Lung-to-kidney weight ratio is signiﬁcantly decreased in CDH (p < 0.001) and improved in all
treatment groups (p = 0.002, p < 0.001 and p = 0.004, respectively). n = 44, 50, 24 and 27 in
the control groups and 23, 32, 10 and 15 in the nitrofen groups, respectively. Weights of pups
from our previous experiment [10] were included to enlarge the data.
* p < 0.05, ** p < 0.01, *** p < 0.001. Bars represent means (SD). White bars represent
control pups, grey bars represent CDH pups. Sil means sildenaﬁl, NS means NS-304.
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Figure 6.4: Disrupted lung morphogenesis is partly resolved after sildenafil treatment (A) Representative
images of H&E stained lungs. Scale bars represent 50µm. (B) Mean saccular airspace diameter
(D2-score) is signiﬁcantly decreased in CDH (p < 0.001), with a signiﬁcant increase after
treatment with sildenaﬁl only (p = 0.001). (C) The mean linear intercept (Lm) is signiﬁcantly
decreased in CDH (p < 0.001), with a signiﬁcant increase after treatment with sildenaﬁl only
(p = 0.048). (D) The average number of air saccules in 1 image per lung was increased in CDH
(p < 0.001) and decreased after sildenaﬁl (p = 0.036) and combination therapy (p = 0.017).
For each group, 4 non-overlapping images on 3 diﬀerent sections for 5 diﬀerent animals were
used.
*p < 0.05, **p < 0.01, ***p < 0.001. Bars represent means (SD). White bars represent control
pups, grey bars represent CDH pups. Sil means sildenaﬁl, NS means NS-304.
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Figure 6.5: RNA expression levels of relevant factors in the NO and PGI2 pathways (A) Quantitative PCR
shows a signiﬁcant increase in Ptgir in CDH (p < 0.001) with no diﬀerences after treatment.
(B) Ptgis is decreased in CDH (p < 0.001) with no improvement after treatment. (C) eNos
expression is increased in CDH (p = 0.041) and shows no improvement after treatment. (D)
No diﬀerences were found in Pde3 between control and CDH pups, but treatment with NS-304
decreased Pde3 expression in both control and CDH (both p = 0.030). (E) Pde5 is increased
in CDH (p = 0.007) with no improvement after treatment. (F) Prkg2 is increased in CDH
(p = 0.013) and decreased after treatment with sildenaﬁl, NS-304 and the combination of both
(p = 0.045, p = 0.002 and p < 0.001, respectively). n = 6 for all groups.
* p < 0.05, ** p < 0.01, *** p < 0.001. Bars represent means (SD). White bars represent
control pups, grey bars represent CDH pups. Sil means sildenaﬁl, NS means NS-304. No
interaction model was used for Ptgir, Ptgis, eNos, Pde3 and Pde5.
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total vasculature volume in CDH. None of the applied treatment modalities showed signiﬁcant
improvement (Figure 6.6B), as we previously reported after prenatal sildenaﬁl monotherapy [10].
However, histological analysis of the lungs revealed an increased thickening of the smooth muscle
layer of the small pulmonary vessels (25− 50µm) in CDH pups, comparable to our previous
results [10]. This augmented thickness of the vascular wall was signiﬁcantly reduced after
treatment with sildenaﬁl as well as with NS-304 alone or the combination of both. Remarkably,
all treated control groups showed an increase in thickness of the medial smooth muscle layer
(Figure 6.6C,D). Immunoﬂuorescence staining showed an increase in Ki67/Sma double-positive
cells in the small pulmonary vessels in CDH pups, which was reversed to normal in all three
treatment groups, indicating reduced proliferation of these cells after treatment (Figure 6.6E,F).
Since we found reduced muscularization of the pulmonary vasculature in CDH lungs after
antenatal vasodilator therapy, we checked the eﬀect of the treatment on the heart. Since
right ventricular hypertrophy is an indication for pulmonary hypertension postnatally [33], we
measured the myocardium of the right ventricle in relation to the total diameter of the heart.
This showed a signiﬁcant increase in CDH with reversion to normal after treatment in all 3
groups (Figure 6.7A,B) showing a potential eﬀect of treatment on the already higher pulmonary
vascular resistance before birth.
Discussion
In this paper we show that antenatal treatment with sildenaﬁl, starting at a clinically relevant
time point, results in a partial reversal of the abnormal development of the lung morphology
and pulmonary vasculature in the nitrofen-induced CDH rat model, whereas the novel PGI2
receptor agonist selexipag only improves the pulmonary vasculature. Combination therapy with
both compounds did not have a synergistic eﬀect. This is the ﬁrst study combining therapies
targeting both the NO and PGI2 pathway for antenatal use in CDH.
In accordance with our previous work [10], sildenaﬁl increased bodyweight and LW/KW
ratio and improved the lung morphogenesis in CDH pups. LW/KW ratio was even reversed
to normal after treatment with selexipag, but sildenaﬁl did not have a synergistic eﬀect when
combined with selexipag. This may be explained by a combined inducing eﬀect of sildenaﬁl
and selexipag on the activation of CYP3A4. This enzyme is involved in the clearance of both
compounds, and, therefore, the combination of these drugs may result in an increased clearance
of both compounds, thereby reducing their window of activity. This is supported by a phase 3
study on selexipag, which predicted a 30% lower exposure to the active metabolite ACT-333679
when used in combination with a PDE-5 inhibitor [34]. The saccular airspaces did not increase
after the use of selexipag and, when added together with sildenaﬁl, it only seemed to reverse the
positive eﬀects of sildenaﬁl, suggesting the enhanced clearance of both compounds. In contrast
to the lung morphology, selexipag caused a decrease in muscularization and proliferation of the
smooth muscle layer and a reduced myocardial thickness of the right ventricular wall. These
eﬀects were also observed after the use of sildenaﬁl as well as the combined sildenaﬁl/selexipag
therapy. The increased proliferation of Sma positive cells in CDH might relate to the pulmonary
hypertension in these pups and was previously shown by others as well [15]. Hypertrophy of the
right ventricular wall has been known to be an early sign of PH postnatally followed by right
ventricular dilatation and eventually heart failure [33]. Normally, early during gestation the
right and left cardiac ventricles are approximately identical in size, whereas later in pregnancy
the right ventricle becomes slightly more dilated [35]. However, in case of right ventricular outlet
obstruction the myocardial mass can already increase antenatally [36]. A previous study in adult
rats with monocrotaline-induced PH showed reduced hypertrophy of the pulmonary arterial
wall and less thickening of the right ventricle after the use of selexipag postnatally [31]. These
combined results indicate a potential eﬀect of this drug on the severity of the PH. Reduced
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Figure 6.6: Both sildenaﬁl and NS-304 reduce muscularization defects in CDH (A) Schematic image of
injection through the right ventricle. (B) Representative images of Microﬁl-injected pulmonary
vessels show decreased branching and volume in CDH with no improvement after treatment
with NS-304 or the combination of sildenaﬁl and NS-304. (C+D) Representative images of
immunohistochemistry staining show increased expression of Sma and an increased thickening
of the vascular wall of small pulmonary vessels (25 − 50µm) in CDH (p < 0.001) and control
lungs treated with all compounds (all p < 0.001). In CDH this thickening is decreased after all
treatments (all p < 0.001). n = 34, 30, 33 and 34 in the control groups and 32, 33, 38 and
33 in the nitrofen groups, respectively. (E+F) Representative images of immunoﬂuorescence
staining show an increase in Ki-67/Sma double-positive cells in small pulmonary vessels in CDH
(p < 0.001) with improvement to normal in all treated groups (p < 0.001, p < 0.001 and
p = 0.001, respectively). n = 12 for all groups. Scale bars represent 10µm.
** p < 0.01, *** p < 0.001. Bars represent means (SD).
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Figure 6.7: Prenatal treatment improves cardiovascular defects Representative images of with Microﬁl
ﬁlled hearts show increased thickness of the right ventricle wall in relation to the total diameter
of the heart (p < 0.001). This thickening improved after treatment with sildenaﬁl, NS-304 and
the combination of both (p = 0.001, p = 0.023, p < 0.001, respectively). Scale bars represent
2 mm. n = 5, 3, 5 and 4 in the control groups and 2, 3, 2 and 4 in the nitrofen groups,
respectively.
* p < 0.05, ** p < 0.01, *** p < 0.001. Bars represent means (SD).
pulmonary vascular pathology was also observed in a prophylactic study by Umeda et al., who
applied a prostacyclin agonist antenatally in CDH [15]. They showed an increased LW/BW
ratio and reduced thickening of the medial wall of pulmonary arteries, as we show as well. In
contrast to our results, they found an improvement of the alveolar and capillary networks with
an increased mean linear intercept at E21. These diﬀerences can possibly be explained by
the thromboxane inhibitory activity of their compound or the early start of treatment at day
E9.5, when development is still at an earlier stage and deviations in lung development have not
yet started. The major advantage of our approach is the start of our treatment at E17.5, a
phase of lung development comparable to 20 weeks of gestation in human when CDH can be
detected, which makes it potentially more clinically relevant. Furthermore, we used an orally
available approved medicine for our treatment, which could be extrapolated easier to clinical
use. As previously described by our group [10], pulmonary vascular volume is decreased in
CDH. Apart from sildenaﬁl, selexipag and combination therapy with both compounds did not
increase vascular volume and branching. This may well be expected since the majority of the
pulmonary vessels is already developed at the start of treatment and treatment will therefore
mostly aﬀect the vascular remodeling.
Conﬁrming the results previously shown by us and others [10–12], sildenaﬁl caused unan-
ticipated diﬀerences in lung structure in healthy controls, with a thickening of the smooth
muscle layer in the pulmonary vessels. However, selexipag induced similar eﬀects in healthy
subjects, which strengthens the idea that inducing vasodilation in already healthy vessels might
be deleterious for the development of the pulmonary vasculature [10].
The possibility of early detection of CDH by ultrasound makes this disease suitable for
antenatal therapies. Some studies have already been performed in the nitrofen rat model on the
antenatal use of sildenaﬁl alone [10, 11] or in combination with steroids [37, 38] or the endothelin
antagonist bosentan [39]. However, the combination with a prostacyclin agonist, which can
safely be used antenatally, has never been studied in this disease. Although antenatal treatment
with selexipag or the combination of selexipag and sildenaﬁl did not seem advantageous over
monotherapy, at least in the nitrofen rat model, the addition of a second drug might still be of
interest because of the variable response to vasodilator therapy of CDH patients in the clinical
setting [1] (Table 6.1). The variability between patients and the altered expression of diﬀerent
vasoactive factors in CDH strengthens the need for ongoing evaluation of the developmental
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sequences of the pathways involved and subsequently, a more precision medicine approach.
We analyzed for the ﬁrst time the feasibility and eﬀects of antenatal use of the novel PGI2-
receptor agonist selexipag in the nitrofen-induced CDH rat model. The positive eﬀects on
the pulmonary vasculature show that the compound successfully entered the fetal circulation.
Embryotoxicity studies in rats and rabbits have shown no malformations, irregularities or
neurological diﬀerences after the use of selexipag during pregnancy [34, 40]. Indeed, no
malformations or abnormalities in histology were seen in diﬀerent organs in our study.
In conclusion, this study demonstrates improvement of lung morphogenesis after antenatal
treatment with sildenaﬁl monotherapy and a reduction in vascular remodeling after antenatal
treatment with both sildenaﬁl and selexipag monotherapy, where no synergistic eﬀect was
present after combination of both compounds. This knowledge creates important possibilities in
the therapy of pulmonary hypertension in CDH patients. Ideally, future research has to reveal
antenatal diﬀerences in expression of vasoactive factors in speciﬁc individual CDH patients
before clinical trials on precision medicine with these compounds can be performed.
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This thesis describes the role of important pathways in the normal and aberrant pulmonary
vascular development in patients with Congenital Diaphragmatic Hernia (CDH) and the
feasibility of antenatal treatment with vasodilator therapy in these patients. Most studies were
performed using the well-established nitrofen-treated rat model for CDH [1], supplemented by
research on exclusive human material of CDH patients. In this chapter the main ﬁndings will
be highlighted in relation to the current clinical standard of protocolized care [2, 3] and future
implications.
Pulmonary hypertension
A large group of patients with CDH suﬀer from severe pulmonary hypertension due to altered
vasoreactivity in combination with pulmonary vascular remodeling. Consequences of pulmonary
hypertension and pulmonary hypoplasia play a signiﬁcant role in the high morbidity and
mortality of these patients [4]. Management of pulmonary hypertension in CDH patients
is still challenging. Current therapy strategies in pulmonary hypertension treatment are
mostly based on targeting the major vasoactive pathways; the Endothelin (ET), Nitric Oxide
(NO) and Prostacyclin (PGI2) pathways. However, in contrast to the promising results in
patients with persistent pulmonary hypertension of the newborn (PPHN) [5], CDH patients
are often unresponsive to current vasodilator therapy. Inhaled Nitric Oxide (iNO) is most
commonly used in the treatment of patients with CDH, but showed no beneﬁt in risk of death
or the use of extracorporeal membrane oxygenation (ECMO) [6–9]. Sildenaﬁl, an inhibitor of
phosphodiesterase-5 (PDE5) which normally converts cyclic guanosine monophosphate (cGMP)
into GMP causing an increase in vasoconstriction, has shown to decrease mortality in patients
with PPHN [10–15]. In CDH, some case reports on the use of sildenaﬁl showed positive eﬀects
on the oxygenation index and pulmonary vascular resistance [16, 17], but contained only a
small number of patients (n = 9 and n = 7, respectively). Other case reports on drugs targeting
the prostacyclin pathway, prostacyclin and the PDE3 inhibitor milrinone, also showed an
improvement of the oxygenation index, but were equally underpowered (n = 6 and n = 9,
respectively) [18, 19]. No information is available on the use of the endothelin receptor antagonist
bosentan in the early stage of treatment of CDH. Bosentan is available only orally, limiting its
application in critically ill patients taking into account the abnormal position of the stomach and
unpredictable absorption rate. Apart from these scarce case reports and some patients included
in other trials, large randomized controlled trials for the treatment of pulmonary hypertension in
CDH are still lacking. Over the last years, several factors involved in the abnormal development
of the pulmonary vasculature in CDH have been identiﬁed, including mutations in some retinoid
related genes, such as STRA6, COUP-TFII and FOG2 [20–22]. However, almost no overlap
can be found in genes expressed in CDH and other forms of pulmonary hypertension. Where
patients with idiopathic pulmonary arterial hypertension (iPAH) show mainly mutations in
genes involved in the TGFβ/BMP pathways, like the well-studied BMPr2 mutation [23], these
mutations could not be found in CDH patients. However, mutations in STRA6, the membrane
receptor for retinol binding protein (RBP1) have been found as well in CDH as in some isolated
cases of alveolar capillary dysplasia (ACD) [20], indicating a possible genetic overlap between
both rare diseases.
TGFβ/BMP pathways
Although almost no mutations in genes of the TGFβ pathway are found in CDH patients,
mutations in the retinoic acid (RA) pathway can inﬂuence TGFβ signaling. RA is a negative
regulator of TGFβ and the absence of RA has been shown to inhibit lung bud formation
through increased TGFβ activity [24]. Furthermore, rats with alveolar hypoplasia caused by
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caloric restriction showed both improvement of the alveolar formation and decreased TGFβ
activity after treatment with RA [25], indicating an interaction between RA and TGFβ in the
development of the lung morphology. RA deﬁciency has also been shown to play a role in the
vasculature by aﬀecting the vasculogenesis of the systemic circulation [26]. Some studies have
shown deviations of both the TGFβ and BMP receptors in an animal model of CDH [27–34],
but the results are inconsistent and not much is known about the downstream activity of this
pathway and especially its role in the pulmonary vasculature. We showed increased activation of
the TGFβ pathway and decreased activation of the BMP pathway in the pulmonary vasculature
of nitrofen-CDH pups, as described in Chapter 3, which might indeed be caused by a relative
RA deﬁciency at organ level in this animal model, since nitrofen has been shown to disrupt the
retinoid signaling pathway [35]. Furthermore, we found increased proliferation of the smooth
muscle cells in pulmonary vessels, indicating a possible aberrant response to the increased TGFβ
activity. The combination of increased TGFβ activity and increased proliferation in the same
cell layer of the vessel wall, might partly explain the already known increased muscularization
of the pulmonary vasculature in CDH.
Vasoactive pathways
Even though patients with CDH are often unresponsive to vasodilator therapy, almost no
information is available on the possible aberrant expression of the targeted molecules of
current drugs in this group of patients. The diﬀerent genetic background combined with the
unresponsiveness to therapy strengthens the idea that diﬀerent factors might be aﬀected in
pulmonary hypertension in CDH compared to, for instance, patients with so-called idiopathic
pulmonary hypertension. We investigated for the ﬁrst time important factors in all 3 major
vasoactive pathways in both human and rat CDH, as described in Chapter 4. This study
showed an increased expression of both the endothelin A (ETA) and B (ETB) receptors and
the endothelin converting enzyme (ECE-1) in human and rat CDH. ECE-1 is a key molecule
in the endothelin pathway which converts endothelin-1 (ET-1) into its active form. Although
some previous studies have shown the increased expression of ETA and ETB in both human
and rat tissue as well [36, 37], the important ECE-1 has never been analyzed before. Apart
from the important increase in receptors and the converting enzyme, increased plasma levels of
ET-1 have been described in patients with CDH and documented PH [38, 39] and an increased
response of arterioles to ET-1 was found in the nitrofen rat model [40]. Overall these results
point to an increased activation and sensitivity of the endothelin mediated vasoconstriction.
Alterations in the NO pathway, currently the most targeted pathway in the treatment of
pulmonary hypertension, have shown contradictory results over the years. Endothelial Nitric
Oxide Synthase (eNOS), an important enzyme that produces NO, has previously been found
decreased, increased or not changed at all in patients with CDH [41–44]. This is probably due
to the investigations performed at autopsy of patients all dying under hypoxia due to therapy
resistant PH. Even animal studies could not provide a decisive answer to this indistinctness
[45, 33, 46]. This variability in results might indicate a less important role of NO in the
pathophysiology of pulmonary hypertension in CDH than expected and could be the reason of
the reduced response to iNO in these patients.
Although prostacyclin agonists are used as compassionate treatment of pulmonary hyper-
tension in CDH, no studies in these patients have been performed on this pathway at all. A
previous study performed by our group showed increased levels of PGI2 and an increased
ratio of PGI2 and thromboxane in the nitrofen rat model [47]. These observations in rat were
complemented by us, showing an increase in expression of the PGI2-receptor at RNA level, as
described in Chapter 4. We showed a gradually increase in the PGI2-receptor in human control
lungs over time which was decreased in CDH patients at both the fetal, preterm and term
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phase of lung development. This decreased expression of the important PGI2-receptor possibly
indicates a reduced activity of this pathway, making it a potential target in the treatment of
pulmonary hypertension in CDH.
All these diﬀerences in expression of important factors in the sporadically targeted prostacyclin
and endothelin pathways point to the need for well-organized randomized controlled trials
in this group of patients. However, although the ET pathway has shown to be aﬀected in
CDH, the use of endothelin receptor antagonists in these newborn patients is complicated
by the clinical availability of oral formulation only. Recently the COdiNOS trial, where iNO
versus intravenous sildenaﬁl will be tested, has been approved by the IRB at the Erasmus MC
Rotterdam in the Netherlands. This study will be conducted within the frame work of the
CDH-EURO Consortium.
Potential antenatal treatment modalities
In general, current treatment of pulmonary hypertension in CDH only starts postnatally.
However, as described in Chapter 4 and previously by our group [48], abnormalities in the
pulmonary vasculature and the major vasoactive pathways already develop earlier during
development. Fetoscopic Endoluminal Tracheal Occlusion (FETO), an antenatal procedure
where a small balloon device is inserted to temporarily occlude the trachea to increase
lung growth, is currently the only clinically used antenatal intervention in an international
randomized controlled trial (NCT 02875860; clinicaltrials.gov). Until now, FETO has shown
to improve survival rate in high risk CDH patients but at the cost of increased morbidity and
premature delivery as the most important and unwanted side eﬀects [49–52]. Apart from FETO,
corticosteroids can be used as an antenatal therapy for lung hypoplasia in CDH. However, no
clear diﬀerences were seen in perinatal mortality, duration of ventilation and hospital stay in
the clinical setting [53] and diﬀerent animal studies showed no increase in lung to bodyweight
ratio after antenatal corticosteroids, but some reported improvement in airway histology [54].
In the past the proposed trial on the use of antenatal corticosteroids was stopped prematurely
due to the lack of inclusion.
Antenatal use of vasodilators is not yet approved for clinical use and these drugs are therefore
only tested in various animal models of CDH. As described in Chapter 4, enhanced activation
of the endothelin pathway is present in the lungs of patients with CDH. However, both selective
and dual endothelin receptor antagonists have shown to be teratogenic, causing craniofacial
and cardiovascular malformations in the unborn fetus [55, 56] and are therefore not eligible for
antenatal therapy. On the other hand, antenatal targeting of the nitric oxide or prostacyclin
pathway are not known to induce abnormal development. We conducted a study using antenatal
sildenaﬁl and the novel orally available prostacyclin receptor agonist selexipag (NS-304), as
described in Chapters 5 and 6. We showed improvement in lung histology, with enlargement of
the decreased alveolar airspaces, and pulmonary vascular development, with less muscularization
of the thickened pulmonary vessel wall, in nitrofen-treated rats after the use of antenatal sildenaﬁl.
Like us, other research on the antenatal use of sildenaﬁl in both rat and rabbit studies has
shown improvement in lung development [57–61]. However, we were the ﬁrst to show positive
eﬀects after starting the treatment at a clinically relevant time point at day 17.5 of gestation,
corresponding with 20 weeks of gestation in human when CDH is usually detected. Apart from
sildenaﬁl, targeting of the prostacyclin pathway using selexipag (NS-304) showed improvement
in the aberrant cardio and pulmonary vascularity. These results correspond with the positive
eﬀects seen on the pulmonary vasculature in the only other available study using an antenatal
prostacyclin agonist [62]. However, again their treatment was started early during development
when deviations in lung development have not yet started. Furthermore, the oral form and
clinical availability of our compound makes it more clinically relevant. Combination therapy of
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sildenaﬁl and NS-304, targeting both the NO and prostacyclin pathway, did not have added value
to both compounds solely, probably because of increased clearance of the active metabolites by
inducement of the same CYP enzyme.
Although positive eﬀects on pulmonary vascular development have now been shown after
antenatal therapies in several animal studies, clinical trials have to be conducted to test the
eligibility of this approach. To date antenatal sildenaﬁl is administered to pregnant mothers in
a trial of severe intrauterine growth restriction to modulate vascular tone and improve growth
of the fetus [STRIDER; NCT02277132 (clinicaltrials.gov)]. The possibility to target diﬀerent
pathways in the treatment of pulmonary hypertension in patients with CDH might provide
added value in the future implementation of a precision medicine approach.
Clinical implications
Since human material of CDH patients is scarce and animal models of this disease are only
comparable to the clinical situation to a limited extent, it is diﬃcult to draw clear conclusions
from current research. However, our studies may have a considerable eﬀect in identifying new
or better targets for pharmacological therapies and may lead eventually to a more precision
medicine approach in which antenatal targeting could even play a potential role. Currently,
clinical postnatal treatment of patients with CDH is mainly trial and error and no properly
designed studies on all used drugs have been performed in this speciﬁc group of patients. The
choice of combination therapy for individual patients is another important step to be made to
enhance the treatment results in the most severely aﬀected patients unresponsive to the current
approaches including ECMO. Vasodilator therapy is mostly based on the major vasoactive
pathways in adults or at best on some trials in neonatal patients with persistent pulmonary
hypertension due to other causes [63]. However, the underlying pathophysiology of pulmonary
vascular defects is most likely diﬀerent in CDH patients, given the poor response to current
therapies. Systematic research on the diﬀerent targeted pathways in these patients is lacking,
making it diﬃcult to use speciﬁc directed treatment. Representative material of CDH patients is
scarce, since age and therapies could cause secondary morphological changes while the patients
usually die under severe hypoxic conditions and the time to harvest material after death is not
standardized either. Therefore, our study on the expression of important target-directed factors
of all major pathways in human material of CDH patients, described in Chapter 4, could be of
great importance to future therapy. Although some studies have been performed previously on
only a few components of these pathways, we are the ﬁrst to combine this important research in
all pathways in both human material and the well-established nitrofen rat model, obtaining a
clear insight of existing alterations in the pulmonary vasculature. Over the last years antenatal
treatment of congenital anomalies has become an upcoming interest in CDH research. The
possibility of early detection at 20 weeks of gestation by ultrasound, makes this disease suitable
for an antenatal approach of therapy. Our studies, described in Chapter 5 and 6, show the
feasibility of antenatal treatment with the phosphodiesterase-5 inhibitor sildenaﬁl and the
novel prostaglandin-I2 receptor agonist selexipag (NS-304) in the nitrofen rat model. Although
further studies are needed to prove safety and eﬃcacy in clinical use, our research might add to
a potential start of a new era in the treatment of CDH with the aim to correct or modulate
the pulmonary vasculature at an earlier stage of abnormal development instead of “damage
control”.
Future research
Before the suggested antenatal therapies can be implemented in the clinical setting, clinical trials
should be initiated to test safety and eﬃcacy of diﬀerent forms of antenatal vasodilator therapy
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in patients with CDH and the optimum dosage should be determined. Ideally, antenatal testing
of the expression of factors that can be targeted would be of great value for the implementation
of a precision medicine approach.
Furthermore, research should become more focused on the actual changes in the aberrant
pulmonary development between diﬀerent diseases of the newborn. Patients with CDH often
develop neonatal chronic lung disease (nCLD), because of their high susceptibility for oxygen
and ventilation damage, indicating an overlap in the pathophysiology of both diseases. And
although the genetic mutations found in CDH diﬀer from those in PPHN, both in CDH and
nCLD as well as in PPHN multiple developmental signaling pathways are aﬀected, of which
for instance TGFβ seems to be a common factor. In Chapter 3 we described the upregulated
activation of TGFβ in the nitrofen rat model, which corresponds to the eﬀects seen on PDGF-Rα
in a mouse model of nCLD, as described in the Appendix. Furthermore, some overlap might
exist between CDH and ACD, which are both developmental diseases associated with severe
pulmonary hypertension mostly unresponsive to current therapies. Further research in both
diseases could have important implications in the approach of treatment in both patient groups.
Conclusions
In conclusion, our work shows important alterations already early during development in
the TGFβ pathway and all three major vasoactive pathways in both human CDH and the
well-established nitrofen rat model. Furthermore, it shows the feasibility of antenatal treatment
of pulmonary vascular defects in this disease with two diﬀerent vasodilators acting on the NO
and PGI2 pathway. These results indicate the importance of a precision medicine approach,
potentially even already starting antenatally. As the mortality of CDH has signiﬁcantly decreased
in the last decade, still around 20-25% of patients die due to a lack of insight in the optimal
therapy for this high risk patient population so far.
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Abstract
Neonatal chronic lung disease (nCLD) aﬀects a signiﬁcant number of neonates receiving
mechanical ventilation with oxygen-rich gas (MV-O2). Regardless, the primary molecular driver
of the disease remains elusive. We discover signiﬁcant enrichment for SNPs in the PDGF-Rα
gene in preterms with nCLD and directly test the eﬀect of PDGF-Rα haploinsuﬃciency on the
development of nCLD using a preclinical mouse model of MV-O2. In the context of MV-O2,
attenuated PDGF signaling independently contributes to defective septation and endothelial cell
apoptosis stemming from a PDGF-Rα dependant reduction in lung VEGF-A. TGF-β contributes
to the PDGF-Rα dependant decrease in myoﬁbroblast function. Remarkably, endotracheal
treatment with exogenous PDGF-A rescued both the lung defects in haploinsuﬃcient mice
undergoing MV-O2. Overall, our results establish attenuated PDGF signaling as an important
driver of nCLD pathology with provision of PDGF-A as a protective strategy for newborns
undergoing MV-O2.
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Introduction
Positive pressure mechanical ventilation with O2-rich gas (MV-O2) oﬀers life-saving treatment
for respiratory failure due to lung immaturity and insuﬃcient respiratory drive in preterm
infants. Unfortunately, this therapy signiﬁcantly increases the risk for an important number
of preterm and a subset of newborns to develop neonatal chronic lung disease (nCLD), i.e.
Bronchopulmonary Dysplasia (BPD) [1–4]. Characterized by defective alveolar septation and
impaired vascularization, nCLD remains the most common complication of preterm birth
[2] and is associated with poor pulmonary and neurological long-term outcomes in aﬀected
infants [5, 6]. The adverse eﬀects of positive pressure MV-O2 on pulmonary development have
been reproduced in experimental models of the disease [7, 6, 8–10], manifesting as increased
lung apoptosis and disordered matrix elastin characteristic of nCLD. Because a myriad of
developmental signals are perturbed in the setting of active disease, it is diﬃcult to distinguish
primary drivers of pathology from secondary eﬀectors or compensatory responses. Yet, if a
defect in a speciﬁc signaling pathway underlies the susceptibility to developing nCLD and
orchestrates the multiple processes that execute disease pathology, it would be critical to identify
this potential therapeutic target.
An essential role for platelet-derived growth factor (PDGF) signaling in alveolar development
was established by the discovery that lungs of ‘knockout’ mice lacking PDGF-A failed to form
alveoli, with animals that survived infancy demonstrating an emphysema-like phenotype of
enlarged distal air sacs [11, 12]. This lung pathology was attributed to failure of migration of
PDGF-Rα positive alveolar smooth muscle progenitor cells (also known as myoﬁbroblasts) into
the distal embryonic lung. Because myoﬁbroblasts are believed to drive normal subdivision of
primitive air sacs into mature alveoli (‘secondary septation’), their absence presumably resulted
in abnormally large distal air sacs due to a failure to execute this process. Deletion of the
cognate receptor, PDGF-Rα, resulted in death in mid-gestation before air sac morphogenesis
initiated [13], but transgenic rescue of the profound craniofacial abnormalities and spina biﬁda
enabled survival through birth. Distal lungs in these mutants also lacked myoﬁbroblasts and
failed to undergo secondary septation [14].
When the PDGF signaling pathway was examined in the lungs of animal models of nCLD
employing mechanical ventilation (MV-O2), reduced abundance of PDGF-A and PDGF-Rα
proteins or mRNA was observed [15, 7, 16], similar to the lungs of neonatal rats exposed to
hyperoxia [17] and preterm infants developing nCLD [18]. These ﬁndings suggest that reduced
PDGF signaling may be involved in the air sac morphogenesis defect of nCLD, but a causal role
has not yet been demonstrated. Furthermore, since microvascular defects were not reported in
the lungs of PDGF mouse mutants that failed to undergo secondary septation, the position
of this pathway in the hierarchy of perturbed signaling in nCLD is uncertain. Here, in a
case-control study of infants with nCLD, we discover signiﬁcant enrichment for SNPs in the
PDGF-Rα gene associated with reduced PDGF-R levels and diminished migration of lung
ﬁbroblasts suggesting that impairment of this pathway might be a primary driver of disease.
We conﬁrm this model using gene-targeted mice haploinsuﬃcient for PDGF-Rα, showing an
interaction with an established model of MV-O2 that reproduces the multiple pathologies of
nCLD, all of which are ameliorated by exogenous administration of PDGF-A protein during
MV-O2. We also dissect the molecular crosstalk that mediate nCLD pathology, showing that
attenuated PDGF-Rα signaling results in a reduction of VEGF-A expression, likely responsible
for the vasculature phenotype through increased endothelial cell apoptosis. We also ﬁnd that
increased TGF-β and mechanical stretch, driving lung injury in the newborn lung, to act in
concert to reduce PDGF-Rα signaling, exacerbating the underlying basal reduction in PDGF-Rα
to a level suﬃcient to result in disease. Our work implicating attenuated PDGF signaling
as driving the air sac and vasculature defects of nCLD, along with our demonstration that
both pathologies can be ameliorated by exogenous PDGF-A protein, provide a strong rationale
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for pursuing augmentation of PDGF signaling as a potential targeted therapy for this serious
disease.
Materials and methods
All the antibodies used in the manuscript could be found in 1DegreeBio database. Study design
for the manuscript experiments is described in Supplemental methods.
Human studies
Patient characteristics
Two study cohorts comprising of 1061 preterm infants at or less than 32 weeks of gestational
age (GA) with and without nCLD, i.e. BPD grade 2 or 3 according to Jobe et al. [19]
(Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of
Severe Sepsis (PROGRESS); German Neonatal Network (GNN)) were included in the SNP
analysis (Ethics Approval #65/07, Homburg, University of Saarland; #145-07, Munich, Ludwig
Maximillians University of Munich and #File 79/01, Giessen, University of Giessen, Germany).
Detailed patient characteristics are in Supplemental methods. 9 patients out of this cohort were
subjected to PDGF-Rα transcriptome analysis in association with presence of single nucleotide
polymorphism (SNPs). Patient characteristics of this cohort are in Supplemental Table A.3A. A
separate study cohort was obtained from Perinatal Center of the Ludwig-Maximilians-University,
Campus Grosshadern (Ethics Approval #195-07, Munich, Ludwig Maximillians University of
Munich, Germany) for SNP and protein analysis uring SOMAscan (n = 13). The patient
characteristics are in Supplemental Table A.3B. Tracheal aspirates of few patients from this
patient cohort were used to isolate primary ﬁbroblasts (n = 6). Patient characteristics of this
cohort are in Supplemental Table A.3C. Sections from human lung were available through
the Department of Pediatric Surgery at the Erasmus Medical Center. Lung samples were
retrieved from the archives of the Department of Pathology of the Erasmus MC, Rotterdam,
following approval by the Erasmus MC Medical Ethical Committee. Patient characteristics
of this cohort are in Supplemental Table A.3D. According to Dutch law following consent to
perform autopsy, no separate consent is needed from the parents to perform additional staining
of tissues. A group of 20 preterm infants from Giessen was subjected to microarray analysis
(Ethics Approval #File 79/01, Giessen, University of Giessen, Germany). The clinical course of
all infants was comprehensively monitored. Approval of the local ethics committee and written
informed parental consent was obtained for all samples studied. All the experiments conformed
to the principles set out in the WMA declaration of Helsinki and Department of Health and
Human Services Belmount Report. The limitation of human material to be tested in case
of neonatal chronic lung disease is well known hence, analysis was performed with samples
available in maximum capacity. Samples were collected from patients randomly. Our datasets
were obtained from subjects who have consented to the use of their individual genetic data for
biomedical research, but not for unlimited public data release. Therefore, we submitted it to
the European Genome-phenome Archive (accession number- EGAS00001002586, study unique
name- ena-STUDY-IMI-24-07- 2017-10:03:30:362-576), through which researchers can apply for
access of the raw data.
SNP and protein analysis
Cord blood samples of 1061 preterm infants at or below 32 weeks of gestational age (n = 492
BPD cases) were collected in Ethylenediaminetetraacetic acid (EDTA) neonatal collection tubes.
Genotypes of this patient cohort for PDGF-Rα SNPs (single nucleotide polymorphisms) were
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determined using Aﬀymetrix Axiom microarrays based on the Axiom CEU array supplemented
with some custom content. Matched controls were selected according to gender, GA, birth
weight < 10th percentile, and country of maternal origin. Case-control analysis adjusted for
relatedness. 117 SNPs were measured in or near the PDGF-Rα. Whole blood samples collected
from a separate patient cohort (n = 13) that were analyzed for 3 signiﬁcant SNPs by Euroﬁns
Geomics was subjected to proteomic screening for PDGF-R and VEGF-A (SOMAscan TM,
SomaLogic, Boulder, USA). For a detailed description please refer to Supplemental methods.
Human primary lung fibroblasts
Human primary lung ﬁbroblasts were extracted from serial tracheal aspirate samples obtained
from ventilated preterm infants (mean GA 24.9±1 weeks, n = 6) later developing nCLD, at
4.7±1 and 21.7±8 day of life (Ethics Approval #195-07, Munich, Ludwig Maximillians university
of Munich, Germany). Human lung ﬁbroblasts were cultured until 80% conﬂuency in DMEM
medium with 2mM L-glutamine, Pen/Strep and 20% FCS (PAN Biotech GmbH). Purity of cell
cultures was > 95% and FACS veriﬁed expression of CD11b (< 3%) (eBiosciences #48-0112-80),
CD11c (< 3%) (BD Biosciences #557401), CD14 (< 5%) (BD Biosciences #09475A), CD45
(< 5%) (BD Biosciences #552848), CD90 (> 95%) (eBiosciences #48-0900-80), and CD105
(> 95%) (Miltenyi Biolabs #130-092-930), diﬀerences between patient samples were < 5%
(Supplemental Figure A.13A). All ﬁbroblast cultures expressed α-SMA as detected in cytosolic
cell lysates by immunoblot analysis. This section is further described in Supplemental methods.
Gene expression microarray analysis
250 − 300µl of whole cord blood was obtained from 20 preterm infants 72 hours after birth
and directly transferred to 750 − 900µl of the PAXgene Blood RNA System (PreAnalytiX,
Heidelberg, Germany). RNA was isolated using PAXgene Blood RNA System (PreAnalytiX,
Heidelberg, Germany) and was subjected to CodeLink Human Whole Genome Bioarrays
(GE Healthcare). PDGF-Rα gene expression in GWAS patient cohort was measured by the
expression of NM 006206 on the human whole genome bioarray and human 10 k I bioarray
by Codelink. For details of blood sampling and RNA analysis please refer to Supplemental
methods.
Human lung slides
Human slides were obtained from paraformaldehyde ﬁxed and paraﬃn embedded autopsy
lungs from preterm infants with diﬀerent BPD grades (n = 7) and an infant that died from
a non-pulmonary cause. Tissue sections were stained for PDGF-Rα, and TGF-β for further
quantiﬁcation. Please refer to Supplemental methods for details of patient characteristics.
In vivo studies
All the studies were performed as per ARRIVE guidelines.
Gene-targeted mice
Gene-targeted mice (B6.129S4-Pdgfratm11(EGFP )Sor/J) referred to in manuscript as PDGF-
Rα+/− or PDGF-Rα happloinsuﬃcient mice, were purchased from Jackson laboratories (Bar
Harbor, Maine, USA). Heterozygous mice are healthy and viable and reported to have no lung
abnormalities [8]. Co-staining for PDGF-Rα and α-SMA showed a reduction in myoﬁbroblasts
(double-positive), and mRNA and immunoblot analysis conﬁrmed the reduced abundance of
pulmonary PDGF-Rα expression in unventilated PDGF-Rα+/− mice when compared to WT
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Figure A.1: Reduced PDGF-R-α abundance in PDGF-Rα happloinsuﬃcient mice (A) Double staining for
PDGF-Rα (red) and α-SMA (green) showed a co-localization of these two proteins as well as a
reduced number of double positive cells (white arrows) in 6-7d old PDGF-Rα+/− mice (right
panel) when compared to PDGF-Rα+/+ (WT) littermates (left panel). * represents alveolar
air space. (B) Quantitative RT-PCR and (C) Immunoblot analysis showing reduced PDGF-Rα
protein and mRNA expression in lungs of PDGF-Rα+/− newborn mice when compared to WT
littermates. n = 4/group. (D) Reduced PDGF-Rα transcript in newborn PDGF-Rα+/− mice
upon MV-O2 for 8h when compared to wildtype littermates. (n = 3 mice/group). In (B-C) the
data is presented as Mean ± SD. *p < 0.05. Statistical test in (B-D) is Two-tailed unpaired
Student’s t test or Mann Whitney test.
littermates (Figure A.1A-C). For the study day 5-8 old neonatal mice both males and females
were used. The experimental protocols were approved by the Bavarian government (TVA no.
55.2-1-54-2532-117-2010). The mice were kept under speciﬁed pathogen-free (SPF) conditions
in a 12/12 hour light cycle in the fully-climate controlled rooms having set points to the new
conventions 2007/526 EC in our central mouse facility. Mice had a two-week adaptation phase
to their new environment and a handling by new nurses before putting them into the experiment.
For each experiment, appropriate sample size (n = 6− 12) was estimated considering the eﬀect
of MV-O2 on viability of newborn mice.
Mechanical ventilation
We used 5-8 day-old (newborn/neonatal) C57B6 wild type (PDGF-Rα+/+) and PDGF-Rα
haploinsuﬃcient (PDGF-Rα+/−) mice, all born at term gestation weighing 4g (WT 3.98±0.55g;
PDGF-Rα+/− 3.93± 0.66g bodyweight (bw)) to perform experiments in four groups of mice
(14-16 mice per group). WT and PDGF-Rα+/− pups received mechanical ventilation with
oxygen-rich gas (40% O2) (MV-O2) for 8h at 180 breaths/min (MicroVent 848; Harvard
Apparatus) after tracheotomy under sedation with ketamine and xylazine (60 and 12µg/g bw),
as previously described [9]. The ventilator setting mimicked the clinical setting to avoid severe
lung injury (mean tidal volume 8µl/g bw; mean airway pressure (11-12 cmH2O)). Tidal volumes
were similar between the MV-O2 groups (WT 8.3± 0.5µl/g bw; PDGF-Rα
+/− 7.9± 0.3µl/g
bw). The ventilation protocol was designed to avoid severe lung injury typically occuring in
response to MV with very high inﬂation pressures and extreme hyperoxia. Hence, we used
modest tidal volumes (mean 8.7µl/g bw) and airway pressures (peak 12-13 cmH2O, mean 11-12
cmH2O), and limited the FiO2 to 40%, thereby simulating the MV strategy of choice for preterm
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Figure A.2: (A) Immunoblot analysis showing similar pSMAD levels in whole lung homogenate of newborn
WT as well as PDGF-Rα+/− mice. (n = 3 mice/group). (B) Representative immunoﬂuo-
rescence image showing similar pSMAD levels (red) in both newborn WT (upper panel) and
PDGF-Rα+/− mice (lower panel). α-SMA is in green and nucleus is stained with DAPI (blue).
Quantiﬁcation of the image showing pSMAD-2 area to 100 nuclei. (n = 3 − 4 mice/group,
4 sections/mice, 10 images/section). (C) Increased apoptosis quantiﬁed by cleaved caspase-3
nuclei to 100 nuclei in newborn PDGF-Rα+/− compared to WT mice. (n = 4 mice/group).
In (A-C) data is presented as Mean ± SD. *p < 0.05. Statistical test is Two-tailed unpaired
Student’s t test (p = 0.0159).
infants with respiratory failure. Respective controls spontaneously breathed 40% O2 for 8h after
receiving sham surgery (superﬁcial neck incision) under mild sedation. During MV-O2, mice
were maintained at neutral thermal environment; sedation with ketamine and xylazine (10µg/g
bw, and 2µg/g bw, respectively) was repeated as needed to minimize spontaneous movement
and assure comfort. At the end of each study, pups were euthanized with an intraperitoneal
overdose of sodium pentobarbital, ∼150µg/g bw, and lungs were excised for various studies
as described below including histological analysis, as well as protein measurement and RNA
expression analysis from frozen lung tissue. For PDGF-A treatment, 10µl/g bw of sterile saline
containing 25ng/ml PDGF-A was administered through the endotracheal tube immediately
before the onset of MV-O2 as described previously. In a subgroup of mice with or without
PDGF-A treatment, tidal volume and maximum tracheal pressure (Ptramax) was measured by
whole body plethysmography (Pulmodyn, Harvard Apparatus). Stepwise increase of the tidal
volume allowed to assess quasi-static compliance [9].
All animals were viable with response to tactile stimulation and adequate perfusion at the end
of each experiment. All surgical and animal care procedures were reviewed and approved by the
Institutional Animal Care and Use Committee (Bavarian Government). Upon ventilation both
the mouse strains showed similar activation of pSMAD-2 while neonatal PDGF-Rα+/− mice
displayed increased apoptosis when compared to wildtype mice (Figure A.2A-C). Allocation of
the newborn mice to the groups was performed on the basis of similarity in weight and age.
When newborn mice from more than one cage were used for the experiments, all pups were
randomized before distribution in the groups. Investigators were blinded for the sex of mice
during allocation. Further the analysis of lungs were performed based on internal serial numbers
allotted to mice blinding the investigator for genetic background and treatment (example
controls or ventilated). All experimental procedures were carried out in a laboratory-controlled
environment during day time.
Quantitative histology and immunostaining
Lungs (n = 6− 11/group) were ﬁxed intra-tracheally with 4% paraformaldehyde overnight at
20 cmH2O, as previously described [7]. Fixed lungs were then excised and their volume was
measured by ﬂuid displacement [10]. Lungs were embedded in paraﬃn for isotropic uniform
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random (IUR) sectioning, as described previously [10]. Tissue sections (4µm) were stained
with hematoxylin and eosin (H&E) for quantitative assessment of alveolar area and number
of incomplete and complete alveolar walls (septal density) in 2-3 independent random tissue
sections per animal using the CAST image analysis system (CAST-Grid 2.1.5; Olympus,
Ballerup, Denmark). Alveolar area, number of incomplete and complete alveolar walls (septal
density) and radial alveolar counts providing an index of alveolar number and were assessed in
a minimum number of 30 ﬁelds of view were quantitatively assessed in 2-3 independent random
4µm H&E tissue sections per animal (CAST-Grid 2.1.5; Olympus) [20]. Tissue sections were
stained for PDGF-Rα, VEGF-A, cleaved caspase-3, CD31 and αSMA for further quantiﬁcation
(see Supplemental methods for detailed description).
Quantification of micro-vessels (20− 100µm).
20 − 100µm diameter blood vessels were assessed in H&E (normalized to 100 alveoli) and
CD-31 stained slides obtained from 8h studies (n = 6 − 8/group) applying a previously
described immunohistochemical and morphometric approach [9] in 30 ﬁelds of view in the distal
lung/animal (400X magniﬁcation).
Protein extraction and immunoblot analysis
After 8h MV-O2, protein extraction from snap-frozen total lungs was done using high urea buﬀer
(KPO4, Urea, AppliChem) with Halt Protease Inhibitor (#1861280, Thermo Fisher Scientiﬁc).
Primary lung ﬁbroblasts were lysed with RIPA buﬀer with Halt Protease Inhibitor (mouse)
or sodium vanedate (human) (#S6508, Sigma) and complete mini (#11836170001, Roche)
followed by sonication. After measurement of protein concentrations (BCA, #23227, Pierce
Scientiﬁc), immunoblots were performed using a Bis-Tris or a Tris-Acetate gel (#NP0321BOX,
#EA0375BOX, Life Technologies) using the following antibodies: PDGF-Rα (C-20, Santa Cruz
Biotechnology #338), VEGF-A (147, Santa Cruz Biotechnology #507), VEGF-R2 (Abcam,
Cambridge, USA #Ab2349), VE-Cadherin (H-72, Santa Cruz Biotechnology #28644), cleaved
caspase-3 (Cell Signalling Technology #9661), cleaved caspase-9 (Cell Signaling Technologies
#7237), eNOS (Cell Signaling Technologies #5880), phospho-ERK (Cell Signalling Technologies
#4370), total ERK (Cell Signalling Technologies #4695), RAS (Cell Signalling Technologies
#8955), PI3K (Cell Signaling Technologies #13666), JAK-2 (Cell Signaling Technologies #3230),
STAT-3 (Cell Signaling Technologies #9139). Images were detected by chemiluminescence
(#RPN2232, GE Healthcare) and quantiﬁed by densitometry (Bio Rad). Details of immunoblot
analysis could be found in Supplemental methods.
In vitro experiments
Mouse primary pulmonary myofibroblasts
Mouse myoﬁbroblasts (MFBs) were extracted by excising lungs of 5-7 day old C57BL6 wild type
mice after intraperitoneal overdose of sodium pentobarbital (∼150µg/g bodyweight). Under
sterile conditions lungs were ﬂushed with PBS after cannulation of the right ventricle. Flushed
lungs were then excised, diced into 1 mm pieces and distributed on a petridish (Corning
#430167, Tewksbury MA, USA). Attachment to the dish was accomplished by incubation
for 15 to 20 min at 37◦C. Afterwards the tissue pieces were gently submerged in media
(Gibco #41966-029, Darmstadt, Germany) containing Pen/Strep (Gibco, #15140-122) and
Gentamycin (Lonza #BE02-012E, Basel, Switzerland) for 48 hours before changing to fresh
media. Experiments were started at 70-80% conﬂuency. Myoﬁbroblasts were characterized with
ﬂuorescence activated cell sorter (FACS LSRII) using multicolor staining technique. Brieﬂy
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myoﬁbroblasts were resuspended in FACS buﬀer (PBS+2% FCS+ 10mM HEPES+0.1% Na-
Azide) and stained with CD90.2 APC FITC (BD Pharmingen, Heidelberg, Germany #561974),
CD 105 PE (BD Pharmingen, Heidelberg, Germany #562759), CD45 FITC (BD Pharmingen,
Heidelberg, Germany #553080), CD11b V450 (BD horizon, Heidelberg, Germany #560455),
CD11c PerCpCy5.5 (Biolegend, Fell, Germany #117328). For detection of internal markers,
Myoﬁbroblasts were ﬁxed with 4% PFA (Alpha Aesar GmbH, Germany #43368) followed by
permeabilization with 0.2% TritonX-100 (Carl Roth GmbH + Co.KG, Karlsruhe, Germany
#3051.2) and blocking with 1% BSA (Sigma) in PBS. Myoﬁbroblasts were then stained in
blocking solution with PDGF-Rα APC (eBiosciences #17-1401-81), α-Smooth Muscle Actin
PE (R & D systems, Minneapolis, MN, USA #IC1420P) and Vimentin Alexa 488. Stained
myoﬁbroblasts were then acquired through BDTMLSR II utilizing BD FACSDivaTMsoftware
version 6.0 and analyzed using Flowjo version 9.6.1. As displayed in Supplemental Figure
A.13B Myoﬁbroblast culture constituted leukocytes (0.6±0.5% CD45+), mesenchymal-like cells
(8.5±4.5% CD105+, 32±8.6% CD90+), myoﬁbroblasts (77.2±14% PDGF-Rα+/Vimentin+,
16.7±12% Vimentin+ and 77.6±27% αSMA+). Antibodies used were CD45 (BD Pharming
#553080), CD105 (BD Pharming #562759), CD90 (BD Pharming Vimentin (Cell Signaling
#561974), PDGF-Rα (eBiosciences #17-1401), #9854) and α-SMA (R&D systems #IC1420P).
Mechanical stretch
Myoﬁbroblasts were seeded on ﬂexible-bottomed laminin-coated culture plates (#BF-3001L,
Flex Cell International Corporation) and stretched at 70-80% conﬂuency (shape/sine; elongation
min 0%, max 8%; frequency 2Hz; duty cycle 50%; cycles 43216) for 24h. A detailed description
of mechanical stretch expriment is available in the Supplemental methods.
Protein analysis
Cells were lysed with RIPA buﬀer including Halt Protease Inhibitor Cocktail (mouse myoﬁ-
broblasts) or sodium vanedate (catalog #S6508, Sigma) and complete mini (Roche, Penzberg,
Germany #11836170001; human lung ﬁbroblasts). After storage at −80◦C, cell lysates were
sonicated and processed for immunoblot analysis (as described in ‘in vivo’ methods).
siRNA transfection of pulmonary mouse myofibroblasts
Primary neonatal mouse myoﬁbroblasts were transfected with either 100nM speciﬁc siRNA
against PDGF-Rα (Santa Cruz Biotechnology, Inc., Germany #sc-29444) or 100nM control
siRNA B (Santa Cruz Biotechnology #sc-44230) suspended in TurboFect (Thermo Fisher
Scientiﬁc, Waltham, MA #R0531) or remained untreated controls in siRNA transfection media
(Santa Cruz Biotechnology, Inc., Germany #sc-36868). Transfection with siRNA was repeated
after 17 hours.
Caspase activity and immunoblot analysis in human umbilical vein endothelial cells
Mycoplasma tested Human umbilical vein endothelial cells (HUVECs) (Commercially obtained
from Lonza #CC-2935) were cultured in EBM-2 Basal Media (#00190860, #cc-4176, Lonza,
mycoplasma free) with EGM-2 Single Quots supplements (Lonza #cc-4176) on 0.2% gelatin
(Sigma Aldrich #G1393) coated 96-well plates (5000 cells/well) or 6-well plates (150,000
cells/well). After obtaining stable culture conditions, HUVECs were incubated with culture
supernatants collected from three groups of mouse myoﬁbroblasts: I) untreated myoﬁbroblasts
(TurboFect), II) control siRNA treated myoﬁbroblasts and III) myoﬁbroblasts treated with
siRNA against PDGF-Rα. For caspase activity assay, incubation with 40µg/ml anti-VEGF
(C-1) antibody (#sc-7269, Santa Cruz) served as a positive control. Caspase activity was
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assessed after 6 hours using the Caspase-Glo 3/7 assay kit (#G8091, Promega). After 6h of
incubation, caspase activity was assessed using the Caspase-Glo 3/7 assay kit (Promega GmbH,
Germany #G8091) according to the manufacturer’s instructions. Cells plated in 6-well plate
were lysed after 6h incubation and lysate was processed for immunoblot analysis with cleaved
caspase 9 (Cell Signaling Technologies #9509) and eNOS (Cell Signaling Technologies #880)
protein.
Luciferase assay
PDGF-Rα promoter inserted in a reporter plasmid was transfected in CCL206 stimulated
with TGF-β1. Luciferase activity was assessed the next day using Dual Luciferase assay. For
generation of reporter please refer to Supplemental methods.
Functional assays for myoﬁbroblasts
Mouse and human myoﬁbroblasts or lung ﬁbroblasts were subjected to analysis of proliferation
(Cell titer Glo assay and manual counting) and migration (Boyden chamber assay and scratch
migration assay) followed by the application of stretch and TGF-β as shown in Supplemental
Figure A.13C. Proliferation assays and scratch migration assay were performed after 48h of
application while migration assay was done after 8h. For detailed description of proliferation,
boyden chamber and scratch migration assays please refer to Supplemental methods.
Statistical analysis
All datasets are presented as mean ± SD. Statistical analysis was performed using Prism 5 and
6 software package (GraphPad, San Diego, CA). Two-way analysis of variance (ANOVA) and
post-hoc test with Bonferroni correction was performed to compare controls and mechanically
ventilated WT (PDGF-Rα+/+) and haploinsuﬃcient (PDGF-Rα+/−) newborn mice. For
in vitro experiments, One-way ANOVA and post-hoc test with Bonferroni correction was
performed to compare more than two groups of Myoﬁbroblasts (immunoblot, migration and
proliferation analysis). For analysis of caspase activity to HUVECs non-parametric Kuskal
Wallis test was performed. To compare datasets from two groups of either WT or PDGF-Rα+/−
mice (immunoblot, migration and proliferation analysis, reporter assays), parametric unpaired
student’s t-test with Welchs correction or the non-parametric Mann-Whitney test (for datasets
with a skewed distribution) was performed with two-tailed or one-tailed analysis. Test groups
were always compared to control group. Diﬀerences were considered statistically signiﬁcant
when the p value was < 0.05. For microarray, data was analyzed in a target gene approach
using the Pearsons correlation coeﬃcient to correlate expression of PDGF-Rα and TGF-β in
preterm infants with and without BPD. Correlation coeﬃcients in preterm infants with and
without BPD were tested using the R-packages psych. Statistical methods applied for the SNP
analysis are outlined above.
Results
Enrichment of PDGF-Rα SNPs associated with reduced protein levels and
migration of lung ﬁbroblasts from ventilated preterm infants developing
nCLD
We conﬁrm reduced PDGF-Rα expression in lung ﬁbroblasts isolated from ventilated preterm
infants. This reduction in PDGF-Rα expression was correlated with increased duration of
MV-O2, as quantiﬁed by immunoﬂuorescence and immunoblot analysis (Figure A.3A). Further,
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a case-control analysis of PDGF-Rα in 1061 newborns (n = 492 with moderate or severe BPD)
identiﬁed 14 SNPs out of 117 with nominal signiﬁcance (p <= 0.05) (Figure A.3B). Three
of these SNPs were highly statistically signiﬁcant, with p-values below 0.001 (Supplemental
Table A.1). The presence of at least one SNP at these 3 positions (rs12506783) was associated
with reduced PDGF-Rα gene expression and PDGF-R as well as VEGF-A protein levels in
blood from ventilated preterm inants (Figure A.3C-E, Supplemental Figure A.11). In human
lung ﬁbroblast this SNP is associated with reduced PDGF-Rα protein level in accordance
with reduced migration (Figure A.3F-G). Analysis of SNPs cis-regulating gene expression for
genes in the PDGF-pathway and its downstream pathways showed enrichment of low p-values
for SNPs linked to the MAPKKK-cascade, JAK/STAT-cascade, apoptosis, cell cycle, DNA
metabolism, lipid metabolism, protein metabolism, and actin and calcium ion homeostasis
(Supplemental Table A.2). Together, these experiments indicate that MV-O2 in humans results
in a reduction of PDGF-Rα expression by alveolar ﬁbroblasts, and suggests that genetic risk
factors for reduced PDGF signaling in human infants is associated with an increased risk of
developing nCLD.
PDGF-Rα haploinsuﬃciency drives the air sac pathology of nCLD in
neonatal mice undergoing MV-O2
In order to test whether attenuated PDGF signaling was indeed a risk factor for the development
of nCLD as suggested by our human SNP data and not restricted to the air sac component, we
obtained gene-targeted mice lacking one allele of PDGF-Rα and subjected them to MV-O2 using
a unique preclinical mouse model. We found that lungs of PDGF-Rα haploinsuﬃcient newborn
mice undergoing MV-O2 for 8h showed a signiﬁcant increase in distal airspace size and decrease in
radial alveolar counts resembling nCLD pathology as assessed by quantitative morphometry when
compared to unventilated controls (Figure A.4A-C), whereas their ventilated WT littermates
were unaﬀected. As expected with this phenotype, there were fewer secondary septae in PDGF-
Rα+/− neonatal mice after MV-O2 for 8h as compared to WT mice (Figure A.4D), with no
signiﬁcant diﬀerence in lung volumes between the groups (WT control 55.3±7.0µl/g bw; WT
MV-O2 56.2±14.2µl/g bw; PDGF-Rα
+/− control 59.7±11.9µl/g bw; PDGF- Rα+/− MV-O2
57.6±23.7µl/g bw; mean and SD each). Atelectasis, as analyzed using ImageJ, involved 14-18%
of the total lung in both groups undergoing MV-O2 (WT MV-O2 17.2±9.6%; PDGF-Rα
+/−
MV-O2 22.8±10.4%; p = 0.61).
Immunoblot and mRNA analysis conﬁrmed reduced pulmonary PDGF-Rα level (Figure A.4G,
Figure A.1D), reﬂected by the reduced number of myoﬁbroblasts localized on septal crests in
ventilated PDGF-Rα+/− mice lungs compared to WT littermates (Figure A.4E-F). Diminished
JAK-2 and STAT-3 in ventilated PDGF-Rα+/− mice reﬂects reduced PDGF-Rα downstream
signaling (Figure A.4H-I).
PDGF-Rα haploinsuﬃciency drives reduced pulmonary micro-vessel density
with increased endothelial cell apoptosis in neonatal mice undergoing
MV-O2
We next asked whether attenuated PDGF signaling would also reproduce the vascular defect
of nCLD. Indeed, we demonstrated by histological analysis of PDGF-Rα+/− mice undergoing
MV-O2, a signiﬁcant reduction in the number of alveolar micro-vessels (20− 100µm), notably
exceeding the eﬀect observed in WT pups (Figure A.5A). This ﬁnding was corroborated by
immunoblot analysis showing reduced lung protein levels of the endothelial cell markers, VEGF-
R2 (Figure A.5B), and VE-Cadherin (Figure A.5C) in ventilated neonatal PDGF-Rα+/− mice,
suggesting a net loss of endothelial cells. Co-staining for apoptosis and endothelial cell markers
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Figure A.3: Enrichment of PDGF-Rα SNPs associated with reduced protein levels and migration of
lung ﬁbroblasts from ventilated preterm infants developing nCLD (A) Decreased PDGF-Rα
expression in human lung ﬁbroblasts (hMFBs) from preterms undergoing MV-O2 (21.7±8 vs
4.7±1 days of life; serial samples 2&5, 3&6) (n = 3 patients/group). (B) Regional association
plot showing -log10 p-values (y-axis) of SNPs according to chromosomal positions (x-axis).
Light blue: Estimated recombination rate (cM/Mb, HapMap CEU population); blue: most
signiﬁcant SNP (rs12506783); red: r2≥0.8, white: r2≥0.2. (C) Levels of PDGF-Rα gene
expression in patients (n = 9) which are carrying at least one SNP (minor allele) compared
to patients with no SNPs (major allele). Major alleles are given in the ﬁgure labels. Minor
alleles of rs10022540 is A, in rs11133311 is T, and in rs12506783 is C. (D-E): PDGF-R (D)
and VEGF-A (E) protein levels in separate patient cohort (n = 13) carrying at least one
SNP (minor allele) at position rs12506783 compared to patients with no SNPs (major allele).
Protein levels were quantiﬁed using SOMAlogic technique. Two-tailed unpaired Student’s t test
(p = 0.0281−0.0863). #p = 0.0863. (F-G): Representative PDGF-Rα levels (F) and migratory
potential assessed by boyden chamber assay (G) in ﬁbroblasts isolated from tracheal aspirates
of patients with nCLD. The ﬁbroblast carrying SNP at both alleles (homozygote minor allele)
displayed reduced PDGF-Rα levels and migration when compared to ﬁbroblasts from patients
carrying SNP at one allele (heterozygote minor allele). (n = 3/4 replicates). In (D-G) data is
presented as Mean ± SD. *p < 0.05
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Figure A.4: PDGF-Rα haploinsuﬃciency drives the air sac pathology of nCLD in neonatal mice
undergoing MV-O2 (A) Representative lung tissue sections (200X) from 5-8d-old PDGF-Rα+/+
(WT) and PDGF-Rα+/− mice after 8h MV-O2 showing increased air space size compared to
respective controls (O2-control) spontaneously breathing 40% O2 for 8h. (B) Quantitative
analysis of lung tissue sections showed increased alveolar area after 8h MV-O2 in PDGF-
Rα+/− mice, whereas no signiﬁcant change was observed in WT mice when compared to
respective controls (n = 6 − 11 mice/group). (C) Radial alveolar counts (alveolar number)
in lung tissue sections from WT and PDGF-Rα+/− mice were reduced after 8h MV-O2
when compared to respective controls (n = 6 − 11 mice/group). (D) Septal density was
signiﬁcantly reduced in PDGF-Rα+/− mice when compared to WT littermates after 8h MVO2
(n = 6− 8 mice/group). (E) Immunoﬂuorescence staining (400X, merged) for PDGF-Rα (red,
white arrows; blue: DAPI) with decreased stain from the septal crests in lungs of ventilated
PDGF-Rα+/− (lower panel) and WT (upper panel) mice undergoing MV-O2. (F) Quantitative
analysis of the immunoﬂuorescence images (200X) showed reduced number of PDGF-Rα+
myoﬁbroblasts located at the septal crests (presented myoﬁbroblasts number per 100 septal
crests; 10 ﬁelds of view in PDGF-Rα and α-smooth muscle actin co-stained sections/animal,
4 animals/group). (G-I) Immunoblot analysis of PDGF-Rα (G) and its downstream proteins
JAK-2 (H) and STAT-3 (I) showing a signiﬁcant reduction of protein level in PDGF-Rα+/−
neonatal mice in contrast to WT mice after MV-O2 for 8h(n = 3 mice/group). PDGF-Rα
levels are displayed as fold change of control. H and I are from same blot hence having same
β-actin bands. In (B-D) and (F-I) data is presented as Mean ± SD. ***p < 0.001, **p < 0.01,
*p < 0.05. Statistical analysis for (B-D) is Ordinary one way anova with Bonferroni’s correction
(p = 0.0001 − 0.029) and (F-I) is Two-tailed unpaired Student’s t test or Mann Whitney test
(p = 0.024− 0.028).
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demonstrated signiﬁcantly increased vascular endothelial cell death in the lung periphery of
ventilated neonatal PDGF-Rα+/− mice compared with WT littermates (Figure A.5E-F).
To further explore the link between reduced PDGF signaling and endothelial cell apoptosis,
we focused on VEGF-A, a critical regulator of pulmonary microvascular development [21–25]
With MV-O2, pulmonary VEGF-A protein level was signiﬁcantly reduced in PDGF-Rα
+/−
mice compared to WT littermates (Figure A.5D). Interestingly, vessel number did not diﬀer
compared to unventilated PDGF-Rα+/− mice (Supplemental Figure A.12).
In order to determine if this reduction was a direct consequence of reduced PDGF-Rα signaling
in myoﬁbroblasts, we isolated primary lung myoﬁbroblasts from WT mice and measured their
production of VEGF-A at baseline as well as following siRNA mediated knock-down of PDGF-
Rα expression in vitro (Figure A.5H, I). We also administered conditioned supernatant from
PDGF-Rα siRNA treated mouse myoﬁbroblasts to human umbilical vein endothelial cells
(HUVECs) in culture, and found reduced endothelial cell survival due to an increase in apoptosis
(Figure A.5G, J) and a reduction in the permeability factor eNOS (Figure A.5K), comparable to
the eﬀect seen with an anti-VEGF-A antibody. These experiments together with Figure A.4G-I
indicate that PDGF-Rα signaling in the myoﬁbroblasts promotes VEGF-A expression, and
corroborates that the microvascular phenotype is downstream of attenuated PDGF signaling.
Supplemental PDGF-A rescues both the air sac and microvascular nCLD
phenotypes induced by MV-O2 in neonatal PDGF-Rα haploinsufficient mice
As suggested by the human SNP data and our experiments above, if the attenuated PDGF
signaling drives the pathogenesis of nCLD in all its manifestations, experimentally augmenting
PDGF signaling in the lungs of ventilated haploinsuﬃcient mice should ameliorate both the air
sac and microvascular phenotypes. To directly test this prediction, we administered exogenous
PDGF-A protein by endotracheal delivery at the onset of MV-O2. The results showed both an
increase in peripheral lung microvessel number (20− 100µm) in treated versus untreated PDGF-
Rα+/− neonatal mice undergoing MV-O2, as well as a normalization of air sac defects, with
increased alveolar and microvessel number compared with untreated controls (Figure A.6A-C).
The reduction in JAK-2, STAT-3, VE-Cadherin and VEGF-A protein expression in the lungs
of ventilated mice was also ameliorated with PDGF-A treatment, supporting reversal of the
endothelial cell apoptosis (Figure A.6E-H). PDGF-A treatment further enhanced PDGF-Rα
protein, associated with increased levels of AKT, suggesting a feed-forward mechanism where
increased endosomal internalization leads to PDGF-Rα recycling in lung myoﬁbroblasts with
subsequent increase in receptor expression [26, 27] (Figure A.6D, I). The lung periphery of
mechanically ventilated PDGF- Rα+/− neonatal mice also exhibited an increase in (secreted)
VEGF-A protein immunolocalized near myoﬁbroblasts, providing further support (Figure A.6J,
M upper panel). Quantiﬁcation of immunoﬂuorescent staining conﬁrmed a pronounced reduction
in apoptotic (cleaved caspase-3 positive) surface area and individual cells, with dramatically
increased CD31 surface area in PDGF-A treated mice (Figure A.6K-L,-M lower panel). A
physiological rescue was also observed, with an improvement in quasi- static compliance by
lung function testing in neonatal mice pre-treated with PDGF-A (Figure A.6N), with no
signiﬁcant diﬀerence in lung volume (PDGF-A 49.8±5.6µl/g bw vs no-PDGF-A 49.3±3.9µl/g
bw; mean±SD, p = 0.99, Two-tailed Mann Whitney test).
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Figure A.5: PDGF-Rα haploinsuﬃciency drives reduced pulmonary micro-vessel density with increased en-
dothelial cell apoptosis in neonatal mice undergoing MV-O2 (A-D) Histologic and Immunoblot
analysis displayed reduced small-vessel number (20−100µm diameter) normalized to 100 alveoli
as well as reduced pulmonary VEGF-R2, VE-Cadherin and VEGF-A protein levels respectively
(n = 6 − 8 mice/group). (E) Immunoﬂuorescent images of lung tissue (400X; merged) from
neonatal PDGF-Rα+/− mice indicating increased cleaved Caspase-3 (red; white arrows; lower
panel) after 8h MV-O2 in contrast to WT mice (upper panel; green: CD31; blue: DAPI). Double
stain revealed increased cleaved Caspase-3+/CD31+ cells normalized to CD31 area in PDGF-
Rα+/− mice after 8h MV-O2 (n = 4 mice/group, 4 sections/mice and 10 images/section).
(F) Representative image conﬁrming increased endothelial apoptosis in neonatal PDGF-Rα+/−
mice after 8h MV-O2 (lower panel; white arrows) with VE-Cadherin (red) and cleaved caspase-
3 (green) and nucleus stained with DAPI (blue) when compared to WT mice (upper panel).
(n = 2 mice/group). (G Increased caspase-3 activation in HUVECs upon incubation with
supernatants for 6h obtained from lung mouse myoﬁbroblasts after PDGF-Rα-siRNA treatment
when compared to control-siRNA (n = 3 experiments). (H-I) In vitro application of PDGF-Rα-
siRNA to primary lung mouse myoﬁbroblasts from WT mice diminished PDGF-Rα (H) protein
(normalized to control), associated with reduced VEGF-A protein (I). (n = 3mice/group). (J-K)
Increased cleaved caspase-9 and reduced eNOS protein levels in HUVECs upon incubation with
supernatants for 6h obtained from lung mouse myoﬁbroblasts after PDGF-Rα-siRNA treatment
when compared to control-siRNA. (n = 3 mice/group). B and C are from same blot hence
having same β-actin bands. Data is presented as Mean ± SD. ***p < 0.001, *p < 0.05 vs
control, #p < 0.05 vs control-siRNA. Statistical test in (A-E) is Two-tailed unpaired Student’s
t test or Mann Whitney test, in (J-K) One-tailed Mann Whitney test (p = 0.02 − 0.05), in G
is Kruskal Wallis H test (p = 0.027) and in I is Ordinary one way ANOVA with Bonferronis
correction (p = 0.0481).
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Elevated TGF-β levels causally relate with reduced PDGF-Rα expression in
nCLD patients and mice undergoing MV-O2 , reducing downstream
signaling and migration in pulmonary myoﬁbroblasts
Clinical and experimental studies have consistently demonstrated activation of pulmonary
TGF-β signaling with MV-O2 [28–35]. We therefore investigated how reduced PDGF-signaling
and its demonstrated consequences are provoked in the neonatal lung. Hence, we characterized
the two potential players mechanical stretch and TGF-β alone and in combination, with respect
to their eﬀect on primary mouse and human lung myoﬁbroblasts.
Immunoﬂuorescent images of tissue sections from nCLD patients (n = 7) showed reduced
expression of PDGF-Rα associated with increased expression of pSMAD-2 compared with a
control lung, supporting the relevance of the ﬁndings to patients suﬀering from nCLD (Figure
A.7A). In parallel, we performed gene expression microarray analysis of blood samples obtained
from 20 preterm infants in the ﬁrst 72h after birth, which similarly demonstrated an inverse
correlation between the levels of TGF-β1 and PDGF-Rα in patients who went on to develop
nCLD that was not observed in patients who did not (Figure A.7B). We next analyzed TGF-β
signaling activity in the lungs of ventilated WT mice, which demonstrated increased p-SMAD
2/3 protein with a concomitant reduction in PDGF-Rα+ alveolar myoﬁbroblasts (Figure A.7C).
To test the impact of TGF-β on PDGF-Rα promoter activity, we conducted a luciferase
assay by transfecting CCL206 cells with a pGal vector carrying a PDGF-Rα promoter insert.
Administration of TGF-β caused a 50% reduction in luciferase activity (Figure A.7D), indicating
that TGF-β aﬀects PDGF-Rα gene transcription, supporting the inverse relationship observed
in nCLD is causal.
Figure A.6 (following page): Supplemental PDGF-A rescues both the air sac and microvascular nCLD
phenotypes induced by MV-O2 in neonatal PDGF-Rα haploinsuﬃcient mice
(A) Improved alveolar structure in 5-8d-old PDGF-Rα+/− mice undergoing
8h MV-O2 after intra-tracheal treatment with PDGF-A (10µl/g bw, 25ng/ml
PDGF-A) when compared to mice receiving sterile saline (200x), conﬁrmed by
quantitative image analysis with increased alveolar counts (B) as well as vessel
number normalized to 100 alveoli (C) (20− 100µM) (n = 2− 4 mice/group).
(D-I) Immunoblot analysis of total lung homogenates showed increased PDGF-
Rα (D) together with increased JAK-2 (E), STAT-3 (F), VEGF-A protein
(G) VE-Cadherin (H) and AKT (I) protein levels in PDGF-A treated PDGF-
Rα+/− mice after 8h MV-O2 when compared to WT littermates (n = 3− 4
mice/group). (J-M) Quantitative image analysis indicated increased VEGF-A
to PDGF-Rα protein levels (K, M; upper panel) together with an increase in
CD31 expression in relation to total tissue (K, M; lower panel) and a decrease
in apoptotic (Cleaved caspase-3) CD31 expressing cells (L) in the lungs of
PDGF-A treated PDGF-Rα+/− mice when compared to saline treated controls
after 8h MV-O2 (n = 2− 4 mice/group). Upper panel in M is PDGF-Rα+/−
mice treated with NaCl (left) or PDGF-A (right) sections stained with VEGF-
A (green), PDGF-Rα (red) dual positive (orange, white arrows) and inserts
show VEGF-A stain (green). Lower panel shows PDGF-Rα+/− mice treated
with NaCl (left) or PDGF-A (right) sections stained with Cleaved-caspase 3
(green), CD31 (red) dual positive (orange, white arrows). Nucleus is stained
with DAPI (blue). (N) Treatment with PDGF-A in ventilated neonatal PDGF-
Rα+/− mice led to improved lung compliance displayed as a function of airway
pressure (Ptramax) and tidal volume when compared to untreated mice (n = 4
mice/group). D-H and E-F are from same blot hence having same β-actin
bands. In (B-L) the data is presented as Mean ± SD. ***p < 0.001, **p <
0.01, *p < 0.05, #p < 0.065. Statistical test used is One-tailed unpaired
Student’s t test (p = 0.023− 0.065), in C and G is Two-tailed Mann Whitney
and unpaired Student’s t test (p = 0.02− 0.05).
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Figure A.7: Elevated TGF-β levels causally relate with reduced PDGF-Rα expression in nCLD patients
and mice undergoing MV-O2, reducing downstream signaling and migration in pulmonary
myoﬁbroblasts (A) Representative immunoﬂuorescence images showing reduced expression of
PDGF-Rα (red) in the lungs of patients (n = 7) developing nCLD (lower left panel, red stain;
white arrows) together with increased pSMAD-2 expression (green; upper middle panel; green
stain; white arrows) as compared to lung sections from a non-nCLD patient (n = 1) (upper
panel) (200x). (B) Negative correlation between PDGF-Rα and TGF-β1 in transcriptome
analysis 72h after birth in preterms with nCLD (n = 11) in contrast to non nCLD (n = 9; scatter
plots log2-gene expression; linear regression (blue), CI (grey), (p = 0.05). (C) MV-O2 reduced
lung PDGF-Rα (main: red stain; white arrows) and increased pSMAD-2 levels (insert: red stain;
white arrows) in neonatal PDGF-Rα+/− (lower panel) when compared to WT mice (upper
panel); (n = 4 mice/group; 10 images/mouse; 200x). (D): Luciferase assay of CCL-206 cells
transfected with pGL4.14 containing PDGF-Rα promoter revealing reduced promoter activity
upon TGF-β application (normalized to control). (n = 3 experiments). (E-G) Immunoblot
analysis showing reduced PDGF-Rα (E), pERK/EKR (F) and VEGF-A (G) protein levels upon
TGF-β application alone in primary pulmonary myoﬁbroblasts from 5-7d old WT mice (n = 6−9
mice/group). (H) Reduced migration of myoﬁbroblasts (MFBs) from neonatal WT mice upon
TGF-β application alone (n = 5 mice/group, 3 technical replicates). (I-J) Translation of the
results in ﬁbroblasts isolated from tracheal aspirates of ventilated preterm infants (hMFBs)
displayed reduced PDGF-Rα levels (I) and migration assessed by boyden chamber assay (J)
upon TGF-β application. (n = 3 − 5 patients/group). (K-M) Representative phase contrast
images (100X) of scratch migration assays in human lung ﬁbroblasts (hMFBs) after 48h of TGF-
β incubation indicating decreased wound closure (K) quantiﬁed by reduced distance travelled
(L) and velocity (M). (n = 3 patients/group). In (E-J) and (K-M) data is presented as Mean
± SD and normalized to control. Statistical test used is Two-tailed unpaired student’s t test
or Mann Whitney test (p = 0.0002 − 0.039). ***p < 0.001, **p < 0.01, *p < 0.05; C:
un-stretched untreated control; Th1: un-stretched myoﬁbroblasts subjected to 5ng/ml TGF-β
(24h)
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We further conﬁrmed the eﬀect of TGF-β on PDGF-Rα signaling in primary pulmonary
myoﬁbroblasts isolated from WT neonatal mice and ﬁbroblasts isolated from tracheal aspirates
of nCLD patients.This analysis showed a signiﬁcant downregulation in PDGF-Rα level, its
signalling measure by pERK/ERK and impaired function displayed as reduced migration (Figure
A.7E-F, H). In accordance with the in vivo data, VEGF-A signaling associated with micro-vessel
development was also diminished by 20% in pulmonary myoﬁbroblasts from neonatal WT
mice incubated with TGF-β (Figure A.7G). Translating this ﬁnding in human we demonstrate
diminished PDGF-Rα levels and migration of ﬁbroblasts (Figure A.7I). Reduced migration upon
TGF-β was conﬁrmed by boyden chamber and wound migration assays showing signiﬁcantly
abrogated velocity and distance travelled by ﬁbroblasts in comparison to untreated controls
(Figure A.7J-M).
Pronounced eﬀect of TGF-β on pulmonary myoﬁbroblasts from
PDGF-Rα+/− mice and in concert with mechanical stretch on both mice
and human myoﬁbroblasts
The inhibitory eﬀect of TGF-β on PDGF-Rα level and downstream proteins JAK-2, STAT-3
and pERK/ERK was dramatic in myoﬁbroblasts isolated from PDGF-Rα+/− mice with more
than 30-50% reduction in the respective proteins (Figure A.8A-C, E).This was accompanied by
reduction in vascular marker VEGF-A and diminished migration (Figure A.8D, F).
Mechanical ventilation has been demonstrated to exert signiﬁcant strain forces on the
developing lung in infants requiring invasive and even non-invasive respiratory support [3]. We
therefore dissected the contribution of mechanical stretch and the impact of growth factor
Figure A.8 (following page): Pronounced eﬀect of TGF-β on pulmonary myoﬁbroblasts from PDGF-
Rα+/− mice and in concert with mechanical stretch on both mice and
human myoﬁbroblasts (A-E) TGF-β application (Th1) to myoﬁbroblasts
(MFBs) isolated from neonatal PDGF-Rα+/− mice reduced PDGF-Rα (A),
JAK-2 (B), STAT-3 (C), VEGF-A (D) and pERK/ERK (E) protein levels when
compared to control. (n = 3−6mice/group). (F) Reduced migration assessed
by boyden chamber in myoﬁbroblasts (MFBs) isolated from PDGF-Rα+/−
mice compared to WT mice. (n = 5 mice/group). (G-J): TGF-β application
in combination with mechanical stretch (S+Th1) in myoﬁbroblasts (MFBs)
isolated from neonatal WT mice showed reduced PDGF-Rα (G) and VEGF-A
(H) protein as well as migratory RAS (I) and pERK/ERK (J) protein levels
when compared to control myoﬁbroblsts as assessed by immunoblot assay.
(n = 6− 9 mice/group). (K) TGF-β application (Th1) as an additional dose
(Th2) on stretched myoﬁbroblasts (MFBs) from WT mice reduced migration
as assessed by boyden chamber assay. (n = 5 mice/group). (L-M) TGF-β
application in combination with stretch (S+Th1) reduced PDGF-Rα protein
levels in ﬁbroblasts (hMFBs) isolated from tracheal aspirates of nCLD patients
when compared to control (C) or stretched (S) myoﬁbroblasts (L) and as
an additional dose (TH2) to stretched ﬁbroblasts reduced migration (M).
(n = 3 − 6 patients/group). A-E and B-C are from same blot hence having
same β-actin bands. Values are normalized to the respective controls except
for B-D. Data is presented as Mean ± SD. Statistical test used in (A, D-
F) is Two-tailed and (B-C) is One-tailed student’s t test or Mann Whitney
test (p = 0.004 − 0.05) and in (G-M) is ordinary One way ANOVA with
Bonferroni’s correction (p = 0.0001 − 0.04). ***p < 0.001, **p < 0.01,
*p < 0.05. C: Un-stretched untreated control; S: stretched myoﬁbroblasts
(24h); Th1: un-stretched myoﬁbroblasts subjected to 5ng/ml TGF-β (24h);
S+Th1: myoﬁbroblasts stretched in parallel to TGF-β application (5ng/ml)
(24h); Th2: re-incubation with 5ng/ml TGF-β (8h).
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Figure A.9: Eﬀect of TGF-β in combination with mechanical stretch on PDGF-Rα signaling and
functional properties of ﬁbroblasts (A) No change in migration of myoﬁbroblasts (MFBs)
from newborn WT mice with mechanical stretch (n = 5 mice/group). (B-D) Analysis of
proliferation (Cell Titer Glo) exhibited no change upon TGF-β (B) or stretch (C) in mouse
myoﬁbroblasts (MFBs) from WT mice, while an increase in proliferation observed when mouse
myoﬁbroblasts were stretched in presence of TGF-β were subjected to an additional dose of
TGF-β (D) (n = 9 mice/group). (E-F) Immunoblot analysis showing increased proliferation
markers like PCNA (E) levels with mechanical stretch and PI3K (F) upon additional TGF-β
incubation on stretched myoﬁbroblasts (MFBs) from newborn WT mice (n = 6 mice/group).
Values here are normalized to respective controls. Data is presented as Mean ± SD. Statistical
analysis in (A-C, E) is Two-tailed unpaired Student’s t test and in (D, F) is Ordinary one
way ANOVA with Bonferroni’s correction. **p < 0.01, *p < 0.05. (p value range =
0.0080−0.0232) C: Un-stretched untreated control; S: stretched myoﬁbroblasts (24h); Th1: un-
stretched myoﬁbroblasts subjected to 5ng/ml TGF-β (24h); S+Th1: myoﬁbroblasts stretched
in parallel to TGF-β application (5ng/ml) (24h). S+Th2: myoﬁbroblasts stretched for 24h
followed by incubation with TGF-β (5ng/ml) for 24h.
exposure on PDGF signaling in vitro. Here we found that mechanical stretch in combination with
TGF-β signiﬁcantly reduced PDGF-Rα level in mouse myoﬁbroblasts together with a matched
reduction in VEGF-A expression conﬁrming our in vivo ﬁndings (Figure A.8G-H). With respect
to myoﬁbroblast function, we found that mechanical stretch in the presence of single or repeat
doses of TGF-β signiﬁcantly reduced migration in primary pulmonary myoﬁbroblasts from
WT mice together with a signiﬁcant reduction in RAS and downstream pERK/ERK protein
level, a signaling downstream of PDGF-Rα with a crucial role in myoﬁbroblasts migration
(Figure A.8I-K) [36, 37]. In addition, mechanical stretch in the presence of TGF-β increased
myoﬁbroblast proliferation, together with proteins associated with proliferation PI3K and
PCNA level (Figure A.9B-F). Whereas TGF-β in the absence of mechanical stretch was able to
achieve comparable eﬀects on myoﬁbroblast migration, PDGF-Rα and VEGF-A protein level
(Figure A.7E, G, H), mechanical stretch alone did not alter the migratory behaviour or protein
expression in the lung myoﬁbroblasts but did increase their proliferative behaviour (Figure
A.8G, H, and Figure A.9A, C).
Translating these eﬀects to primary human ﬁbroblasts obtained from tracheal aspirates
of preterm nCLD patients, we found a signiﬁcant reduction in PDGF-Rα protein level and
migration by TGF-β in combination with stretch (Figure A.8L-M). In line with this, repeated
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application of TGF-β in combination with stretch markedly reduced the migration of human
lung ﬁbroblasts (Figure A.8M).
Taken together, these results indicate that elevated TGF-β signaling in the setting of MV-O2
contributes to the development of nCLD, exacerbating the deﬁciency in PDGF signaling by
inhibiting expression of PDGF-Rα on lung myoﬁbroblasts.
The central role of the PDGF signaling cascade closely intertwined with upstream eﬀectors
and downstream eﬀects with critical consequences for cellular functions in the injured neonatal
lung as well as its recue with administration of PDGF-A is depicted in Figure A.10.
Discussion
Neonatal chronic lung disease (nCLD), formerly known as Bronchopulmonary Dysplasia, has
long-term health consequences not only for lung but also neurologic function. Invasive and
non-invasive mechanical ventilation with oxygen-rich gas (MV-O2) is necessary for the survival
of preterm babies suﬀering from respiratory failure due to lung immaturity and insuﬃcient
respiratory drive after birth. Nontheless, both treatments are known to contribute to adverse
pulmonary outcome, i.e. the development of nCLD [3]. Hence it is critical to pursue medical
treatments that can prevent or treat nCLD in neonatals requiring ventilatory support. Here, we
provide causal evidence supporting a surprising cellular and molecular model for the development
of nCLD. As shown in mouse and human, PDGF signaling not only aﬀects secondary septation
but signiﬁcantly impacts on the micro-vascular structure in close relation with the omnipresent
TGF-β in the injured neonatal lung (Figure A.10A). This close intertwinement of growth factor
signalling in nCLD pathology with PDGF as a central driver holds promising potential for
therapeutic approaches.
The integration of PDGF-Rα haploinsuﬃcient mice with a unique pre-clinical model of nCLD,
together with tailored biochemical and in vitro assays of human and mouse primary lung cells,
allowed us to elucidate the molecular pathogenesis of this disease to an unprecedented level of
understanding. Building upon previous observations suggesting a role for reduced PDGF-Rα
signaling in lung pathology [13, 11, 38, 39, 12, 18], we dissected upstream and downstream
molecular regulators of nCLD, including a crosstalk with VEGF-A and TGF-β with mechanical
stretch (Figure A.10A).
Our ﬁnding that impairment of the PDGF signaling pathway - previously associated only
with myoﬁbroblast migration and secondary septation of air sacs - is capable to produce both
the alveolar structural and microvascular pathology of nCLD is surprising. Is it possible
that due to the dynamic intercellular crosstalks required to generate the highly stereotyped
and architecturally complex arrangement of alveoli, disruption of a single program indirectly
disrupts closely coordinated, but distinct, processes? There is some precedent for this model,
since inhibition of VEGF in lung development has been shown to result in reduced epithelial
proliferation and impaired sacculation [40]. However, as we show in the case of PDGF-Rα,
the causal relationship may be more direct, since VEGF-A is apparently produced not only
by lung epithelial cells, but also by myoﬁbroblasts in response to PDGF and its down- stream
signalling through JAK and STAT [41, 42]. Perhaps this additional level of patterned VEGF-A
production is important for ensuring proper investment of newly-forming secondary septal walls
by the microvascular network. In any case, our demonstration of the therapeutic activity of
exogenously administered PDGF-A (Figure A.10B) for rescuing both the air sac septation
and microvascular defects is highly promising, particularly since previous attempts to improve
vascularization by administering exogenous VEGF-A not only failed to rescue nCLD, but
actually induced capillary leakage [43].
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Figure A.10: Model for how attenuated PDGF signaling and positive pressure ventilation interact to
produce the distinct phenotypic manifestations of nCLD (A) MV-O2 in vivo, a combination
of O2 i.e. oxygen and stretch (purple arrow) and/or TGF-β alone or in combination with
mechanical stretch in vitro (yellow arrow) reduce platelet derived growth factor receptor
α (PDGF-Rα) levels and its downstream signaling through JAK-2 and STAT-3 in the
pulmonary myoﬁbroblast (MFB).This reduction in turn abrogates vascular endothelial growth
factor expression (VEGF-A and VEGF-R2), leading to increased apoptosis in pulmonary
endothelial cells (EC). Whereas myoﬁbroblast migration is diminished through reduces RAS
and pERK/ERK signaling, stretch alone increases their proliferation, hence depicting the
diﬀerential eﬀect of the most important denominators of nCLD development in the premature
lung undergoing MV-O2. (B) Application of PDGF-A to premature lung increases PDGF-Rα
levels in an AKT dependent manner in turn activating the downstream cascade through JAK-
2, STAT-3 signaling. This then activates VEGF-A secretion and VEGF-R2 activity reducing
apoptosis in endothelial cells (ECs).
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Supplemental methods
Study design
Preterm infants born below 32 weeks of gestational age and matched control infants with respect
to gestational age, gender, percentage of individuals considered small for GA, and country of
maternal origin were selected for the study. Exclusion criteria were oligo- or anhydramnios,
severe congenital malformations, severe metabolic disorders and prepartum treatment of the
mother with cytostatic or immunosuppressive medication other than for lung maturation.
Mice were randomly selected from each litter to undergo mechanical ventilation. 6-11 mice
were utilized per group for histological analysis as well as 3-6 mice per group for protein analysis.
Tissue sections from the respective mouse lungs were selected randomly for hematoxylin
and eosin as well as immunostainings. In vitro experiments were performed on myoﬁbroblasts
obtained from 3-9 diﬀerent mice. Functional assays on both mice myoﬁbroblasts and human lung
ﬁbroblasts (proliferation and migration analysis) constituted 3 biological replicates consisting of
2-3 technical replicates each resulting in a total of 5-9 samples from diﬀerent mice analyzed per
condition (stretch and/or TGF-β treatment).
Human studies
SNP and protein analysis
All relevant perinatal diagnoses were provided for statistical analysis. Patients with moderate or
severe BPD according to the deﬁnition by Jobe et al. from both cohorts were considered cases
(Jobe, 2011). Exclusion criteria were oligo- or anhydramnios, severe congenital malformations,
the diagnosis of severe metabolic disorders and prepartum treatment of the mother with
cytostatic or immunosuppressive medication other than for lung maturation led to exclusion
of the neonate. Cases (controls) had a median GA of 26.6 (27.0) weeks, 42.5 (45.7) % were
female, and 28.0 (26.7) % were found to be small for GA. Duration of oxygen supplementation
was 80 (15) days in median. Genotypes of PDGF-Rα SNPs (single nucleotide polymorphisms)
were determined in neonates using Aﬀymetrix Axiom microarrays based on the Axiom CEU
array supplemented with some custom content. Among the 1061 individuals with genetic data
passing QC, 492 developed BPD grade 2 or 3 and were considered cases. Cases and controls
were balanced for sex, gestational age at birth, status ‘small for gestational age’, and country of
origin of the mother. 117 SNPs within 100 kB upstream and downstream of PDGF-Rα, present
on the array, and passing QC were selected for analysis; case-control analysis was adjusted for
relatedness to account for multiple births. The PDGF signaling pathway and several pathways
downstream of PDGF signaling were analyzed for evidence regarding genetic regulation of
gene expression of their pathway elements. From our genome-wide dataset, genetic markers
were identiﬁed either directly or via linkage disequilibrium as corresponding to SNPs found
to contribute to genetic regulation of gene expression (i.e. eQTL SNPs) in several studies
[22, 44–47]. The distribution of p-values for these SNPs was analyzed using the R-package
snpMatrix [48] to identify pathways for which p-values in our BPD-association analysis showed
nominally more evidence for association than would be expected by chance. A part of patients
from this cohort (n = 9, Supplemental Table A.3A) were subjected to PDGF-Rα transcriptome
analysis as described in microarray methods section.
A separate patient cohort consisting infants with or without later development of BPD and
a GA < 32 weeks with excluding growth retardation was included at the Perinatal Center of
the Ludwig-Maximilians-University, Campus Grosshadern (n = 13). Patient characteristics
of this cohorts are given in Supplemental Table A.3B. Whole blood samples were collected
at days 22-58 after birth in Ethylenediaminetetraacetic acid (EDTA) neonatal collection
tubes. Generated plasma samples were stored at −80◦C and later subjected to proteomic
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screening (SOMAscanTM, SomaLogic, Boulder, USA). For the assay high quality samples
were used and protein binding to 1129 individual high aﬃnity molecules (SOMAmerR�) was
quantiﬁed by custom Agilent hybridization array [49]. Even low amount samples (90− 160µl)
showed high reproducibility. The SNP genotyping of this samples for the most signiﬁcant
SNP position rs12506783 was performed by Euroﬁns Genomics. Brieﬂy, sequences forward
CAAAATACCTGGAAGCTCTGGAG and reverse CCAGCATTCAATTCATACTTGCTG
were generated using a re-sequencing approach. According to the reference sequence, the
necessary primers were deﬁned in order to create overlapping PCR fragments and for subsequent
sequencing to have the region of interest covered in a satisfactory manner. PCR puriﬁcation
was performed with 10% PolyEthylenGlycol (PEG8000) in 30% Isopropyl alcohol/1M NaCl
for precipitation and a washing step with 80% Ethanol. All sequences were generated using
BigDye terminator chemistry (version 3.1), if necessary in combination with dGTP BigDye
terminator chemistry (version 3.0) (Thermo Fisher Scientiﬁc, Waltham, MA USA) following
standard protocols. For sequencing reactions peqStar 96 HPL (PEQLAB Biotechnologie GMBH,
Erlangen, Germany) or GeneTouch (Biozym Scientiﬁc GmbH, Oldendorf, Germany) thermal
cyclers were used. Sequencing reaction cleanup was done either manually or on a Hamilton
Starlet robotic workstation (Hamilton Robotics GmbH, Martinsried, Germany) by gel-ﬁltration
through a hydrated Sephadex matrix ﬁlled into appropriate 96 well ﬁlter plates followed
by a subsequent centrifugation step. Finally all reactions were run on ABI3730xl capillary
sequencers equipped with 50 cm capillaries and POP7 polymer (Thermo Fisher Scientiﬁc,
Waltham, MA USA). Sequencing data was generated using the original ABI Software including
the KB-basecaller, which assigns quality values to all called bases similar to PHRED [50].
Additional basecalling was performed using the PeakTrace basecaller from Nucleics Pty Ltd
(Woollahra, AUS) according to SOP SEQ PeakTrace to improve the single peak resolution and
quality values and therefore increase the reading lengths. Primer sequences used were forward
GTACTGGGATTACAGGTGTGAG and reverse ATAACATCCCAGGAGGCCTAC.
Human primary lung fibroblasts
Patients for tracheal aspirate analysis were recruited following the same in- and exclusion
criteria as outlined above. Samples from 6 patients were used. Two patients provided serial
samples; two patients were recruited with individual samples with respect to the early and later
time point for PDGF-Rα expression analysis. Tracheal aspirates were obtained from preterm
infants undergoing MV-O2 who later developed nCLD, i.e. mild, moderate or severe BPD
(gestational age 24± 1.4 weeks, birth weight 650± 80.2g, MV-O2 43± 24 days (mean ± SD)).
Patient characteristics are mentioned in Supplemental Table A.3C. First samples were obtained
early after the initiation of MV-O2 (4.7±1 day of life); second samples were taken during the
third week of life (21.7±8 day of life). Primary human lung ﬁbroblasts were cultured 80%
conﬂuent in DMEM medium with 20% FCS (PAN Biotech GmbH, Aidenbach, Germany), 2mM
L-glutamine, and penicillin/streptomycin (Thermo Fisher Life Technologies, Carlsbad, CA).
FACS analysis was performed to check the purity of the cultures as described in the manuscript.
Blood sampling, RNA isolation and microarray analysis
Brieﬂy, blood was sampled from an indwelling umbilical artery catheter at birth. RNA isolation
was performed according to the manufacturer’s recommendations (PreAnalytiX). RNA was
hybridized on CodeLink Human Whole Genome Bioarrays (GE Healthcare) using the CodeLink
Expression Assay Kit (GE Healthcare) and samples processed using CodeLink Expression
Software V4.1 (GE Healthcare). The dataset was initially prepared using the manufacturer
recommended subtract background correction and median normalization. Data was then ﬁltered
for transcripts with high rates of missing values, low expressed values, or outlier values. Missing
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values were imputed using the sequential nearest neighbor (SeqKNN) approach [51]. The dataset
was then normalized using the quantile normalization method [52]. For data preparation the
Bioconductor packages SeqKnn and limma for quantile normalization were used.
Human lung slides
Human slides were obtained from paraformaldehyde ﬁxed and paraﬃn embedded autopsy
lungs from preterm infants with diﬀerent BPD grades (n = 7) and an infant that died from a
non-pulmonary cause. Median gestational age of BPD patients was 26+0 weeks (25+4 - 31+0)
and gestational age of the control infant was 26+5 weeks. All patients died between 28 and
66 days after birth and none were treated with extracorporeal membrane oxygenation. No
chromosomal or other congenital anomalies were present in all patients. Tissue sections were
stained for PDGF-Rα, and TGF-β for further quantiﬁcation. The patient characteristics are
mentioned in Supplemental Table A.3D.
In vivo studies
Assessment of protein expression in distal lung
PFA-ﬁxed lung tissue sections were stained for PDGF-Rα (C-20) (Santa Cruz Biotechnology #sc-
338), α-SMA (Sigma Aldrich #A5228), VEGF-A (C-1) (Santa Cruz Biotechnology #sc-7269),
CD31 (Dianova, Hamburg Germany #DIA-310), cleaved caspase-3 (Cell Signaling Technology
#9661S), VE-Cadherin (H-72, Santa Cruz Biotechnology #28644), pSMAD-2/3 (Santa Cruz
Biotech #SC-8828) and DAPI (Sigma Aldrich #D8417) alone or in combination. Number
of total nuclei as well cleaved caspase-3 and CD-31 positive cells were quantiﬁed in eight
diﬀerent ﬁelds of view/slide (400x magniﬁcation) using Imaris Software (Zurich, Switzerland).
For cell surface or extracellular markers, areas with positive stain were quantiﬁed in separate
color channels in 10 ﬁelds of view/animal (200x magniﬁcation) using the BIOQuant Software
(BIOQUANT Image Analysis Corporation, Nashville, TN, USA).
Protein extraction and immunoblot analysis
Lungs from 8h studies (n = 5−8/group) were excised, weighed and snap-frozen in liquid N2, and
stored at −80◦C for later protein extraction. Protein extraction was performed using high urea
buﬀer (KPO4 , Urea, AppliChem, Darmstadt, Germany) with added Halt Protease Inhibitor
Cocktail (catalog #1861280, Thermo Fisher Scientiﬁc). Measurement of protein concentrations
was done using the bicinchoninic acid (BCA) assay (catalog #23227, Pierce Scientiﬁc Rockford,
IL, USA) and immunoblots were performed using a Bis-Tris (catalog #NP0321BOX, Life
Technologies, Darmstadt, Germany) or a Tris-Acetate (catalog #EA0375BOX, Life Technologies)
Gel according to the manufacturer’s instructions. After protein transfer (Nitrocellulose/Filter
Paper, catalog #LC2006, Life Technologies) and blocking using 5% skim milk (catalog #70166,
Sigma Aldrich) in 0,1% TBS-T buﬀer, the membranes were incubated with the following
antibodies at 4◦C overnight: PDGF-Rα (C-20, Santa Cruz Biotechnology #338), VEGF-A (147,
Santa Cruz Biotechnology #507), VEGF-R2 (Abcam, Cambridge, USA #Ab2349), VE-Cadherin
(H-72, Santa Cruz Biotechnology #28644), cleaved caspase-3 (Cell Signaling Technology #9661),
phospho-ERK (Cell Signaling Technologies #4370), total ERK (Cell Signaling Technologies
#4695), RAS (Cell Signaling Technologies #8955), PI3K (Cell Signaling Technologies #13666).
After washing the membranes were incubated with secondary antibodies (1:5000 dilution) as
follows: for PDGF-Rα, VEGF-A, VE-Cadherin, cleaved caspase-3, phosphor ERK, total ERK,
RAS, PI3K: goat anti-rabbit IgG (Santa Cruz Biotechnology #2301) and for VEGF-R2: donkey
anti-goat IgG-HRP (Santa Cruz Biotechnology #2020) conjugated to horseradish peroxidase for
1-2 hours at 4◦C followed by 3 washes. As an internal loading control, membranes were stripped
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and re-probed with 1:5000 dilution of a mouse polyclonal anti-β-actin antibody (Santa Cruz
Biotechnology #sc-81178) followed by 1:5000 dilution of goat anti-mouse IgG-HRP (Santa Cruz
Biotechnology #2060). Images were detected by chemiluminescence ECL prime Detection Kit
(GE Healthcare, Buckinghamshire, Great Britain #RPN2232) and quantiﬁed by densitometry
using a Gel Documentation System (Bio Rad, Munich, Germany).
RNA extraction and quantitative real-time PCR
Lungs from 8h studies (n = 4 − 5/group) were excised, weighed, snap-frozen in liquid
N2, and stored at −80
◦C for subsequent two-step mRNA extraction using Roti-Quick-Kit
(Carl Roth GmbH #A979.1) and puriﬁcation with peqlab-Gold Total RNA-Kit (Peqlab,
Erlangen, Germany #12-6834- 01). Quantitative real-time PCR was applied to measure
lung mRNA expression of PDGF-Rα (forward 5’-TGTGCCGTTTCTCACTTCTCCAG-3’,
reverse 5’- TACCTTTGTTTCTCACTTCTCCAG-3’) using proprietary primer-probes (Euroﬁns
mwg operon, Ebersberg, Germany).
In vitro experiments
Mechanical stretch experiment Human
lung ﬁbroblasts and mouse myoﬁbroblasts were seeded on ﬂexible-bottomed laminin-coated
culture plates (Flex Cell International Corporation catalog no.: BF-3001L) to undergo in vitro
stretch at 70-80% conﬂuence (cyclic strain by vacuum pressure: shape / sine; elongation min
0%, max 8%; frequency 2Hz; duty cycle 50%; cycles 43216; duration 24h) for 24h. As shown
in Supplemental Figure A.13C, one set of myoﬁbroblasts was kept as un-stretched untreated
control (C). Myoﬁbroblasts undergoing stretch for 24h were termed as S and those undergoing
stretch with parallel application of 5ng/ml TGF-β for 24h were termed as S+Th1. A set of
myoﬁbroblasts was also subjected to 5ng/ml TGF-β alone i.e. without any additional application
of stretch and was termed as Th1. This step was considered as ﬁrst hit on the myoﬁbroblasts.
A part of pre-stretched myoﬁbroblasts (S+Th1) was separated from group and re-incubated
(second hit) with 5ng/ml TGF-β (S+Th1+Th2). The dose of TGF-β and stretching parameters
caused the injury without inducing apoptosis in myoﬁbroblasts (Supplemental Figure A.14A-B).
Apoptosis was detected using Annexin V FITC stain (BD Pharmingen #51-65874X) and
Propidium Iodide stain (Sigma Aldrich #P4864) as per manufacturer’s instructions and the
data was analyzed using ﬂuorescence antibody cell sorting device (FACS LSRII). Viability was
determined using luminescence based Cell titer glo assay (Promega GmbH, Germany #G757)
as per manufacturer’s instructions and reading were taken with Berthold multimode microplate
reader LB 941 (Berthold Technologies GmbH, Germany)
Generation of reporter constructs and Luciferase assay
The mouse PDGF-Rα promoter construct spanning from -1074 to +280 from initiation of
transcription manufactured by gene synthesis (Life Technologies) was cloned into pGL4.14
(Promega, Madison, WI). Construct sequence was conﬁrmed by sequencing (Supplemental
Figure A.15). CCL206 cells were stimulated with TGF-β1 1 ng/ml (Peprotech, Rocky Hill, NJ)
followed by transfection (TurboFect, ThermoFisher) with reporter plasmids (1 µg) and PGK
Renilla (50 ng, Promega). Luciferase activity was determined using the Dual Luciferase Assay
(Promega) the next day and values of Fireﬂy Luciferase were normalized to values of Renilla
Luciferase. The baseline reporter activity of unstimulated cells was set to 1.0. α-smooth muscle
actin expression was determined as positive control read-out to prove TGF-β1 activity using
Western blot analysis 48 hours later.
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Proliferation assay
After ﬁrst hit of stretch with/without TGF-β as shown in supplemental ﬁgure A.12, mouse
myoﬁbroblasts and human lung ﬁbroblasts were seeded in a 24 well plate (75000 cells) for
manual counting or in 96 well plates (5000 cells/well) for luminescence based Cell titer glo
assay while performing second hit of TGF-β keeping respective controls. For manual counting
myoﬁbroblasts were trypsinized after 48h of incubation with second hit of TGF-β and counted
using Neubauer chamber. Cell titer glo assay was performed as per manufacturers instructions
after 48h of incubation with second hit of TGF-β (Cell Titer-Glo assay kit; Promega GmbH,
Germany, #G7571). Brieﬂy, reagent equivalent to the amount of media in each well was added.
Plates were shaken gently and kept at 37◦C for 10 min followed by reading the plate using
plate reader (Berthold technologies Tristar LB 941, Bad Wildbad, Germany).
Boyden chamber or transwell migration assay
Cell culture inserts i.e. transwells (8µm pore size), were placed in wells of 24 well plates
containing media (10% FCS) either with 25ng/ml PDGF-A (control) or 25ng/ml PDGF-A and
5ng/ml TGF-β. PDGF-A acted as chemoattractant for migration of myoﬁbroblasts. After ﬁrst
hit of stretch and/or TGF-β (Supplemental Figure A.13C), myoﬁbroblasts were seeded in the
wells as described above followed by incubation for 8h at 37◦C. After washing oﬀ the media,
myoﬁbroblasts on the upper side of the membrane were scratched and removed. Migrated
myoﬁbroblasts on the lower side of the membranes were then ﬁxed in Methanol for 20 min at
−20◦C and stained with 0.5µg/ml DAPI solution (Sigma Aldrich #D8417) for 10 min. After
incubation with 4% PFA for 15 min, cut membranes were mounted with Fluorescent mounting
media (Dako North America Inc. #S3023). Images were taken with ﬂuorescence microscope
and quantiﬁed using Imaris 8.1 software.
Scratch migration assay
Human lung ﬁbroblasts were seeded in a 24 well plate and were grown until conﬂuency of 90%.
A scratch was prepared in the middle of the well followed by 5ng/ml TGF-β application keeping
respective control. Images were taken every 10 min for 48h using a time lapse microscope.
Quantitative analysis of velocity and distance accumulated by the cells was performed using
ImageJ as well as chemotaxis and migration softwares.
Supplemental ﬁgures and tables
Table A.1: Genetic association results of PDGF-R related SNPs with BPD. Position information is referring
to genome build hg18.
*p≤0.05, **p≤0.001
rs-number Chr Position Allele A Allele B N homo minor N hetero N homo major N missing beta SE p-value
rs10010509 4 54851963 T G 18 245 795 3 0.1034 0.1251 0.4089
rs10022540 4 54739808 A G 174 518 369 0 -0.3038 0.0899 0.0008**
NA 4 54739883 A G 266 509 275 11 -0.2333 0.0839 0.0055*
rs1004564 4 54937382 A C 322 522 217 0 0.1206 0.0885 0.1734
rs11728027 4 54896943 A G 144 489 425 3 0.0429 0.0902 0.6348
rs11735716 4 54896828 T C 43 379 634 5 -0.1443 0.1045 0.1679
rs11737133 4 54717553 T C 152 475 433 1 0.2192 0.0894 0.0144*
rs12233727 4 54768027 T C 248 554 258 1 -0.2826 0.0898 0.0017*
rs12500279 4 54775074 T C 94 444 523 0 0.256 0.0964 0.008*
rs12511976 4 54857028 T C 893 160 7 1 -0.1854 0.1605 0.2484
rs13118725 4 54690466 T C 630 364 67 0 -0.2356 0.1018 0.0208*
rs1492769 4 54952368 A C 747 285 29 0 -0.1425 0.1195 0.2333
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rs17084051 4 54782338 A C 36 329 696 0 0.123 0.1135 0.2789
rs17084241 4 54946036 A G 9 146 905 1 0.1937 0.1586 0.2222
rs17690091 4 54924101 T C 48 380 632 1 0.1779 0.1065 0.095
rs17690232 4 54929582 C G 697 324 40 0 -0.189 0.1119 0.0917
rs17739921 4 54859623 A C 329 526 202 4 -0.1739 0.0883 0.0492*
rs17746992 4 54932752 C G 40 325 696 0 0.1951 0.1119 0.0815
rs1907814 4 54940014 A G 78 461 521 1 -0.0493 0.0994 0.6202
rs1994810 4 54924241 A G 67 435 559 0 -0.095 0.1021 0.3523
rs2412564 4 54934704 A G 248 527 286 0 0.1359 0.0881 0.1236
rs35597368 4 54834528 T C 858 191 12 0 -0.0213 0.1457 0.8839
rs4572929 4 54940498 A G 68 418 573 2 0.2292 0.1 0.0222*
rs4864510 4 54883219 T C 370 501 188 2 -0.0968 0.0881 0.2725
rs6811920 4 54945988 C G 168 505 386 2 -0.0349 0.0894 0.6964
rs6832891 4 54751401 T C 587 412 62 0 -0.1216 0.1032 0.2386
rs6840522 4 54725132 A G 795 247 19 0 -0.021 0.1297 0.8717
rs7656613 4 54836600 T C 564 423 74 0 0.2 0.1002 0.0461*
rs7659654 4 54731166 T C 536 429 95 1 -0.2163 0.0958 0.0241*
rs7660560 4 54829151 A G 17 209 833 2 0.1542 0.1323 0.2442
rs7684220 4 54893055 T C 351 517 186 7 -0.0898 0.088 0.308
rs894905 4 54916706 T C 251 539 270 1 0.0684 0.0889 0.4419
rs9991165 4 54819348 A G 791 247 23 0 -0.1153 0.1267 0.3629
rs2228230 4 54846797 T C 19 250 792 0 0.0673 0.1294 0.6032
rs3690 4 54856570 A C 798 244 19 0 -0.0888 0.1301 0.4951
rs56404781 4 54698999 T G 793 251 17 0 0.0151 0.1308 0.9081
rs7378056 4 54739260 A G 63 413 584 1 0.1423 0.1021 0.1638
rs34148754 4 54751806 A G 52 415 591 3 0.1304 0.1034 0.2075
rs12506783 4 54781154 T C 244 541 275 1 0.3076 0.0886 0.0005**
rs61320297 4 54782932 A G 37 328 695 1 0.1306 0.112 0.2438
rs7673984 4 54783518 T C 36 327 697 1 0.1073 0.1125 0.3404
NA 4 54784627 A C 871 181 9 0 0.0443 0.1519 0.7708
rs2114039 4 54787383 T C 583 403 74 1 -0.0667 0.1 0.5049
rs7678144 4 54797182 T C 696 328 37 0 -0.0953 0.1132 0.3999
NA 4 54810805 C G 0 139 915 7 -0.0824 0.1527 0.5896
rs7677751 4 54819217 T C 17 219 824 1 0.0353 0.1331 0.791
rs73252946 4 54820749 A G 22 243 796 0 0.117 0.1279 0.3605
rs58435984 4 54822747 T C 834 209 17 1 -0.113 0.1364 0.4078
rs55947416 4 54824588 T C 5 152 903 1 0.2635 0.1632 0.1067
rs67279506 4 54825439 A G 835 209 16 1 -0.0655 0.1374 0.6337
rs58727676 4 54825551 T G 837 207 17 0 -0.088 0.1372 0.5212
rs7688997 4 54826207 A C 17 209 834 1 0.1276 0.1345 0.3431
rs56145315 4 54826446 T C 17 209 835 0 0.1039 0.1369 0.4481
rs28600756 4 54826489 A C 21 205 833 2 0.0951 0.1296 0.4635
rs67600360 4 54826919 A G 834 209 17 1 -0.1168 0.1364 0.3921
rs28650939 4 54828716 T C 17 207 837 0 0.1054 0.1372 0.4424
rs28528897 4 54829096 C G 834 209 17 1 -0.0956 0.1364 0.4834
rs7691129 4 54829223 T C 835 209 17 0 -0.1039 0.1369 0.4481
rs12641563 4 54830204 C G 834 209 17 1 -0.0967 0.1364 0.4787
rs12506290 4 54830889 A T 17 210 828 6 0.0818 0.1245 0.5112
rs10028020 4 54838334 A G 11 186 862 2 0.0095 0.1423 0.947
rs4289498 4 54840189 A G 775 256 22 8 -0.1087 0.1235 0.379
rs1547905 4 54841511 A C 20 246 794 1 0.0349 0.1272 0.7838
rs2291591 4 54842526 T C 7 158 894 2 -0.0988 0.1543 0.5219
rs7677708 4 54844015 A G 784 254 22 1 -0.1039 0.1263 0.4108
rs55732997 4 54849648 T C 792 249 20 0 -0.0755 0.1287 0.5578
rs10004857 4 54850737 A G 18 244 796 3 0.0354 0.1253 0.7773
rs11133317 4 54850848 T G 20 249 792 0 0.1086 0.1287 0.3989
rs2276948 4 54851157 A G 19 245 792 5 0.1033 0.1212 0.394
rs13147194 4 54851891 T G 792 248 21 0 -0.1163 0.1281 0.3639
rs55784333 4 54854148 C G 798 245 18 0 -0.0805 0.1307 0.538
rs3733540 4 54856011 T C 792 248 21 0 -0.1163 0.1281 0.3639
rs4864878 4 54868472 T C 149 488 424 0 0.0743 0.0909 0.4138
rs6858442 4 54868690 A G 192 497 370 2 0.0849 0.0875 0.3323
rs28889275 4 54870830 A G 149 488 422 2 0.0661 0.0901 0.463
rs17084148 4 54891377 T C 146 487 427 1 0.0782 0.0907 0.3886
rs73252935 4 54710879 T C 874 180 7 0 0.004 0.155 0.9792
rs62297645 4 54732370 A G 844 190 18 9 0.0601 0.1353 0.6571
rs6852007 4 54739176 A G 11 193 856 1 0.0853 0.1436 0.5524
rs13135841 4 54740496 T C 174 515 371 1 -0.281 0.0895 0.0017*
rs13145280 4 54751622 T C 75 382 602 2 0.1935 0.0984 0.0494*
rs11133311 4 54762121 T C 158 527 373 3 -0.3007 0.0904 0.0009**
rs28622224 4 54782850 T C 74 404 582 1 0.1039 0.0995 0.2966
rs4864857 4 54784571 T C 680 326 36 19 -0.0596 0.1083 0.5819
rs7698425 4 54785413 T C 37 328 694 2 0.0793 0.1109 0.4749
rs1800810 4 54788788 C G 692 327 37 5 -0.1224 0.1117 0.2733
rs1800813 4 54789224 A G 34 330 696 1 0.0604 0.1132 0.594
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rs7689569 4 54791155 A G 35 326 698 2 0.0777 0.1118 0.4871
rs7679903 4 54792130 T C 696 328 37 0 -0.0953 0.1132 0.3999
rs6554163 4 54797316 A T 36 325 696 4 0.0678 0.1093 0.5347
rs67432867 4 54799211 A T 694 329 37 1 -0.096 0.1128 0.3947
rs73252942 4 54799361 T C 692 331 35 3 -0.0732 0.113 0.5172
rs4864864 4 54827082 T C 17 209 834 1 0.0719 0.1346 0.5931
rs41279519 4 54828988 C G 5 154 899 3 0.2559 0.1547 0.0985
rs869978 4 54834773 T C 39 316 706 0 -0.0365 0.1128 0.7466
rs73252950 4 54836257 T C 9 181 843 28 -0.0803 0.1026 0.4343
rs67388297 4 54837448 C G 859 190 12 0 -0.0103 0.1459 0.9436
rs28698464 4 54837867 A G 842 207 12 0 -0.1139 0.1423 0.4237
rs1316926 4 54838043 A G 257 516 242 46 0.1026 0.0785 0.1915
rs28374326 4 54838078 T C 5 192 859 5 -0.046 0.1397 0.7417
rs2412556 4 54840015 A G 784 253 21 3 -0.1256 0.1263 0.3203
rs2162136 4 54756155 T G 43 355 662 1 0.097 0.1088 0.3729
rs6832597 4 54770994 A C 41 351 668 1 0.0933 0.1096 0.395
rs7681399 4 54785643 T G 695 328 38 0 -0.1071 0.1127 0.3422
rs1800812 4 54789386 T G 37 328 696 0 0.0953 0.1132 0.3999
rs4864862 4 54795246 A G 37 328 696 0 0.0953 0.1132 0.3999
rs4864863 4 54795588 A G 696 328 37 0 -0.0953 0.1132 0.3999
rs2229307 4 54824835 T C 834 210 17 0 -0.1102 0.1367 0.4203
rs2307049 4 54824911 A G 18 209 834 0 0.1195 0.1359 0.3796
rs7686588 4 54829385 A G 832 210 18 1 -0.1202 0.1353 0.3746
rs12644709 4 54830337 A G 834 208 17 2 -0.0955 0.1361 0.4832
rs1547904 4 54841146 T C 20 249 792 0 0.0755 0.1287 0.5578
rs2412557 4 54844214 A C 785 254 22 0 -0.0957 0.1267 0.45
rs4864872 4 54847041 T G 20 256 782 3 0.1116 0.1227 0.3633
rs10020847 4 54847891 T C 19 250 789 3 0.0256 0.124 0.8362
rs10021728 4 54848866 T C 19 250 792 0 0.0673 0.1294 0.6032
rs11733839 4 54849284 C G 22 253 786 0 0.1029 0.1268 0.4173
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Figure A.11: Gene expression data based on SNP analysis in nCLD patients. PDGF-Rα gene expression
in patients (n = 8) that carry at least one SNP (minor allele) compared to patients with no
SNPs (homozygote major allele). Major alleles are given in the ﬁgure labels. Minor alleles of
rs10022540 is A, in rs11133311 is T, and in rs12506783 is C. 0 represents homozygote minor
allele, 1 represents heterozygote minor allele and 2 is homozygote major allele.
Figure A.12: Vessel count in wildtype and PDGF-Rα+/− mice. Histological analysis showed similar small-
vessel number (20− 100µm diameter) normalized to 100 alveoli in both unventilated wildtype
and PDGF-Rα+/− mice. (n = 10− 11 mice/group).
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Figure A.13: Characterization of human lung fibroblasts and mouse myofibroblasts and experimental
design for in vitro studies. (A-B) Quantitative analysis of characterization of (A) human
lung ﬁbroblasts and (B) mouse myoﬁbroblasts performed using ﬂuorescence antibody cell
sorting (FACS) analysis indicated abundance of myoﬁbroblast markers (CD90, CD105, PDGF-
Rα, α-SMA and Vimentin). Data is displayed as percentage positive cells. For mouse
myoﬁbroblasts n = 6 mice/group and for human lung ﬁbroblasts. (n = 5 samples/group). (B)
Immunoﬂuorescence images (200X) of mouse myoﬁbroblasts co-stained for Vimentin or α-SMA
(green), CD31 (red) and nucleus stained with DAPI (blue) are shown in ﬁgure. (C) Schematic
representation of experimental strategy used for primary pulmonary mouse myoﬁbroblasts and
human lung ﬁbroblasts. Brieﬂy myoﬁbroblasts underwent in vitro stretch with or without
additional 5ng/ml TGF-β incubation for 24h (S+Th1 and S respectively). A set with only
TGF-β application (Th1) and an un-stretched untreated control (C) was performed. This was
considered to be the ﬁrst hit model. A part from S+Th1 Myoﬁbroblasts was re-incubated with
5ng/ml TGF-β for 24h (S+Th1+Th2). This was considered to be second hit model. In (A-B)
the data is presented as mean ± SD. Statistical test is Two-tailed unpaired Student’s t test
or Mann Whitney test.
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Figure A.14: Viability of mouse myoﬁbroblasts upon application of stretch and TGF-β. Mouse myoﬁbrob-
lasts subjected to mechanical stretch with or without additional application of TGF-β as shown
in supplemental Figure A.13. (A) For viability analysis Cell titer Glo assay was performed as
per manufacturer’s instructions. Luminometric readings displayed approximately 80% viable
cells after all the applications for 24h-48h (n = 3 mice/group). (B) Annexin V FITC and
propidium iodide staining of mouse myoﬁbroblasts subjected to mechanical stretch with or
without additional application of TGf-β as shown in Supplemental ﬁgure A.13, for analysis of
apoptosis. FACS analysis revealed 10-15% apoptosis upon application of stretch with/without
TGF-β application as ﬁrst as well as second hit (n = 3 mice/group). In (A-B) the data is
presented as Mean ± SD.
CATTCAAAAATAGAGCGCAAGTCGAAGGCCCTCCCTTCCCCCACCCGCTCCGGGAAGTCCCGCTTCGCCCAGGTT
TGGTTCCTGGAGTGTCAGCGCCCCCTTTCCCTCGCCAGCAGGATCGCCGTGTCCCAACTGTCTCTCGCTGGGTGTCTTGGGTTCCCTGGTTTGTGGCTCAAACGTCCTGAAAGCTTTCCTAGGGTACGTCGCGTGCGACCCACTCGGAAGGGTGGAATTTAGGAGGATAAAAATCCTTCTGCCATCAAGATGCAGAGGGCAGGCATTTGGTAGTCACGCCTAGCCTGAGCGTTTTCATATGAAGATAGAAGAAGCGAGGACCAGATAACCCCCGAAAACAAAGGCAGGACCAGATAAGTGGCTCCGAAGGGATAAAGGTCGTTCTTTCCTTCTTCCGGAGAACATCCCAAAGGTACGCCGAGCAACCGTTATTTGCACACCGCCTCACAATCCAGCCTTTCAAAAACCCATCATCTTCCTATTAGACTCCACAGTTTCCTAATCCCATTAAAGGATTAGCAACTACACGGCACTTTCCCTTAAGACCCCCAGTTCAAAACGACGCAGCCGCGTTAGAATTTCTCCCCAGGGCCATATTTCTAGCGAGGCCCAGACTGTCTATAGAAAGGATAATTTGAATTCTAGATTTATATTCGTTTTAGAAATGAGCAGCAATTTTACGTGTATTTTCTTTTCGAAGAGAATACAAAACAATAGCACCCCCACCCCCAAATT
GGGAAGTCAACTCATTTTGGAAATGATGGCTGTTTGTAGTTTCCTGAAACCTCTTTCCCGGCAGAACGTCAACACCTCCCCCTTCGGCCCCCCACCCCACCCCATCTGGTTTGCTCCCCCCTCCTCGTTGTTGTTGAAGTCTGGGGGTTGGGACTGGCCCCCCTGATTGCATAAGAGCAAAAAGCAAAGAAGAGGTCTTGAGCCTGAGAGAGTCAGAGAGCAAGGAGTCCTAGGGAAACTTTTATTTTGAAGAGACCAAGGGGGGGGGGGACTTCATTTCCTGACAGCTATTTACTTTAAGCAAATGATTAGTTTTTGGAGGACGGACTATAACATTGAATCAATTACAAAATGCGGGTTTTGAGCCCATTACTG
TTGGAGCTTGAGGGAGAGAAACAAACGGAGGAGCTGCGGGGAAGGACTGGAAGCTTGGGGCTTACTTTTCACTCC
GGGTATCGGATTTTCTTTGCAAATTGACATAGAAGGAGAAGGTAAGGGAGAGGAAAAAGTGACTTTTGTTTCTCA
AGAAGGTCCCTGATCATAACTTGGGGCTGCAAGAAGCTAAGTAACTTCAAATTTTGGGCAACGAGGAAAACAAAA
ACAA 
Figure A.15: SNPs in preterm infants with and without BPD
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Table A.2: Analysis of SNPs in PDGF-related pathways PDGF-related pathways with overrepresentation
of nominally BPD-associated cis-eQTL SNPs
Pathway Nominally
associated
genes / all
pathway genes
Nominally associated genes Best p-values of
nominally associated
genes
Reference eQTL database
JAK / STAT
Cascade
6 / 10 EPS8, GRB2, NUP62,
PPP2CA, STAT1, STAT3
0.0013 - 0.044 dixon, fehrmann, kirsten 2014, seeQTL,
zeller
MAPKKK
Cascade
7 / 14 DUSP1, DUSP6, EGF,
MAP2K1, MAPK9, PPP2CA,
PRKCA
0.00015 - 0.044 dixon, fehrmann, kirsten 2014, seeQTL,
zeller
Apoptosis 8 / 22 AKT1, LTA, NFKB1, NUP62,
PPP2CA, PRKCA, RASA1,
STAT1
0.00015 - 0.044 dixon, fehrmann, kirsten 2014, seeQTL,
zeller
Cell Cycle 5 / 19 DUSP1, DUSP6, PPP2CA,
PRKCA, STAT1
0.00015 - 0.044 dixon, fehrmann, kirsten 2014, seeQTL,
zeller
DNA
Metabolism
5 / 9 ATF2, CREB1, EGF, NUP62,
PPP2CA
0.0013 - 0.044 dixon, kirsten 2014
Lipid
Metabolism
3 / 9 PIK3R1, PPP2CA, PRKCA 0.00015 - 0.044 dixon, kirsten 2014, seeQTL, zeller
Protein
Metabolism
14 / 39 ACTR2, AKT1, ATF2, CREB1,
DUSP1, DUSP6, GSK3B,
IKBKB, MAP2K1, MAP3K2,
MAPK9, PPP2CA, PRKCA,
RPS6KA5
0.00015 - 0.044 ding, dixon, fehrmann, kirsten 2014, seeQTL,
zeller
Actin and
Calcium Ion
Homeostasis
6 / 15 ACTR2, EGF, PRKCA, RASA1,
STAT1, STAT3
0.00015 - 0.042 ding, dixon, kirsten 2014, seeQTL, zeller
Table A.3: Characteristics of patients from which the samples for (A) protein data corresponding to SNP
analysis and (B) gene expression data corresponding to SNP analysis were derived and those
which were used for (C) isolation of ﬁbroblasts and (D) immunostaining.
A B C D
Patients n = 9 n = 13 n = 6 n = 8
BPD grades 0 (n = 1) 0/1 (n = 9) 0/1 (n = 2) 0 (n = 1)
1/2/3 (n = 7) 2/3 (n = 4) 2/3 (n = 4) 1/2/3 (n = 7)
Gestational age (weeks) 26.5±2.4 26.2±1 25±1 27.3±2
Birth weight (grams) 858.9±234 774.6±136 563±98
Mechanical ventilation (days) 56.3±14 74±23
Age of death (days) 37.75
Died of respository failure n = 6
Males/females n = 6/n = 3 n = 5/n = 8 n = 4/n = 2 n = 5/n = 3
Early onset infection n = 6
Days of culture 3− 14
Congenital infection n = 2
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Summary
Congenital diaphragmatic hernia (CDH) is a severe anomaly characterized by a diaphragmatic
defect, lung hypoplasia and pulmonary hypertension. Speciﬁc genetic abnormalities have
been identiﬁed in some aﬄicted children, such as deletions in FOG2, COUP-TFII and SOX7,
but in over 80% of cases the cause of CDH remains unknown. The associated pulmonary
abnormalities are responsible for the high morbidity and mortality among patients with this
disease. Vasodilator therapy often has no eﬀect and little is known about the possibly aberrant
expressions of the targeted factors of current drugs.
Chapter 1 describes the therapeutic approaches of CDH-related pulmonary hypertension over
the years and the corresponding pathways. Both postnatally and antenatally, these approaches
are still a matter of trial and error and have not been studied in randomized controlled
trials or comparative eﬀectiveness trials. Previous morphological studies have shown excessive
muscularization of the pulmonary arteries and abnormal pulmonary vascular remodeling in
patients with CDH, in which several pathways have found to be involved. Furthermore, a
variety of chromosomal abnormalities have been reported. Chapter 2 presents a review of the
literature on pulmonary vascular development in health and in diﬀerent diseases of the newborn
associated with pulmonary vascular abnormalities, including CDH. In the study presented in
chapter 3 we focused on one of the pathways involved in CDH, transforming growth factor
β (TGFβ). This pathway is regulated by retinoic acid signaling, which has been known to
be disrupted in CDH. In the nitrofen rat model we found increased activation of TGFβ and
reduced activation of bone morphogenetic protein.
Current treatment of pulmonary hypertension typically consists of targeting receptors and
other important factors in the three major vasoactive pathways: the nitric oxide (NO), endothelin
(ET) and prostacyclin (PGI2) pathways. Although inhaled NO (iNO) is the most common
used drug in the neonatal setting, studies failed to show consistency of its eﬃcacy in CDH
patients. Apart from iNO therapy, the phosphodiesterase-5 inhibitor sildenaﬁl and prostacyclins
are sporadically used as rescue therapy, with variable and unpredictable results. In the study
presented in chapter 4 we analyzed the expressions of the drug related factors in all three
pathways. In human CDH lungs, we found upregulation of the endothelin A and B receptors
and of the endothelin converting enzyme. The latter is a key molecule in the endothelin pathway,
by converting endothelin-1 (ET-1) into its active form. Expression of the prostacyclin receptor
in human control lungs gradually increased over time, but was decreased in CDH lungs in the
fetal, preterm and term phases. The aberrant expressions of the above-mentioned factors could
explain why treatment of pulmonary hypertension in patients with CDH fails.
As ultrasound studies at 20 weeks of gestation can already detect CDH, fetal treatment is a
potential option. In the study presented in chapter 5, rats with nitrofen-induced CDH were
antenally given sildenaﬁl. We found that the decreased saccular airspaces had enlarged again,
and that the pulmonary vessel wall was less muscularized. We expanded our study by analyzing
the eﬀect of antenatal treatment with the novel prostacyclin receptor agonist selexipag (NS-304)
alone or in combination with sildenaﬁl, as described in chapter 6. Treatment with NS-304 alone
was followed by improvement in the aberrant cardiac and pulmonary vascularity. Combination
therapy of sildenaﬁl and NS-304 did not have added value to each of these compounds separately,
indicating a limited eﬀect of treatment with vasodilatory therapy at this stage of development
or a diﬀerent eﬀect of activation of both pathways.
CDH is often associated with neonatal chronic lung disease (nCLD), as these patients are
highly susceptible for oxygen and ventilation damage. The pathophysiology of both diseases
seems to overlap. In both, multiple developmental signaling pathways are aﬀected, with TGFβ,
for example, as a shared factor. In the appendix we describe that in a mouse model of nCLD
we found increased activation of TGFβ and reduced expression of platelet derived growth factor
receptor α (PDGF-Rα), which corresponds to our ﬁndings in the nitrofen-CDH rat model.
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The clinical implications of our research are discussed in chapter 7, which includes a
recommendation to develop a precision medicine approach that might even already be applied
antenatally.
Samenvatting
S
u
m
m
a
ry
Samenvatting
Congenitale hernia diafragmatica (CHD) is een ernstige aangeboren afwijking, met als kenmerken
een gat in het middenrif, long hypoplasie en pulmonale hypertensie. Bij sommige patie¨nten
zijn bepaalde genetische afwijkingen aangetoond, zoals deleties in FOG2, COUP-TFII en
SOX7, maar in meer dan 80% van de gevallen blijft de oorzaak onbekend. De bijkomende
longafwijkingen zijn verantwoordelijk voor de hoge morbiditeit en mortaliteit onder kinderen
met CHD. Vaatverwijdende therapie helpt vaak niet en mogelijk vertonen de factoren waarop
de huidige medicatie is gericht een afwijkende expressie.
Hoofdstuk 1 geeft een overzicht van de therapeutische aanpak van CHD-gerelateerde
pulmonale hypertensie over de jaren en beschrijft de bijbehorende pathways. Zowel voor als na
de zwangerschap vormt het vinden van de juiste therapie nog steeds een uitdaging. Dit is nog niet
eerder onderzocht in gerandomiseerde gecontroleerde trials of vergelijkende eﬀectiviteitsstudies.
Morfologisch onderzoek heeft aangetoond dat bij kinderen met CHD de longvaten extreem
verdikt zijn, en bij dit proces zijn verschillende pathways betrokken. Hoofdstuk 2 geeft een
overzicht van de literatuur over de normale ontwikkeling van het pulmonale vaatbed en de
ontwikkeling bij verschillende aangeboren afwijkingen waarbij het pulmonale vaatbed abnormaal
is, zoals CHD. Hoofdstuk 3 richt zich op een van deze pathways, transforming growth factor
β (TGFβ). Deze wordt gereguleerd door retino¨ınezuur, waarvan de expressie verstoord is in
CHD. In het nitrofen-CHD rat model vonden we een toegenomen activatie van TGFβ en een
afgenomen activatie van bone morphogenetic protein, een andere belangrijke transcriptiefactor
in dit pathway.
De huidige behandeling van pulmonale hypertensie is gericht op receptoren en andere
belangrijke factoren in de drie belangrijke vasoactieve pathways: stikstofoxide (NO), endotheline
en prostacycline. Inhaled NO (iNO) is het meest gebruikte middel onder pasgeborenen, maar
het is nog niet duidelijk of het eﬀect heeft bij kinderen met CHD. Naast iNO worden sildenaﬁl
en prostacylclines sporadisch gebruikt als een laatste redmiddel. Deze geven echter wisselende
en onvoorspelbare resultaten. In hoofdstuk 4 hebben we de expressie geanalyseerd van de
factoren die aan deze middelen zijn gerelateerd; dit is gedaan voor alle drie bovengenoemde
pathways. In longen van patie¨nten met CHD vonden we een toegenomen expressie van de type
A en B endothelinereceptoren en het endotheline-converting enzym. Dit enzym is belangrijk
omdat het de inactieve vorm van endotheline omzet naar de actieve vorm. De expressie van
de prostacyclinereceptor nam toe gedurende de zwangerschap in gezonde longen, maar in
CHD-longen was dit lager in alle zwangerschapsfasen. De afwijkende expressie van al deze
factoren zou kunnen verklaren waarom de behandeling van pulmonale hypertensie bij kinderen
met CHD niet goed aanslaat.
Omdat CHD al bij 20 weken zwangerschap ontdekt kan worden door middel van echograﬁe, is
behandeling tijdens de zwangerschap een mogelijke optie. In de studie beschreven in hoofdstuk
5 hebben we ratten met door nitrofen ge¨ınduceerde CHD tijdens de zwangerschap behandeld
met sildenaﬁl. Bij deze ratten waren de longblaasjes van normale grootte en was de vaatwand
minder verdikt. In een vervolgstudie hebben we de werking geanalyseerd van een nieuw medicijn,
selexipag (NS-304), afzonderlijk en in combinatie met sildenaﬁl, zoals beschreven in hoofdstuk
6. Behandeling met alleen NS-304 gaf een verbetering van de afwijkingen in het hart en de
longvaten. De combinatie van sildenaﬁl en NS-304 had geen toegevoegde waarde boven elk van
de afzonderlijke medicijnen. Het ziet ernaar uit dat vaatverwijdende therapie in deze fase van
de ontwikkeling slechts een beperkt eﬀect heeft. Ook kan het zijn dat deze twee medicijnen elk
een ander eﬀect hebben.
Patie¨nten met CHD hebben vaak ook neonatale chronische longziekte (nCLD), omdat zij
gevoelig zijn voor schade door zuurstoftoediening en mechanische beademing. De onderliggende
mechanismen van beide aandoeningen lijken te overlappen. In beide gevallen tonen meerdere
pathways een abnormale ontwikkeling, waarvan TGFβ bijvoorbeeld een gezamenlijke factor is.
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In de appendix beschrijven we een muismodel van nCLD waarin er een toegenomen activatie
van TGFβ was en platelet derived growth factor receptor α (PDGF-Rα) een lagere expressie
vertoonde. Dit komt overeen met onze bevindingen in het nitrofen-CHD ratmodel.
De implicaties van ons onderzoek voor de kliniek worden besproken in hoofdstuk 7. Dit
hoofdstuk bevat tevens een aanbeveling voor een individueel gerichte behandeling die mogelijk
al voor de geboorte kan worden toegepast.
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